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Abstract 
Cystic fibrosis (CF) is a genetically inherited condition most prevalent amongst 
Caucasians. In previous studies, it has been demonstrated that bacterial, fungal and 
viral pathogens cause lung function decline and ultimately result in death due to 
respiratory failure.  
Patients with CF produce sputum daily, which makes it an ideal infection to study in 
terms of access to samples. However, it is unknown how transport of the samples 
from the patient to the laboratory will affect the results of molecular microbiological 
analysis. We found that the bacterial community profiles were significantly different 
in samples stored at room temperature from those which were refrigerated. 
Furthermore, a significant increase in bacterial load and numbers of Pseudomonas 
spp. and a significant decrease in number of H. influenzae were seen in the samples 
stored at room temperature.  
In this study we also aimed to characterise the factors which have an effect on the 
bacterial and fungal communities present in the CF lung in patients who possessed 
the F508del CFTR allele. We found that gender was a significant factor in the 
assembly of bacterial communities, due to a reduction in bacterial diversity and 
community evenness. Furthermore, we identified that P. aeruginosa colonisation 
affected bacterial community composition. We have also identified that bacterial 
community assembly in the CF lung appears to be stochastic. However, our data also 
shows that gender and P. aeruginosa colonisation affect assembly suggesting that, in 
some respects, a deterministic community assembly is also being observed. Our data 
also suggests that fungal communities are more diverse than is currently recognised. 
Additionally, we have found that patients who are homozygous for the F508del 
CFTR mutation harbour more rich fungal communities than patients who are 
heterozygous. 
A further objective was to follow these patients longitudinally to determine the 
stability of the CF lung microbiota, to determine the effects of antibiotic therapy, and 
to assess if any changes occurred in the CF lung during times of pulmonary 
exacerbation which could be identified as the causative agent. We did not find a 
significant relationship between exacerbations and the bacterial communities present 
in CF. However, in one patient we found that a particular bacterial taxa was present 
when the patient presented with an exacerbation but was absent when the patient was 
stable, suggesting that acquisition of a new bacterial taxa can potentially cause an 
exacerbation. We also found that an increase in bacterial load was not the cause of 
exacerbations in our cohort. Furthermore, the presence and abundance of fungal 
species was found not to be the cause of exacerbations. 
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1. Introduction 
 
Cystic fibrosis (CF) is the most common lifespan reducing autosomal recessive 
condition in the U.K. Most of the morbidity and mortality in CF can be attributed to 
the chronic lung pathology caused by microbial infection and the subsequent 
inflammatory immune response. Traditionally, Haemophilus influenzae, 
Staphylococcus aureus, Pseudomonas aeruginosa and members of the Burkholderia 
cepacia complex have been seen as the key pathogens in CF due to their link with 
lung function decline (Cystic Fibrosis Foundation 2009). However, recent analyses 
using molecular techniques and more investigative culture techniques has 
demonstrated a wealth of microorganisms that were previously unidentified as 
colonisers of the CF lung, including many strictly anaerobic bacteria that had 
previously been regarded as contaminating commensal bacteria from the oral cavity 
(Rogers et al. 2003; Tunney et al. 2008). These studies have highlighted the 
drawbacks of microbial culture by revealing that the true microbial diversity of the 
CF lung may be one or possibly even two orders of magnitude greater than 
previously recognised and suggest that we need to reassess our understanding of CF 
microbiology (Rogers et al. 2003; Klepac-Ceraj et al. 2010). One approach would be 
to adopt a community based perspective to studies of CF microbiology that 
recognises the polymicrobial nature of this disease and acknowledges the potential 
contribution of the entire microbial community. This may lead to a more thorough 
understanding of chronic pulmonary infections based on the complex community 
involved, as well as demonstrating the role specific organisms, that are frequently 
found in CF infections, play in the pathogenesis of the disease. 
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Recent studies on the CF lung have utilised techniques that were traditionally 
applied to environmental microbiology to examine the relationship between the CF 
lung microbiology and patient specific factors (Klepac-Ceraj et al. 2010; van der 
Gast et al. 2010). These studies have found that bacterial colonisation of the lower 
respiratory tract of children with CF is influenced by CFTR genotype, the use of 
inhaled antibiotics and colonisation by P. aeruginosa (Klepac-Ceraj et al. 2010). 
Furthermore, a recent study has identified that bacterial diversity and community 
richness decreases with patients‟ age. Similarly, CF patients with a homo or 
heterozygous F508del mutation are more likely to acquire the emerging fungal 
pathogen Geosmithia argillcaea (Giraud et al. 2010). Further studies applying this 
knowledge may demonstrate linkages between chronic respiratory infections in CF 
to patient, environmental factors and the microbial ecology of the lungs which will 
lead to more effective treatment strategies to improve patient quality of life. 
 
1.1 CFTR structure and function 
 
Cystic fibrosis is a monogenic disease caused by mutations in a gene that codes for 
the cystic fibrosis transmembrane conductance regulator (CFTR) protein, the gene is 
approximately 250 kb in length and is located on the long arm of chromosome 7. 
This sequence encodes an mRNA molecule of 6.5 kb which is translated into a 
protein that is 1,480 amino acids long (Kerem et al. 1989; Riordan et al. 1989). The 
CFTR protein is a transporter for chloride ions (Cl
-
) and a regulator of other ion 
channels which is located on the apical membrane of epithelial cells. At the apical 
membrane the CFTR protein forms a Cl
-
 channel that is responsible for the transport 
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of salts between the luminal space and the cytoplasm of the cell. The CFTR protein 
is made up of two hydrophobic membrane spanning domains (MSD) that each 
consists of six helical transmembrane domains (TMD): two hydrophilic nucleotide 
binding domains (NBD) associated with the TMD and a regulatory domain (R) 
(Riordan et al. 1989).  
There are over fifteen hundred mutations identified in the CFTR gene to date that 
can cause CF (CF mutation database). Most CFTR mutations are due to missense 
(40.85%), frameshift (16.23%) or splice-site (12.39%) mutations of the CFTR gene 
(Dorfman et al. 2008). The genetic defects of CFTR have been grouped into five 
classes which are associated with the synthesis and maturation of CFTR protein 
(Welsh & Smith 1993). In class I, mutations result in no CFTR at the apical 
membrane due to transcription of a severely truncated mRNA molecule that is not 
translated into protein. Class II mutations also result in no CFTR expressed at the 
apical membrane but are caused by degradation of mis-folded proteins by the 
proteosome within the endoplasmic reticulum. Class III mutations result in some 
CFTR expression at the apical membrane but cannot be activated due to missense 
mutations. Class IV mutations result in expression of activated CFTR at the apical 
membrane but with limited functionality. Class V mutations result in expression of 
activated CFTR at the apical membrane but in lower numbers than in healthy 
individuals. Restoration of CFTR protein activity has been a major focus of CF 
research for over a decade with gene therapy being seen as the most viable treatment 
strategy. There have been two major vectors investigated to restore CFTR protein to 
the respiratory epithelium; viral vectors and liposomes (Hyde et al. 2000; Flotte & 
Carter 1997). However, no major clinical trials have been conducted to date due to 
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caveats in the systems leading to immune response to the vector or insufficient 
uptake by the respiratory epithelium (Atkinson 2008). 
 
1.2 Epidemiology of CF 
 
Epidemiology, in a clinical sense, is the study of the prevalence and distribution of a 
particular disease on a global scale in order to monitor any temporal changes. Many 
problems are encountered when studying the epidemiology of CF globally. In 
countries where CF is less prevalent, it is not screened for at birth, resulting in lower 
detected incidence rates when actually the incidence rate may be much greater 
(Raskin et al. 2008) . Even in countries where CF is screened for at birth, accurate 
identification is problematic due to non CF specific clinical manifestations and 
different genotypes resulting in different phenotypes which have differing clinical 
consequences that are difficult to detect (Farrell et al. 2008). The prevalence of a 
mutated CFTR gene in the U.K. is thought to be in the region of 1 mutated CFTR per 
25 individuals of Caucasian decent (World Health Organisation 2002). Furthermore, 
the prevalence of CF is approximately 1 in every 2,600 live births in the U.K. but 
can be as low as 1 in up to 350,000 live births in Japan (World Health Organisation 
2002). In the general U.K. population, CF is only responsible for approximately 0.17 
deaths per 100,000. However, CF reduces lifespan and causes of 1-2% of all deaths 
in the U.K. in patients aged 5 – 24 (Walters & Mehta 2007). Nevertheless, survival 
of young patients with CF is improving which will hopefully see all CF patients 
surviving in to adulthood (Kulich et al. 2003). 
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The most common CFTR mutation is F508del which accounts for 66% of global 
mutations with the next most prevalent being G542X which is the cause of 2.4% of 
CF globally (Dorfman et al. 2008). However, F508del incidence varies greatly when 
observed on a global scale with incidence ranging from 90% in Danish populations 
to 20% in Turkish populations where other mutations are most prevalent. Many 
geographical relationships such as this are observed in CFTR prevalence which 
makes the origin or cause of the disease difficult to pinpoint (Walters & Mehta 
2007).  
There has been much speculation surrounding the cause of the high incidence levels 
of CFTR mutation and why different populations have markedly different 
distributions of each genotype. The first of these hypotheses was that CFTR 
heterozygotes had a fertility advantage over their peers (Jorde & Lathrop 1988). 
However, this theory was discredited in 1988 when a study on the Mormon 
population revealed that CFTR heterozygotes had no reproductive advantage over 
the control group (Jorde & Lathrop 1988). A second hypothesis was that there was a 
selective advantage of carriers against infectious diseases. For example, some 
evidence links the spread of F508del mutation across Europe with the decreased risk 
of intestinal infectious disease arising from cattle pastoralism (Alfonso-Sánchez et 
al. 2010). Most compellingly is the observed resistance to Salmonella typhi 
infection, the causative agent of typhoid fever, being significantly reduced in 
heterozygote and homozygote F508del population of mice compared to those 
expressing wild type CFTR (Pier et al. 1998). This study demonstrates that 
translocation of S. typhi into the intestinal submucosa of F508del heterozygote 
„carrier‟ mice was 86% less than those expressing wild type CFTR and almost zero 
in the homozygote F508del population. There is also a correlation between CFTR 
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genotype and prognostic factors such as lung function, nutritional status, pancreatic 
insufficiency and P. aeruginosa colonisation (McKone et al. 2006). McKone et al. 
(2006) also demonstrated that high risk CF patients had a mean mortality of 24.2 
years and low risk patients had a mean survival age of 37.6 years, highlighting the 
fact that more research needs to be carried out to improve both the length and quality 
of patients. 
 
1.3 Systemic effects of CFTR mutation 
 
As CFTR is found on the surface of epithelial cells the disease manifestations are 
present in many organs such as pancreas, gastrointestinal tract and lungs. Much of 
the problems in CF are due to impaired activity of CFTR that causes reduced 
chloride ion transport into the lumen which results in osmotic potential that drives 
water out of the lumen and in to the epithelium (Quinton 1990). Likewise, 
unregulated influx of sodium ions (Na
+
) through the epithelial sodium channel 
(ENaC) exacerbates the movement of water out of the airway lumen resulting in 
dehydration of mucosal membranes (Stutts et al. 1995). This results in mucus plaque 
formation at the epithelial surface which can impair the function of the effected 
organs. In CF sufferers factors that affect nutrition can cause severe problems. In 
neonates meconium ileus can be the first clinical symptom of CF and effects 10-15% 
of CF sufferers, although it is not specific to CF (Ziegler 1994). Meconium is the 
first stool passed by a child and is made up of undigested products from its time in 
the uterus. Meconium ileus is the mechanical blockage of the ileum, due to viscous 
mucus, by the meconium in CF. However, G.I. tract complications do not end in 
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infancy. The small intestine is known to be colonised more readily by Gram-negative 
bacteria in CF sufferers than healthy individuals (Littlewood 1992; Lewindon et al. 
1998; Fridge et al. 2007). Small intestine bacterial overgrowth (SIBO) may be due to 
several factors including; abnormal accumulation of mucus; suppression of gastric 
acid to maintain lipase activity and slowed intestinal transit (Borowitz et al. 2005). 
SIBO may be present in up to 50% of CF patients studied and it is thought that SIBO 
may contribute to malnutrition often observed in CF patients because of bacterial 
competition for nutrients and inflammation caused by bacterial enterotoxic 
metabolites (Borowitz et al. 2005). This hypothesis has been tested in a murine 
model where CF mice and wild type were compared (Norkina et al. 2004). The 
results of this study show that CF mice treated with antibiotics were only 10% 
smaller than the wild type mice, whereas the untreated CF mice were 30% smaller. 
Furthermore, 16S rRNA analysis of the small intestine showed significantly reduced 
bacterial species diversity with ~90% of the community belonging to the 
Enterobacteriaceae family (Norkina et al. 2004). After a link between SIBO and 
reduced ability to thrive in CF had been established, De Lisle (2007a) took this line 
of investigation further and examined gastric emptying and intestinal transit in CF 
mice. De Lisle (2007b) confirmed one hypothesis put forward by (Borowitz et al. 
2005) in that small intestinal transit was slower in CF mice than wild type controls. 
De Lisle (2007a) then went on to show that treatment of CF mice with laxative 
reduced the inflammation, mucus accumulation and bacterial load in the small 
intestine as well restoring intestinal transit to normal levels. Analysis of 
inflammatory markers has provided evidence to support the claim that CF patients 
have increased intestinal inflammation and that this inflammation can be reduced by 
administration of probiotics (Bruzzese et al. 2004). Furthermore, a pilot, random, 
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placebo-controlled, cross-over study on 19 CF patients established that treatment 
with probiotics reduced the number of pulmonary exacerbations and hospitalisations 
than placebo treated patients and increased FEV1 and body weight than those treated 
with the placebo suggesting that intestinal status in CF patients in related to 
pulmonary health (Bruzzese et al. 2007).  
 
1.4 Respiratory immune dysfunction 
 
Pulmonary disease in CF has been linked to several factors relating to CFTR 
dysfunction. Impaired activity of CFTR causes reduced Cl
-
 transport into the lumen 
of the bronchi which results in osmotic potential that drives water out of the airway 
lumen and in to the epithelium (Quinton 1990). This is exacerbated by unregulated 
influx of Na
+
 through the ENaC pump causing the movement of water out of the 
airway lumen (Stutts et al. 1995). Both CFTR and ENaC transporters play an 
important role in the maintenance of the airway surface liquid (ASL) which is ~7 µm 
high in ciliated cells of healthy individuals and consists of two distinct layers (Tarran 
et al. 2001). The purpose of the lower or periciliary layer (PCL) and the upper mucus 
layers is to trap and transport inhaled bacteria out of the lower respiratory tract 
(LRT) assisted by “beating” of the cilia, a process known as mucociliary clearance 
(MCC). CF epithelial cell lines have shown that sufficient hydration of the ASL 
cannot be maintained. In CF, the mucus is severely dehydrated, due to unregulated 
ion transport, resulting in depletion of the PCL to a point where the mucus layer is 
extremely viscous causing the cilia to collapse resulting in cessation of MCC 
(Matsui et al. 1998). Furthermore, attachment of the dehydrated mucus layer to the 
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ciliated epithelium causes formation of mucus plaques which cannot be removed by 
cough clearance. The rate of MCC varies between CF patients that could be due to 
several factors such as the class of CFTR mutation, with patients having the less 
severe class IV and V mutations having greater MCC function (Boucher 2007). 
Other problems resulting from the cessation of MCC include cleavage of 
antimicrobial peptides that would normally aid bacterial clearance (Rogan et al. 
2004) and migration of neutrophils (Matsui et al. 2005). Furthermore, CFTR can 
internalise P. aeruginosa from the epithelial cell surface which prevents the chronic 
colonisation that is seen in CF lung disease (Pier 2000). However, many CF patients 
will not constitutively express CFTR at the epithelial cell surface due to degradation 
by the proteosome, thus, allowing P. aeruginosa to colonise the airways. Other 
research has shown that acidification of lysosomes is insufficient in CFTR deficient 
mice (Di et al. 2006; Teichgräber et al. 2008). The first example of this phenomenon 
has shown that alveolar macrophages from CFTR deficient mice display normal 
internalisation but defective intracellular killing of P. aeruginosa (Di et al. 2006). 
Acidification of the lysosome in alveolar macrophages is known to be CFTR 
dependent (Barasch et al. 1991). Di et al. (2006) posited that the defective/absent 
CFTR present in CF sufferers would cause reduced acidification of the lysosome, 
resulting in survival of any internalised pathogen. Furthermore, it has been suggested 
that the anaerobic nature of the mucous plaques present in the CF lung prevent the 
generation of reactive oxygen species by leukocytes, resulting in further impairment 
in bacterial killing (Döring et al. 2011). The second mechanism regarding 
acidification in CF mice is due to alkalinisation of vesicles due to absence of CFTR 
(Teichgräber et al. 2008). The alkalinisation causes a disruption in the balance 
between formation and breakdown of ceramide leading to accumulation of ceramide 
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in the airways. The ceramide deposits result in an increase in inflammation resulting 
in epithelial cell death which, in turn, leads to DNA deposits in the respiratory tract. 
The DNA deposits can be used by respiratory pathogens, namely P. aeruginosa, for 
adherence which increases the risk of pulmonary infection (Teichgräber et al. 2008).  
 
1.5 Sampling strategies for polymicrobial communities in CF 
 
All studies to date that have been used to analyse the microbiota of the CF lung have 
used whole sputum samples or bronchoalveolar lavage fluid (BALF). The likelihood 
is that these samples are far too large to sample individual microbial communities 
and it is more probable that many communities are pooled making changes in the 
microenvironment difficult to tease out. Gutierrez et al. (2001) found, during 
analysis of BALF samples, that the bacteria isolated were not homogeneously 
distributed between lobes and advised that multiple lobes be sampled in order to get 
a comprehensive view of the microbiota. Likewise, research utilising computed 
tomography to identify disease in the lungs of children with CF demonstrated that 
during a pulmonary exacerbation, airway inflammation is confined to a particular 
area of the lung as opposed to being widespread (Davis et al. 2007). These data 
suggests that only a small proportion of the total microbial community throughout 
the lung is the causative agent of exacerbations.  
A recent paper by Rogers et al. (2010) highlighted the need for more thorough 
sampling strategies to be applied to sputum from CF patients. In this study, they took 
an initial expectorated sputum sample then induced sputum four times at five minute 
intervals and found that each sample individually only harboured ~58% of the 
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overall microbial community observed from all of the samples in combination. It is, 
therefore, important to fully assess the merits of each sample type that can be 
obtained. BALF samples are advantageous because they bypass the oral cavity and 
directly sample the lung, thus reducing the risk of contamination from oral bacteria. 
However, these samples are invasive, unpleasant for the patient and not routinely 
sought due to easy expectoration of sputum. Most molecular studies based upon 16S 
rRNA gene have utilised expectorated sputum and identified metabolically active 
anaerobes commonly disregarded as merely contaminating mouth flora (Rogers et al. 
2005). Rogers et al. (2006) went on to demonstrate no significant difference between 
sputum and mouthwash samples obtained from a set of CF patients. Similarly, 
Tunney et al. (2008) showed that anaerobic bacteria could be isolated, enumerated 
and identified by culture of sputum from the CF lung. They demonstrated that a 
mixed anaerobic population could be isolated from 64% of samples and, by 
quantitative culture, that these bacteria were present in similar or sometimes greater 
numbers than common CF pathogens such as P. aeruginosa. Furthermore, it has 
been demonstrated that anaerobes can persist in the lung and are not susceptible to 
common antibiotics used in the management of CF respiratory disease (Worlitzsch et 
al. 2009).  
Both RNA and DNA can be used to analyse microbial communities in CF sputum, 
both of which have their relative merits. Traditionally, RNA extraction would be 
considered difficult due to its instability at room temperature which would need a 
stringent sample handling protocol to get the sample from the ward to the laboratory 
without degradation or a shift in expression pattern. However, the advent of RNA 
preservation agents has made the analysis of RNA much simpler. The major 
advantage of RNA extraction allows characterisation of the metabolically active 
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community and when, for example, aetiology is under examination, the causative 
agent is most likely to be metabolically active. However, in the case of microbial 
infection in CF it is the immune response which adds to the pathology and causes 
symptoms so there is a strong argument for analysing both DNA and RNA (Balough 
et al. 1995; Rapaka & Kolls 2009). Similarly, to achieve full coverage of respiratory 
viral communities then both DNA and RNA need to be examined. However, there is 
also a case for this when analysing bacteria because an organism that is present but 
not metabolically active may merely be dormant and when environmental conditions 
shift they can become active and play a part in the community function (Prosser et al. 
2007). One method of tackling this problem in clinical samples has been 
demonstrated (Rogers et al. 2008; Rogers et al. 2010). Prior to DNA extraction, 
propidium monoazide (PMA) was incubated with the sample which intercalates with 
the DNA of dead cells and extracellular DNA (eDNA), live cells are not affected by 
the treatment because PMA cannot traverse the cell membrane. Rogers et al. (2008) 
show that untreated samples have extra taxa when compared to PMA treated 
suggesting that eDNA or DNA from non-viable cells is contributing to the microbial 
community fingerprint and thus causing an over estimation of microbial diversity at 
that time. The PMA treatment strategy was taken forward and it has also been 
proven that non-viable cells contribute to quantification of microbial communities 
using qPCR (Rogers et al. 2010). 
In many animal and plant communities there are few species of many individuals 
and many more species of fewer individuals. This can also be said of microbial 
communities (Dunbar et. al. 2002). Dunbar et al. (2002) sampled bacterial 
populations from four Arizona soils in an attempt to assess the number of species 
present. In all four soil samples acidobacteria accounted for approximately 50 % of 
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clones where as there are many divisions which account for less than 5 % of clones. 
This research also highlights important issues about sampling strategy for 
assessment of microbial communities. Dunbar et al. (2002) estimate that in order to 
reproduce the top 50 % of bacteria in a population containing 4,000 species then a 
samples size of 285,400 individuals would be required to obtain a ≥ 95 % confidence 
limit.  
 
1.6 Microbial community assembly in CF 
 
The oral mucosa and upper respiratory tract are huge reservoirs of bacteria that, with 
the failing of MCC, can bypass the host defence system and colonise the lung 
(Bittar, Richet, et al. 2008; Rogers et al. 2004; Harris et al. 2007). Traditionally, 
children with CF will most likely suffer from transient infections caused by S. 
aureus, H. influenzae and P. aeruginosa respectively (Cystic Fibrosis Foundation 
2009). However, a recent molecular study on BALF from children with CF (mean 
age ~9 y.o.) has contradicted this data and shown a complex microbial community is 
already established in the lung (Harris et al. 2007). Similarly, Bittar et al. (2008b) 
developed a bacterial community data set that showed children as young as one 
colonised with up to 8 different species of bacteria. These studies demonstrate that 
bacteria can invade and colonise the lung in young CF patients and that early 
colonisation of the CF lung may not be restricted to „classic‟ CF pathogens. Duan et 
al. (2003) demonstrated in a single patient that P. aeruginosa and the “normal oral 
flora”, which includes Staphylococcus and Streptococcus spp., are the only constant 
colonisers over an 11 year period. However, specific members of the “normal oral 
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flora” were not elucidated and it, therefore, cannot be concluded which members, if 
any, are chronic colonisers of the CF lung.  
Routine work in pathology suggests that S. aureus and H. influenzae are early 
colonisers and are succeeded by mucoid phenotypes of P. aeruginosa by age 13 and 
members of the Burkholderia cepacia complex (Bcc) later in life (Cystic Fibrosis 
Foundation 2009). However, a study conducted that looked at intensity of anti-
Staphylococcal therapy on P. aeruginosa acquisition showed that patients were more 
likely to acquire P. aeruginosa if they had received constant therapy that would 
eradicate S. aureus in contrast to patients who had no or impromptu therapy (Ratjen 
et al. 2001). An in-vivo study on rats suggests that P. aeruginosa can lyse S. aureus 
and use it as a source of iron in low iron environments (Mashburn et al. 2005). This 
could be a key finding relating to the development of chronic P. aeruginosa infection 
in the CF lung. Although the CF lung has a high iron content it remains uncertain 
whether the amount of available iron present is indeed elevated or depleted (Reid et 
al. 2002; Reid & Kirov 2004; Kim et al. 2003; Zeng & Kim 2004).  
Two key publications examining the microbial communities of the CF lung have 
shed some light on the effects of intrinsic and extrinsic factors in community 
development (Klepac-Ceraj et al. 2010; Cox et al. 2010). The first of which 
demonstrated that younger CF suffers had a more diverse microbial community than 
older CF suffers and that this was, in part, due to the younger individuals being 
culture negative for P. aeruginosa (Klepac-Ceraj et al. 2010). The authors cite the 
time hypothesis that the reduced diversity seen in more elderly patients is due to 
chronic antibiotic therapy regimens selecting for taxa which are more suited to this 
type of habitat and eliminating those which are susceptible. The second paper 
supports the temporal finding of Klepac-Ceraj et al. (2010) but they find an increase 
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in the bacterial diversity up to 11 years of age followed by a decrease thereafter (Cox 
et al. 2010).  
There are two ecological theories that have been applied to microbial community 
assembly, neutral theory and niche (deterministic) theory. Neutral theory was first 
used to examine species diversity on oceanic islands (MacArthur & Wilson 1963; 
MacArthur & Wilson 1967). Neutral theory assumes all taxa to be of equal fitness 
and that diversity is driven by random immigration and extinction of species derived 
from a meta-community. MacArthur and Wilson (MacArthur & Wilson 1963; 
MacArthur & Wilson 1967) used this theory to explain the number of avian species 
on oceanic islands and found that islands with a greater area had a larger species 
number than islands which were smaller. This theory came to be known as the 
species-area relationship. Microbial ecologists have recently started using neutral 
theory to examine bacterial communities and have found that a taxa-volume 
relationship exist in several systems (van der Gast et al. 2006; Woodcock et al. 
2007). However, this theory has not been applied to the bacterial communities 
associated with infectious diseases. 
 In a study examining metabolically active bacterial communities, patients had 
diverse communities consisting of different bacterial taxa which suggests that a 
deterministic community assembly between CF patients has not been observed 
(Rogers et al. 2005). Therefore, the microbial communities present in the LRT of CF 
patients may be assembled in a stochastic manner which means that neutral theory 
could possibly be applied to polymicrobial infection. Further studies examining the 
microbial diversity of the CF lung have also found that a patient specific microbial 
community exists (Harris et al. 2007; Bittar et al. 2008b). Although neutral theory 
provides a theoretical framework in which to examine microbial communities one of 
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its major caveats is to provide a useful indication of how and why the major taxa 
associated with infectious diseases come to the fore. For example, why is there an 
extremely high prevalence of P. aeruginosa amongst CF patients?  
Niche or deterministic community assembly states that taxa exist in a community 
because they have specific traits which allow them to exploit the available resources. 
The inclusion of the individual‟s fitness in niche theory means that predictions can 
be made on the composition of the community at a given time point or under certain 
conditions. In CF, evidence for the CFTR genotype affecting microbial distribution 
in the CF lung has been demonstrated (Klepac-Ceraj et al. 2010). CF patients in this 
study were assigned in to three groups; F508del homozygous; F508del heterozygous 
and patients without an F508del allele. The findings of this analysis showed that 
patients who were either F508del homozygous or heterozygous had more similar 
communities than those who had no F508del allele. Likewise, CFTR genotype has 
also been implicated in susceptibility to fungal infections with F508del homo- and 
heterozygous patients being more susceptible to infection by G. argillacea (Giraud et 
al. 2010). Evidence emerging from investigations into the G.I. tract also supports 
niche theory where, in a mouse model, the major histocompatibility complex 
genotype has an effect on the bacterial flora (Toivanen et al. 2001). Furthermore, 
recent work on the infant gut microbiota suggested a largely deterministic 
community assembly process at the phylum level (Trosvik et al. 2010). 
However, CFTR genotype is not the only factor which affects the microbial diversity 
in the CF respiratory tract. Unsurprisingly, antibiotic therapy too affects the 
microbial diversity of the CF lung (Klepac-Ceraj et al. 2010). Patients who were 
receiving long term antibiotic therapy displayed a decrease in overall species 
richness when compared to patients who were not regardless of P. aeruginosa 
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colonisation. However, patients who were receiving long term antibiotic therapy and 
were colonised by P. aeruginosa had a reduced phylogenetic diversity compared to 
those who were not as well as having a more distinct microbial community 
composition from each other.  
One of the major flaws of niche theory is the large amount of factors that need to be 
considered in order to make an accurate prediction in complex microbial ecosystems. 
 
1.7 Interaction in microbial communities 
 
Examining interactions in microbial communities using evolutionary theory has 
received a lot of attention recently, and provides a useful framework for designing 
experiments that examine the social mechanisms of microbes. In broad terms social 
interactions have fitness consequences for the „actor‟ and the recipient and can be 
assigned to one of four classes (West et al. 2007). Mutualism is where there is a 
benefit for both the actor and the recipient which is an act contrary to spite where 
both suffer a loss (West 2006). Selfishness is where the actor benefits to the 
detriment of the recipient and altruism is where the actor sacrifices fitness to the 
benefit of the recipient (West et al. 2006). An example of a spiteful behaviour is 
bacteriocin production because it has a negative effect on the producer (actor) and 
the recipient (Gardner et al. 2004). Bacteriocin producing strains of P. aeruginosa 
have been isolated from the CF lung and it is thought, with a greater understanding 
of microbial interaction, that the frequency of bacteriocin producing strains in the 
population could be manipulated in CF to reduce bacterial virulence (Inglis et al. 
2009).  
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There are numerous types of competition which can be competitive or cooperative in 
nature (Duan et al. 2009). Passive competition is the simple interaction that can 
occur between competing for space in an ecosystem or a particular carbon source. 
Active competition is where one species releases a compound that interferes with the 
process of another to gain an advantage (Duan et al. 2009). Recent work has shown 
that interactions can occur between Candida albicans and P. aeruginosa through 
various signal mediated pathways (Hogan et al. 2004; Cugini et al. 2007). Farnesol, a 
signalling molecule produced by C. albicans, has the ability to repress pyocyanin 
production by P. aeruginosa (Hogan et al. 2004). The ability of P. aeruginosa to 
sequester iron is paramount to its survival and therefore this interaction could be 
exploited to reduce the fitness of P. aeruginosa in-vivo. Cooperative behaviours can 
also be passive or active and are difficult to explain like those found in social 
evolution theory. In both cases, kin selection theory (Hamilton 1964) is cited as the 
main cause. Kin selection theory states that the more closely related two organisms 
are the more likely they are to behave favourably to one another to pass on their 
genes, albeit indirectly, to future generations. Syntrophic relationships are formed 
between bacteria to facilitate the metabolism of a resource from which both bacteria 
benefit (Duan et al. 2009). It may be the case that syntrophic relationships are 
formed between different bacterial taxa in the CF lung which has an effect on the 
spatial distribution of microorganisms in a biofilm resulting in for example, the 
waste products of one organism being utilised by another. In a relevant 
environmental biofilm model of commensalism with Burkholderia and 
Pseudomonas spp., it has been established that the carbon source supplied to the 
bacteria has an effect on the biofilm architecture (Nielsen et al. 2000). When a 
carbon source that could be metabolised by both organisms was supplied, two 
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distinct biofilms were formed. In contrast, when one organism was dependent on the 
other for a metabolic by-product from the initial carbon source the organisms formed 
a mixed biofilm. The ability of metabolites to shape microbial communities is 
becoming an increasingly important area of research in microbial ecology and could 
help us to fully understand which members of the community interact to produce a 
negative impact on overall patient health.  
Recently a medium was synthesised that reflects the nutrients present in the CF lung 
(Palmer et al. 2007). The Synthetic Cystic Fibrosis Sputum Medium (SCFM) was 
formulated by analysis of CF sputum by chromatography to calculate the average 
amount of ions, free amino acids, glucose and lactate from the sputum of 12 adult CF 
patients. This medium could be utilised, with addition of mucin, in both aerobic an 
anaerobic conditions to look at gene expression and or protein expression profiles 
when organisms exist in monoculture and then compared with co-culture and even as 
a whole community. This would give an insight into how microorganisms may 
interact with each other in the CF lung to determine, for example, whether other 
organisms that may colonise the lung can exacerbate virulence in a neighbouring 
species. However, care would need to be taken as there would be no immune factors 
present in the media which may be a factor in the cause of pulmonary exacerbations. 
This could be combated by using a Drosophila model that has been developed to 
simulate CF lung disease (Sibley et al. 2008a). This study established that P. 
aeruginosa strain PA01 was able to cause infection in a Drosophila model. The 
authors then went on to examine the ability of human oropharyngeal flora (OF) 
isolates to cause disease in the flies in monoculture followed by co-culture with 
PA01. Three classes of OF isolate were described, class 1; virulent isolates which 
could kill the flies in monoculture and enhance killing in co-culture with PA01, class 
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2; avirulent strains which could not kill the flies or enhance killing in co-culture and 
class 3; could not kill the flies in monoculture but could enhance killing in co-culture 
with PA01.   
 
1.8 Current knowledge of CF microbial pathogenesis 
 
1.8.1 Bacterial colonisation 
Although classical culture methods have identified a subset of organisms that are 
isolated from the CF lung the advent of molecular techniques that exploit conserved 
regions of the 16S rRNA subunit have unearthed a wealth of organisms that have 
been missed by culture (van Belkum et al. 2000; Rogers et al. 2003; Rogers et al. 
2004; Rogers et al. 2005; Harris et al. 2007; Bittar et al. 2008b; Sibley et al. 2008b) 
The molecular studies show some concordance with culture and find S. aureus, P. 
aeruginosa, S. maltophilia as some of the most commonly isolated bacteria from the 
CF lung (Bittar et al. 2008b). However, they also show the increased prevalence of 
oral Streptococci such as the Streptococcus milleri group (SMG), Prevotella spp. and 
Neisseria spp. as common isolates (Harris et al. 2007). The molecular studies based 
upon 16S rRNA gene have also identified metabolically active anaerobes commonly 
disregarded as merely contaminating mouth flora picked up during expectoration of 
sputum (Rogers et al. 2005). The presence of a large number of microbial taxa from 
the respiratory tract of CF patients, including emerging organisms, such as non-
tuberculosis Mycobacteria, Nocardia spp. and Inquilinus limosus suggests that 
further work remains to determine their role as potential pathogens (Tomashefski et 
al. 1996; Barrio et al. 2008; Bittar et al. 2008a). Members of the Burkholderia 
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cepacia complex (Bcc) are frequently isolated from CF respiratory samples of older 
patients and have been shown to have a negative impact on survival rate (Jones et al. 
2004; Kalish et al. 2006). This group of organisms were first isolated from CF 
sufferers in 1984 (Isles et al. 1984) and are now found in 2.9% of patients (Cystic 
Fibrosis Foundation 2009). However, this number may be a gross underestimate due 
to difficulties in distinguishing between the high number of Gram-negative rods 
isolated from CF based on their colony morphology and difficulties in identifying 
Bcc species based upon their biochemical profiles which means they are commonly 
misidentified or completely overlooked (Larsen et al. 1993; McMenamin et al. 
2000). Infections with Bcc in people with CF are highly transmissible which makes 
it even more important that they are identified early (LiPuma et al. 1990). It is, 
therefore, timely that a multi-locus sequence tag method capable of both species and 
strain identification was devised to ensure that patients colonised with Bcc can be 
isolated from those who are not to reduce the risk of patient to patient transmission 
(Baldwin et al. 2005). The applicability of this technology has been further improved 
with the discovery that it can be applied direct to sputum samples rather than isolated 
colonies, allowing early identification of Bcc in patients who were previously 
deemed uninfected (Drevinek et al. 2010). The severity of Bcc infection varies 
depending on the genomovar. Jones et al. (Jones et al. 2004) showed that acquisition 
of B. cenocepacia (genomovar III) was associated with chronic infection and shorter 
survival time post infection than patients infected with B. multivorans (genomovar 
II) or P. aeruginosa, although both groups infected with Bcc had deaths attributed to 
„cepacia syndrome‟. „Cepacia syndrome‟ is characterised by pyrexia, progressive 
respiratory failure, leukocytosis and an increased erythrocyte sedimentation rate 
(Isles et al. 1984). It was initially thought that „cepacia syndrome‟ had an early onset 
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after initial colonisation but Blackburn et al. (Blackburn et al. 2004) have 
demonstrated that „cepacia syndrome‟ can occur up to 9 years after initial isolation 
meaning that effective treatment strategies for Bcc are urgently needed.  
1.8.2 Fungal colonisation 
 
Many fungal species are frequently isolated from the sputum of CF patients with 
Candida and Aspergillus species being most common (Bouchara et al. 2009). This 
study showed that 70% of patients were colonised with at least one fungal species 
with up to four species being identified in one patient. Duan et al. (2003) have 
shown that recurrent C. albicans infection occurs over a ten year period, suggesting 
that fungi may be capable of chronically colonising the lung. This data is supported 
by the small amount of longitudinal data produced in a later study (Bouchara et al. 
2009). It is now the case that more unusual fungal species are being isolated from the 
CF lung (Cimon et al. 2005). Sudfield et al. (Sudfeld et al. 2010) demonstrated from 
a population of 614 CF patients 10 species of filamentous fungi and two species of 
yeasts, as well as an undefined subset, were isolated. The most prevalent of the 
filamentous fungi was Aspergillus fumigatus which was present in 36.3% of patients 
followed by non-fumigatus species of Aspergillus (26.1%), yeasts were present in 
28.5% of patients but a breakdown of the yeast data was not given due to a change in 
laboratory practice.  
 
1.8.3 Respiratory viral infection  
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Several viral pathogens have been identified in the respiratory tract of CF patients. 
Respiratory syncitial virus (RSV) Influenza virus (A and B), parainfluenza virus, 
adenovirus and rhinoviruses have been detected in several studies and in some cases 
implicated as causative agents of pulmonary exacerbations (Ong et al. 1989; Pribble 
et al. 1990; Armstrong et al. 1998; Hiatt et al. 1999). A recent metagenomic study 
looking at DNA viruses has shown in a small patient cohort that certain eukaryotic 
and prokaryotic viral taxa are associated with CF when compared to healthy 
individuals (Willner et al. 2009). There has also been work done which shows that 
bacteriophage are also present in the sputum of CF patients colonised with P. 
aeruginosa (Tejedor et al. 1982). This study found that seven distinct bacteriophage 
were present in the sputum of seven CF sufferers plus one non-CF sufferer with one 
CF patient having four different bacteriophage isolated. The high diversity of the CF 
lung suggests that these organisms are able to act both synergistically and 
antagonistically to gain an advantage over each other, and possibly more importantly 
the hosts immune defence.  
 
1.9 Biofilm formation in the CF lung 
 
Biofilm formation by bacteria may be a key stage in CF lung disease which 
ultimately leads to chronic infection and respiratory failure due to the protection they 
provide against antimicrobial chemotherapy and the immune system (Stewart & 
Costerton 2001; Leid et al. 2005). P. aeruginosa is a key pathogen in CF that is able 
to attach to CF airway epithelial cells more readily than in healthy individuals 
(Saiman et al. 1992). P. aeruginosa is also able to attach to mucin, which is abundant 
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in the CF lung (Arora et al. 1996; Arora et al. 1998). P. aeruginosa forms biofilms 
with a distinct architecture when bound to mucin as opposed to DNA or glass 
showing reduced motility and increased tolerance to tobramycin which could be due 
to the increased thickness and biomass in the mucin derived biofilm (Landry et al. 
2006). Furthermore, research has found that P. aeruginosa forms tight microcolonies 
when grown in an artificial CF sputum media (Sriramulu et al. 2005). Several genes 
were required for tight microcolony formation and that amino acids were important 
for development of colony morphology, lipopolysaccharide alterations and hyper 
expression of outer membrane pumps (Sriramulu et al. 2005). The architecture of P. 
aeruginosa biofilms has been described as “mushroom” shaped with a hollow pileus 
filled with live motile bacteria and autolysed dead cells and a stipe which consists 
mostly of a solid biofilm matrix (Ma et al. 2009). Thus, data only show P. 
aeruginosa biofilm structure in monoculture and it has been demonstrated that in co-
culture with other CF isolates the architecture of the biofilm can be dramatically 
different. In a flow chamber biofilm model co-culture with S. maltophilia, P. 
aeruginosa biofilm architecture became filamentous like that of S. maltophilia (Ryan 
et al. 2008). The presence of both P. aeruginosa and S. maltophilia in a multispecies 
biofilm demonstrated an increased resistance to polymixins (Ryan et al. 2008). 
Furthermore, it has been shown that P. aeruginosa biofilms from CF airways are 
attached to mucus in the intraluminal space as opposed to attaching directly to the 
epithelium (Worlitzsch et al. 2002).  
H. influenzae also has the ability to bind to mucins present in the airways and it is 
suggested that the mucins protect the respiratory epithelium from invasion (Davies et 
al. 1995). It has also been demonstrated that clinical isolates of H. influenzae have 
the ability to form biofilms on airway epithelial cells with increased resistance to 
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antibiotics (Starner et al. 2006). However, it has been revealed that different clinical 
isolates of H. influenzae form biofilms with varying degrees of success (Murphy & 
Kirkham 2002). The eDNA released into the biofilm matrix during the formation of 
H. influenzae biofilms adds structural stability to the biofilm, but more importantly 
spans channels in the biofilms, through which water and potentially substrates and 
signalling molecules can be transported into the biofilm and waste products 
transported out demonstrating that microbial biofilms have complex structures 
designed to maximise survival (Jurcisek & Bakaletz 2007). 
Fungi have also been shown to have the ability to form biofilms in a human host. C. 
albicans, a common CF isolate, has been shown to form biofilms that increase its 
resistance to antimicrobials (Chandra et al. 2001). The biofilms formed by C. 
albicans are shown to have a similar make-up to those formed by bacteria with a 
cellular component encased in a matrix of extracellular cell-wall like polysaccharides 
(Chandra et al. 2001). A. fumigatus has also been shown to form biofilms with 
reduced susceptibility to antifungal agents on bronchial epithelial cells (Seidler et al. 
2008). With all of these common CF isolates plus many others having the ability to 
form biofilms it would be prudent to investigate how these organisms are spatially 
distributed in the airways of CF patients in order to examine their social behaviour. 
Recently a retrospective study on CF biofilms has demonstrated the need for better 
antibiotic sensitivity testing for CF isolates (Keays et al. 2009). The participants in 
this study were divided into two groups and antimicrobial chemotherapy was 
assigned using susceptibility testing results from planktonically grown cells or cells 
from the same sample in a biofilm. Using the planktonic antibiotic sensitivities 60% 
of patients were treated with combinations that inhibited bacterial growth. However, 
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when the same bacteria were tested using biofilm method only 22% of patients had 
all of their isolates remain susceptible to antibiotics (Keays et al. 2009). 
Furthermore, the patients who had at least one susceptible isolate compared to none 
using the biofilm method had shorter periods of hospitalisation (Keays et al. 2009). 
This study highlights the necessity for routine screening of CF isolates grown in 
biofilms which better match the in-vivo conditions and improve clinical outcomes.  
 
1.10 Acute pulmonary exacerbations? 
 
A pulmonary exacerbation in CF can be defined as changes in many factors such as 
patient wellbeing, cough, dyspnoea, loss of appetite and/or weight and changes in 
spirometric tests (Goss & Burns 2007). It is this vague definition of pulmonary 
exacerbations in CF that makes concordance between studies tackling aetiology and 
treatment difficult. Many studies have attempted to find an absolute definition for an 
exacerbation in CF, a criterion commonly used by authors is administration of 
intravenous (I.V.) antibiotics either in hospital or at home, but a general consensus is 
yet to be reached (Dakin et al. 2001; Rosenfeld 2001; Rabin et al. 2004; Marshall 
2004). In the clinic it is desirable to prevent an exacerbation to reduce the burden on 
hospital facilities and on patient health. Recent research has found that exacerbations 
cause not only a short bout of ill health, but also that over time; they contribute to 
lung function decline (Amadori et al. 2009; Sanders, Bittner, et al. 2010). Pre-
emptive treatment of patients thought to be in the early stages of an exacerbation 
without severe symptoms has been vindicated in adults and children (Sanders et al. 
2010a; Sanders et al. 2010b). Recently, several biomarkers were assessed for the 
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ability to predict the start and resolution of pulmonary exacerbations (Gray et al. 
2010). Serum calprotectin decreased significantly following the resolution of an 
exacerbation and also gave an indication of the duration until the next exacerbation 
(Gray et al. 2010). Routine testing for markers such as this can help to inform the 
treatment given by clinicians and hopefully improve patient outcomes. 
Pulmonary exacerbations in CF are attributed to a number of phenomenon including 
increase in bacterial load, decrease in susceptibility to antimicrobials and acquisition 
of a new organism. In a study on infants with CF, respiratory viruses were identified 
in 52% of cases that required hospitalisation. RSV was the most common agent 
identified (44%) as cause of respiratory disease (Armstrong et al. 1998). Similarly, 
Hiatt et al. (Hiatt et al. 1999) have linked RSV infection in infants with pulmonary 
exacerbations in CF. This study showed that there was an increased incidence of 
hospitalisation in CF patients who presented with RSV compared to controls. 
Although RSV is the most commonly associated viral pathogen in CF pulmonary 
exacerbations, other respiratory viruses have been identified in the respiratory tract 
of CF patients. Influenza virus (A and B), parainfluenza virus, adenovirus and 
rhinoviruses have been detected in several studies (Ong et al. 1989; Pribble et al. 
1990; Armstrong et al. 1998; Hiatt et al. 1999). Pribble et al. (1990) looked at 
pulmonary exacerbations in older patients with CF and identified Influenza virus (A 
and B) as the most common viral pathogen. Pribble et al. (1990) also went on to 
demonstrate that infection with Influenza virus was associated with decrease in lung 
function compared with patients with non-Influenza viral infection or patients with 
no viral infection. Willner et al. (2009) has shown that the functional genes present 
in the viral communities were distinct between CF and non-CF patients suggesting 
that the available resources and selective pressures may be a cause of respiratory 
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problems in CF. It would be interesting to note the differences in functional genes 
between clinically stable specimens and those collected when a patient is having an 
acute pulmonary exacerbation.  
Another theory for the cause of pulmonary exacerbations in CF is increased density 
of P. aeruginosa (Regelmann et al. 1990). In this study, it was shown that during an 
exacerbation, treatment with antibiotics prevented proliferation of P. aeruginosa 
which resulted in increased lung function, a similar story to that seen in the clinic. 
Evidence suggests that viral infection facilitates bacterial colonisation of the lung in 
CF patients. Armstrong et al. (1998) found that 35% of hospitalised patients who had 
an exacerbation acquired P. aeruginosa in the following 60 months, compared to 6% 
of non-hospitalised patients. Similarly, Collinson et al. (1996) found that 32% of 
children acquired a new bacterial species following a viral infection. Most of these 
new bacterial species (10/12) were isolated during or within three weeks after an 
upper respiratory tract infection. The organisms isolated were P. aeruginosa (6/12), 
H. influenzae (4/12), S. aureus (1/12) and B. cepacia (1/12).  
If viral infection is able to disrupt the microbial community it is a logical possibility 
that a new bacterial or fungal pathogen may also be able to disrupt the flora of the 
CF lung. A recent paper has possibly identified such a group of organisms, the SMG 
(Sibley et al. 2008b). It was recently shown that the organisms that make up the 
SMG have been found in CF patients only when presenting with an exacerbation and 
that treatment of these organisms can alleviate the symptoms upon eradication of the 
SMG (Sibley et al. 2008b). However, this was only a small study and further 
investigations in larger patient cohorts are required. It has been shown that the gene 
expression pattern of P. aeruginosa can be altered when present in co-infection with 
a member of the OF (Duan, 2003). This study demonstrated that a member of the 
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genus Streptococcus isolated from a CF sputum sample that would be considered OF 
in the presence of P. aeruginosa had the capacity to significantly increase lung 
damage without increasing P. aeruginosa load. The genes that were increased 
include several virulence factors such as lasB which encodes the virulence factor 
elastase. All of these theories regarding pulmonary exacerbations have credence and 
it may be the case that each of these mechanisms individually has the potential to 
trigger an exacerbation event. Alternatively, several of these factors may occur 
simultaneously or as part of a series of events that results in the initiation of an 
exacerbation. For example, recent research has found that rhinovirus infection causes 
biofilm dispersal in mucoid isolates of P. aeruginosa which stimulates a greater 
proinflammatory response which may result in an exacerbation (Chattoraj et al. 
2011). 
Shifts in microbial diversity may be able to cause exacerbation in CF. Similarly, in 
the vaginal ecosystem an increase in the diversity of the vaginal microbial 
community is associated with bacterial vaginosis (BV) with members of the phyla 
Actinobacteria and Bacteroidetes strongly associated with the disease community 
(Oakley et al. 2008). A change in microbial diversity causing disease is not 
sequestered to BV; it is also prevalent in oral and gastrointestinal disease states. In 
patients with ulcerative colitis (UC) the microbial community contained greater 
numbers of Bacteroides and Prevotella species than healthy individuals (Lucke et al. 
2006). Furthermore, a change in microbial diversity may be facilitated by invasion of 
the lung by a reservoir of pathogenic species in the oral cavity. Poor oral hygiene 
practices have been found to cause colonisation of the lower respiratory tract with 
potential pathogens in cases of pneumonia (Pugin et al. 1991; Abe et al. 2005). 
Therefore, a rigorous oral hygiene routine would reduce the abundance and diversity 
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of oral microbial taxa potentially reducing the likelihood of LRT infection and 
possibly pulmonary exacerbations in CF patients. However, care needs to be taken 
when choosing oral hygiene practice as some oral hygiene products are not sterile 
(Kutty et al. 2007). Kutty et al. (2007) have shown that alcohol free mouthwash was 
contaminated with B. cenocepacia which has a negative impact on the life 
expectancy of CF patients (Isles et al. 1984). 
 
1.11 Treatment of exacerbations  
 
Currently, CF patients suffering from pulmonary exacerbations are hospitalised and 
administered I.V. antibiotics based upon the results of planktonically grown isolates. 
A recent study has identified that antibiotic sensitivity testing using planktonic 
cultures provides an inaccurate analysis of the susceptibilities of the bacterial cells 
in-vivo (Keays et al. 2009; see above). The patients in this study who were suffering 
an exacerbation and had at least one biofilm susceptible isolate had better clinical 
outcomes than those who had no biofilm susceptible isolates (Keays et al. 2009). The 
Calgary biofilm device used in this study has been recently validated for use on 
whole sputum rather than individual isolates (Spasenovski et al. 2010). This 
development, if combined the serial sputum induction method (Rogers et al. 2010) 
could allow for „community antimicrobial susceptibility assays‟ which could make 
allowances for the interactions that occur between bacteria when put under stress. 
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1.12 Microbial ecology techniques 
 
Most microbial ecology techniques utilise PCR of the 16S rRNA gene, which 
contains highly conserved regions across the domain bacteria and hypervariable 
regions that can be used to resolve the differences between species of bacteria in 
some cases. These techniques were first used to describe the bacterial communities 
inhabiting environmental samples such as soil (Muyzer et al. 1993; Liu et al. 1997). 
More recently, however, terminal restriction fragment length polymorphism (T-
RFLP), length heterogeneity PCR (LH-PCR), clone libraries, phylochip and next 
generation sequencing have all been applied to investigate the polymicrobial nature 
of the CF lung (Rogers et al. 2003; Bittar, Richet, et al. 2008; Klepac-Ceraj et al. 
2010; Armougom et al. 2009). T-RFLP, LH-PCR and DGGE are examples of 
communities fingerprinting techniques. T-RFLP analysis of bacterial communities 
requires the 16S rRNA gene to be amplified by PCR using dye labelled primers and 
the resultant fragment to be digested using a restriction enzyme. The digested 
fragments are then passed through a gel along with a size standard and the length of 
the labelled (terminal) end of the fragment can be measured (Liu et al. 1997). The 
fragments produced are of differing length due to the hypervariable regions of the 
16S rRNA gene, allowing for the discrimination of different species. The advantage 
of this technique is that in-silico analysis can be used to select for the restriction 
enzyme with the best resolving power. Furthermore, T-RFLP is seen to be a 
relatively in-expensive technique after the initial outlay required for the equipment 
and in-silico analysis can provide the user with putative species identities based upon 
the fragment length. However, in some cases, different bacteria from the same genus 
32 
 
and sometimes different genera can produce fragments of equal length, thus, 
preventing the allocation of definitive species identities (Rogers et al. 2004).  
Clone library studies remain the gold standard in microbial ecology studies as they 
can be used to amplify fully length16S rRNA fragments which can then be cloned 
into a suitable vector using competent E. coli followed by Sanger sequencing to give 
greater confidence when calling taxa to the species level when compared to 
fingerprinting techniques which only utilise a portion of the 16S rRNA gene (Harris 
et al. 2007). However, a major drawback to clone library studies is determining the 
proportion of the community that has been sampled. For example, Dunbar et al. 
(2002) sampled bacterial populations from four Arizona soils using clone libraries. 
In all four soil samples Acidobacteria accounted for approximately 50 % of clones 
where as there are many divisions which account for less than 5 % of clones. Dunbar 
et al. (2002) estimate that in order to define the most abundant 50 % of bacteria in a 
population containing 4,000 species then a clone library would need to sample 
285,400 individual clones per soil to obtain a ≥ 95 % confidence limit. The drawback 
of this type of analysis is that the financial costs to fully elucidate a community of 
this size would be astronomical. One potential way of reducing the cost is to screen 
the clones prior to sequencing using restriction enzymes (Harris et al. 2007). This 
method allows the researcher to assess the relative abundance of particular taxa by 
counting the number of clones with a given RFLP pattern but only sequencing one 
clone from each RFLP type. However, due to the conserved nature of large portions 
of the 16S rRNA gene and the choice of restriction enzymes this method can still 
underestimate the total community diversity. 
Recently, new molecular methods such as microarray and pyrosequencing have been 
utilised for microbial ecology studies. DNA microarrays, such as the Phylochip, 
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have been produced that can resolve up to 8,000 bacterial species based upon 
positive and negative binding of oligonucleotide probes complementary to the 16S 
rRNA gene (DeSantis et al. 2007). These studies can identify up to two orders of 
magnitude greater species diversity in a given sample than molecular finger printing 
techniques and at the fraction of the cost of a comprehensive clone library (Cox et 
al., 2010). However, microarrays represent a „closed system‟ of identification where 
the potential member species are selected a priori. Furthermore, many researchers 
use these microarray studies for microbial community analysis but still feel that the 
taxa can only be resolved to the genus or family level. In pyrosequencing reactions, 
16S rRNA genes are amplified using primers with an 8bp barcode sequence attached 
to the 5‟ end so that the sequences can be assigned to a given PCR reaction post 
pyrosequencing (Acostamartinez et al. 2008). These bar-coded fragments are bound 
to beads and dNTPs are added sequentially to the reaction mix and are incorporated 
into the target strand by DNA polymerase (Ronaghi 2001). This reaction produces a 
pyrophosphate which is equivalent to the number of dNTPs incorporated into the 
complementary strabd by the DNA polymerase. The pyrophosphate is then 
converted to ATP by an ATPase and the ATP is used to convert luciferin to 
oxyluciferin which produces light. The amount of light produced is proportional to 
the amount of pyrophosphate and therefore the number of dNTPs incorporated into 
the sequence. The excess dNTPs are removed by an apyrase enzyme and then the 
next dNTP is added and this cycle is repeated until the reaction is complete (Ronaghi 
2001). This technique has similar drawbacks to clone library where the number of 
fragments to be sequenced to fully identify the community can only be determined 
after the reaction. Furthermore, the size of the fragments that can be analysed by the 
currently available instrumentation is only ~500bp meaning that fully length analysis 
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of the 16S rRNA gene is not possible, resulting in taxa being identified to the genus 
level (Armougom et al. 2009). One advantage of pyrosequencing to microarray is 
that it is an open system so currently unidentified taxa can be detected using this 
technique. Furthermore, a greater amount of data can be gained by pyrosequencing at 
a fraction of the cost of clone libraries which, with further development of the 
technology may allow for full length 16S rRNA sequencing which means that 
pyrosequencing may replace clone libraries as the gold standard in the years to come.   
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2. Aims and objectives 
 
The aim of this research was to characterise the intrinsic and extrinsic factors which 
have an effect on bacterial and fungal communities present in the CF lung in a cohort 
of patients who were homo- or heterozygous for the F508del CFTR allele. 
Furthermore, the aim was to follow these patients longitudinally to determine the 
stability of the CF lung microbiota, to determine the effects of antibiotic therapy, and 
to assess if any changes occurred in the CF lung during times of pulmonary 
exacerbation which could be identified as the causative agent. 
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3. Methods 
 
3.1 Culture of common CF isolates 
 
Common bacterial isolates from CF patients were cultured in order to construct a 
“ladder” of known organisms that could be loaded onto a DGGE gel along with 16S 
rRNA fragments from sputum samples. The isolates were taken from the National 
collection of typed cultures (NCTC), Laboratory of Microbiology, University of 
Ghent (LMG) or fully identified wild type strains from the Freeman hospital (FRH). 
No. Species Reference 
1 Pseudomonas aeruginosa NCTC 10662 
2 Staphylococcus aureus NCTC 6571 
3 Stenotrophomonas maltophilia NCTC 10257 
4 Haemophilus influenzae NCTC 11931 
5 Burkholderia cepacia LMG 17997 
6 Burkholderia multivorans LMG 17588 
7 Burkholderia cenocepacia LMG 18828 
8 Burkholderia stabilis wild strain FRH 18870 
9 Burkholderia vietnamiensis LMG 10929 
10 Burkholderia dolosa LMG 18941 
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11 Achromobacter xylosoxidans wild strain FRH 604914 
12 Pseudomonas fluorescens NCTC 10688 
13 Ralstonia pickettii NCTC 11149 
14 Peptostreptococcus anaerobius NCTC 11460 
15 Streptococcus oralis NCTC 11427 
H. influenzae was cultured on NADsens agar (Appendix 2) at 37 ºC in a static 
incubator with 5 % CO2 saturation overnight. All other organisms were inoculated 
onto Luria-Bertani (LB) agar (Appendix 1) and incubated overnight at 37 ºC in 
aerobic conditions except for S. oralis which was grown in anaerobic conditions. The 
colony morphologies were checked by eye to ensure pure growth and a single colony 
was inoculated into LB broth overnight at 37 ºC except H. influenzae which was 
inoculated into NADsens broth and incubated overnight in a microaerophilic 
environment. The broth was checked for pure growth by inoculating agar plates (as 
described above) with 10 µL of culture. The broths were subsequently used for DNA 
extraction.  
 
3.2 Collection of sputum samples 
 
Spontaneously expectorated sputum samples were collected from patients attending 
an adult CF clinical at the Royal Victoria Infirmary, Newcastle upon Tyne and taken 
directly to the microbiology department at the Freeman Royal Hospital, Newcastle 
upon Tyne where they were immersed in RNAlater® (Ambion) and stored at 4 ºC 
prior to nucleic acid extraction. The samples were washed three times with 
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phosphate buffered saline to remove any contamination from oral flora (Rogers et al. 
2006) and the viscous bolus of sputum was digested with Sputasol (Oxoid) by 
mixing equal volumes of sputum and Sputasol. 
 
3.2.1 Sample collection for sample handling study 
 
Five spontaneously expectorated sputum samples were collected from adult patients 
attending a CF clinic and were immediately divided into two equal aliquots. One set 
of aliquots were immediately treated with RNAlater® (Ambion), which is 
bacteriostatic, and stored at 4 °C. The second set of aliquots were initially incubated 
at room temperature (20 °C) for 24 hours. After 24 hours these aliquots were treated 
with RNAlater® (Ambion) and RNA extraction was then performed on all aliquot 
samples.  
 
3.2.2. Sample collection for assessment of intrinsic and extrinsic factors study 
 
Twenty-nine spontaneously expectorated sputum samples were collected from a 
clinically stable adult population were stored at -20˚C prior to DNA extraction and 
routine microbial culture. Information regarding patient gender, age, CFTR 
genotype, forced expiratory volume in one second and the percentage predicted 
(FEV1 % predicted), body mass index (BMI) and oral antibiotic therapy. 
Subsequently, results from routine microbiology were also obtained (Appendix 11). 
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3.2.3 Sample collection for temporal stability of the CF lung microbiota 
 
From the initial 29 patient cohort, eighteen patients, who were considered to be 
frequently presenting at the clinic with exacerbations, were enrolled in the study and 
gave a total of 149 (Mean 8.3 sample/patient; Range 4 – 16) spontaneously 
expectorated sputum samples across a 20 month time period from October 2008 to 
July 2010. After expectoration the samples were stored at -20˚C until processed. 
Information regarding the patients‟ age, gender, CFTR genotype, clinical status, 
FEV1 % predicted, oral and I.V. antibiotic therapy and results from microbial culture 
were collected. The patients‟ clinical status was classified as Stable, exacerbation 
and Routine I.V. (Appendix 12). An exacerbation was defined as deterioration in 
their clinical status with an increase in cough, sputum or chest symptoms, and/or a 
fall in FEV1 and was subsequently treated with I.V. antibiotics, except in one 
instance where the patient received oral antibiotics for treatment of the exacerbation. 
Furthermore, when using cluster analysis to determine if patients who presented with 
an exacerbation had a characteristic bacterial community, routine I.V. samples were 
classified as stable because they had not qualified as exacerbation as defined above. 
All patients survived until the end of the study period except patient 13. 
 
3.3 DNA extraction (UltraClean™ Microbial DNA isolation kit) 
 
A 1.8 mL aliquot of broth or Sputosol treated sputum was pipetted into a sterile 
microfuge tube and centrifuged at 10,000 x g for 30 seconds. The supernatant was 
discarded and then centrifuged for a further 30 seconds at 10,000 x g. The remaining 
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supernatant was aspirated making sure that the cell pellet was undisturbed. The pellet 
was reconstituted in 300 µL MicroBead solution and vortexed gently for 10-15 
seconds and then transferred to a MicroBead tube. Microbead solution is a cell lysis 
buffer which contains guanidine thiocyanate. A 50 µl aliquot of solution MD1 was 
added then the mix was heated at 65 ºC for 10 minutes. Solution MD1 is a cell lysis 
buffer which contains SDS to breakdown fatty acids and lipids which make up the 
cell membrane. The MicroBead tube was secured in a flat pad vortex head (MoBio) 
and vortexed at full speed for 10 minutes to mechanically lyse the bacterial cells. 
The MicroBead tubes were centrifuged at 10,000 x g for 30 seconds at room 
temperature and the supernatant (~300-350 µL) was transferred to a sterile 
microfuge tube. 100 µL of solution MD2 was added, the mix was vortexed for 5 
seconds, and then incubated at 4ºC for 5 minutes to precipitate cell debris and 
protein. The resulting suspension was centrifuged at room temperature for 1 minute 
at 10,000 x g to separate the liquid phase (DNA) from the solid phase (cell debris). 
The entire volume of supernatant (~450 µL) was pipette into a sterile microfuge tube 
ensuring that the pellet is not disturbed then 900 µL of solution MD3 was added to 
the supernatant and vortexed for 5 seconds. Solution MD3 is a high salt solution 
which facilitates DNA binding to the silica membrane of the spin filter. Then 700 µl 
of the supernatant mix was passed through a 0.22 µm filter and pipetted into a spin 
filter and centrifuged at 10,000 x g for 30 seconds and the flow through discarded. 
The remaining supernatant was added to the spin filter and centrifuged for a further 
30 seconds at 10,000 x g and the flow through discarded. 300 µL of solution MD4 
was added to the spin filter and centrifuge at 10,000 x g for 30 seconds to clean the 
DNA bound to the spin filter membrane by removing excess salt and other 
contaminants. The flow through was discarded and the empty spin filter was 
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centrifuge at 10,000 x g for 1 minute to remove any residual MD4 that may remain. 
The spin filter was transferred to a sterile microfuge tube and 50 µl of solution MD5, 
a low salt solution, was pipetted directly onto the centre of the spin filter membrane 
and centrifuged for 30 seconds at 10,000 x g to elute DNA from the spin filter 
membrane. The eluate was stored at -20 ˚C before use in downstream reactions. 
 
3.4 RNA Extraction from sputum (UltraClean™ Microbial RNA isolation kit) 
 
A 1.8 mL aliquot of Sputasol (Oxoid) treated sputum was added to a microfuge tube 
and centrifuged at 10,000 x g for 30 seconds. The supernatant was decanted and 
centrifuge at 10,000 x g for a further 30 seconds. The remaining supernatant was 
aspirated ensuring that the cell pellet remained undisturbed. The pellet was 
reconstituted in 300 µL of solution MR1 and vortexed gently for 10-15 seconds and 
the resulting mix was transferred to a MicroRNA bead tube. Solution MR1 is a lysis 
buffer used to lyse cells and inhibit RNases. 15 µL of solution MR2 was added to the 
mix and vortexed briefly to homogenise. Solution MR2 contains dithiothreitol which 
will further inhibit RNase activity. The solution was heated to 65 ºC for 10 minutes. 
Heating at 65˚C makes the cells more amenable to lysis and causes shearing of the 
genomic DNA to prevent contamination of the final RNA eluate. The MicroRNA 
bead tube was secured in a flat pad vortex head and vortexed at full speed for 10 
minutes to mechanically lyse the cells. The MicroRNA bead tubes were centrifuged 
at 10,000 x g for 30 seconds and the supernatant (~300-350 µL) was transferred to a 
sterile microfuge tube. 500 µL of buffer MR3 was added to the supernatant and 
vortex for 5 seconds then 250 µL of buffer MR4 was added, the solution vortexed 
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for 5 seconds, then incubated at 4 ºC for 5 minutes. Solution MR3 and MR4 
precipitate proteins and facilitate binding of the RNA to the silica membrane of the 
spin filter. The mix was centrifuged at 10,000 x g for 1 minute to separate the solid 
phase from the liquid phase. The liquid phase was passed through a 0.22 µm filter in 
to a sterile microfuge tube ensuring that the solid phase is not disturbed to remove 
any potential pathogens that have not been lysed. A 650 µL aliquot of the liquid 
phase was added to a spin filter and centrifuged at 10,000 x g for 30 seconds. The 
flow through was discarded and the previous step was repeated with the remainder of 
the liquid phase. 300 µL of Solution MR5 was added to the spin filter and 
centrifuged for 30 seconds at 10,000 x g to removes excess salts and some 
contaminants. The flow through was discarded and the spin filter was centrifuged for 
1 minute at 10,000 x g to remove any residual solution MR5. The spin filter was 
placed into a sterile microfuge tube and 50 µL of RNase free water was pipetted 
directly onto the centre of the spin filter membrane which was then centrifuged at 
10,000 x g for 30 seconds. The spin filter was discarded and the eluate was stored at 
-20 ºC, before use in downstream reactions.  
 
3.5 Reverse transcription 
 
A 10 µL aliquot of RNA was pipetted into a PCR tube along with 1 µL of dNTPs 
(New England Biolabs; 25 mM) and 1 µL of random hexamer primers (QIAGEN; 
0.4 µg/µL) and heat the mixture to 65 ºC for 5 minutes. Then chill the mixture on ice 
and add 4 µL of 5x first strand buffer, 2 µL of Dithiothreitol (0.1 M) and 1 µL of 
RNaseOUT™ (Invitrogen; 40 U/µL) and mix by pipette. Incubate the mixture at 25 
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ºC for 2 minutes and add 1µL of Superscript™ II RT (200 U) and mix by pipette. 
Incubate the mixture at 25 ºC for 10 minutes, 42 ºC for 50 minutes and 70 ºC for 15 
minutes. The cDNA is now ready to be used in a PCR reaction. 
 
3.6 Routine culture of CF sputum samples 
 
Sputum samples were cultured by routine pathology using the Health protection 
agency recommendations (Health protection agency 2009). Briefly, a bolus of 
sputum was incubated with an equal volume of Sputosol (Oxoid) and vortexed until 
liquid. A 10 µL aliquot of the liquid sputum was diluted in 2 mL of sterile saline and 
used to inoculate blood, chocolate and chocolate bacitracin agar plate and incubated 
at 37 ˚C in a microaerophilic atmosphere for 48 hours to detect H. influenzae, 
Moraxella catarrhalis, S. aureus and Streptococcus pneumoniae. The sputum-saline 
mix was also used to inoculate a mannitol trehalose salt and a cysteine lactose 
electrolyte deficient agar plate and incubated at 37 ˚C for detection of S. aureus and 
Enterobacteriaceace or Pseudomonads respectively. The early identification of 
members of the Bcc requires inoculation of the sputum onto a Burkholderia cepacia 
selective agar plate which is incubated at 30 ˚C for five days. Sputum samples from 
CF patients are routinely screened for fungi by inoculating a Sabouraud agar plate 
and incubating it at 35 ˚C for five days. Any clinically relevant isolates were sub 
cultured for antibiotic sensitivity testing using the disc diffusion method. 
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3.7 Polymerase chain reaction 
 
3.7.1 Bacterial 16S rRNA amplification 
 
PCR amplification of the V3 region of the bacterial 16S rRNA gene was performed 
to analyse the bacterial community of CF sputum samples. The primers used are V3f 
(5‟- CCT ACG GGA GGC AGC AG-3‟) and V3r (5‟- ATT ACC GCG GCT GCT 
GG-3‟) (Muyzer et al. 1993). In order to run the products on DGGE the PCR 
products from the initial reaction are re-amplified in a second round of PCR using 
the above forward primer with a 40 bp GC-clamp (5‟-CGC CCG CCG CGC GCG 
GCG GGC GGG GCG GGG GCA CGG GG G GCC-3‟) attached to the 5‟ end. The 
reaction was performed with 0.5 mM each primer 1x EX-Taq buffer, 0.3 mM each 
dNTP, 1 mM of MgCl2, 500 mg BSA, 1.25 U Ex-Taq (Takara) and 1 µL of gDNA or 
cDNA template made up to 50 µL with sterile 18.2 MΩ/cm H20. The cycling 
conditions used were an initial denaturation for 5 min at 95 ˚C followed by 20 cycles 
of 95 °C for 1 min, 65 °C (-0.5 °C per cycle) for 1 min and 72 °C for 30 s followed 
by 15 cycles of 95 °C for 1 min, 55 °C for 1 min and 72 °C for 3 min with a final 
extension at 72 °C for 30 min. A negative control was setup for all PCR reactions to 
ensure that the reaction mix and components were not contaminated. The 30 minute 
final extension step was included in all PCR cycles that were to be analysed by 
DGGE to prevent visualisation of spurious double bands which would hinder 
accurate analysis of the gel images and make excision of bands difficult (Janse et al. 
2004). 
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3.7.2 Fungal 28s rRNA amplification 
 
PCR amplification of the fungal community of sputum was amplified using PCR 
primers specific for the 28s rRNA region of the fungal genome. The primers used 
were U1 (5‟-GTGAAATTGTTGAAAGGGAA-3‟) and U2-GC (5‟-CGC CCG CCG 
CGC GCG GCG GGC GGG GCG GGG GCA CGG GGG GGA CTC CTT GGT 
CCG TGT T -3‟) (Sandhu et al. 1995). The reaction was performed with 0.5 µM 
each primer 1x Ex Taq buffer, 0.3 mM each dNTP, 1 mM of MgCl2, 500 mg BSA, 
1.25 U Ex Taq (Takara) and 1 µL of cDNA template, the reaction was made up to 50 
µL with sterile 18.2 MΩ/cm H20. The cycling conditions used were an initial 
denaturation for 5 min at 95 ˚C followed by 10 cycles of 95 °C for 1 min, 60 °C (-1 
°C per cycle) for 1 min and 72 °C for 30s followed by 25 cycles of 95 °C for 1 min, 
50 °C for 1 min and 72 °C for 30 s with a final extension at 72 °C for 30 min (Janse 
et al. 2004). A negative control was setup for all PCR reactions to ensure that the 
reaction mix and components were not contaminated. 
 
3.7.3 Confirmation of successful PCR 
 
A 1% (w/v) agarose gel was prepared to confirm that PCR had been successful by 
electrophoresis of the PCR product. 0.3 g of agarose (Melford) was added to 30 mL 
1x TAE (Appendix 3) and boiled until fully dissolved. The agarose was cooled to 
approximately 50 ºC then 5 µL of SYBR Safe (Invitrogen; 10,000x) was added to 
the molten agarose, mixed, and poured into the gel cast and left to set. The agarose 
gel was submerged in 1x TAE and a 5 µL aliquot of PCR product was added to 1 µL 
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of 6x bromophenol blue (Appendix 4), mixed by pipetting, and then loaded in to the 
wells of the agarose gel alongside a 5 µL of Hyperladder 1 (Bioline). The 
electrophoresis tank was connected to a power pack and ran at a constant current of 
120 mA for 20 minutes. The gel was removed from the cast and viewed under U.V. 
light on BIO-RAD gel doc 2000 using quantity one™ software (v4.1.1.)  to confirm 
presence of pure PCR product of correct size by comparison with fragments from 
Hyperladder 1. Hard copies were produced using Mitsubishi Video copy processor 
(Model P91 attached to gel doc). 
 
3.8 Denaturing gradient gel electrophoresis (DGGE) 
 
3.8.1 Assembly of gel cast 
 
Glass plates used for DGGE were cleaned using ethanol before use to remove any 
residue that may interfere with the gel casting. The spacers used to separate the glass 
plates had a thin film of silicon grease applied to the inner edges to prevent leakage 
of the denaturant during the run (Brinkhoff & van Hannen 2001). The large glass 
plate (20 cm x 16 cm) was placed on the bench and spacers were aligned with the 
outside edge of the plate. The small glass plate (16 cm x 16 cm) was placed on top of 
the spacers ensuring that they remain aligned. The plates were secured in plastic 
brackets with the arrows facing towards the glass plates. The brackets were stood 
upright and the alignment card was inserted between the glass plates to ensure the 
spacers were correctly aligned. The brackets were adjusted so that there is resistance 
when the alignment card is removed. If two gels were to be electrophoresed on the 
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same run then repeat as described above, if only one gel was ran then a balance plate 
was setup as above without the spacers to prevent the buffer leaking from the upper 
chamber during electrophoresis.  
 
3.8.2 Casting the gel 
 
The gel cast was clamped in the gel cast stand and a 19 gauge needle fitted with a 
tube and Y-fitting was attached to the centre of the plates. Two plastic 50 mL tubes 
were stood in a rack and labelled high and low and the reagents described below 
were added to the tubes, the lids secured, and inverted to mix. 
 
Reagent High Low 
DCODE dye (Appendix 4) 100 µL 0 
Denaturing solution 
(Appendix 5) 
25 mL  25 mL  
APS (10% w/v)  216 µL 216 µL 
TEMED 21.6 µL 21.6 µL 
 
A syringe with rubber tubing was used to draw 16 mL of solution from the tube 
labelled high and was then attached to the Y-fitting, this was repeated with a 
different syringe for the low solution. The syringes were secured in a Model 475 
gradient former and the cam wheel was turned to dispense the solutions into the gel 
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cast ensuring that the gel stream runs in a straight line for an equal gradient. Once 
the solutions had been dispensed into the cast the needle was removed and a 16 well 
comb was put into the gel cast. 
 
3.8.3 Running the gel 
 
The buffer used for DGGE was made up with 140 mL of 50x TAE (Appendix 3) in 7 
L of distilled water in the buffer tank. The DGGE control unit was placed in the 
buffer tank, the thermostat was set to heat the buffer to 60 ºC and the stirrer was 
switched on. Once the buffer had come to temperature the control unit was removed 
and the gel casts were lowered into the buffer chamber ensuring the red mark is on 
the right hand side and then the upper chamber was filled with the buffer. A 15 µL 
aliquot of sample was mixed with an equal volume of 2x DGGE loading buffer 
(Appendix 4) and loaded onto gel. The DGGE control was replaced and left until the 
temperature had returned to 60 ºC. The power pack was set to 200 V for 4.5 hours 
for bacterial community analysis or 70 V for 17 hours for fungal community 
analysis. 
 
3.8.4 Staining  
 
The gel cast was removed from the buffer tank and the cast was disassembled. A 25 
µL of SYBR green I (Invitrogen, 10,000x) was diluted in 250 mL of 1x TAE in a 
staining tank. The gel was removed from the glass plates and submerged in the 
staining solution for 30 minutes on an orbital shaker then the solution was decanted. 
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The gel was de-stained in dH2O to remove any excess stain and viewed under U.V. 
light on BIO-RAD gel doc 2000 using Quantity One™ software (v4.1.1.) and the 
resulting image was captured. 
 
3.8.5 Excision of bands 
 
Bands were excised from DGGE gels whilst exposed to U.V. light once an image of 
the gel had been taken for analysis. The bands of interest were excised using a 
scalpel and placed in a microfuge tube. The bands were immersed in 10 µL of 18.2 
MΩ water and vortexed for 1 minute. The bands were stored at 4 ºC overnight to 
allow DNA to elute from the gel, then vortexed and a 1 µL aliquot of the eluate was 
used in a PCR reaction as described above.  
 
3.9 Sequencing of PCR products 
 
3.9.1 Calculating PCR product concentration 
 
An estimate of PCR product concentration was calculated when confirming 
successful PCR by agarose gel electrophoresis. Hyperladder 1 (Bioline) was used to 
estimate concentrations as it produces bands of a known size and concentration when 
5 µL is loaded onto an agarose gel (Appendix 6). The intensity of the PCR products 
when viewed under U.V. light was compared to the equivalent band in Hyperladder 
1 (Bioline) to get an estimate of the concentration of the PCR products loaded onto 
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the agarose gel.  This value was used to calculate the concentration of the PCR 
product in ng/µL and the concentration required for sequencing (Appendix 6) was 
adjusted by either drying to concentrate or addition of water to dilute taking into 
account the subsequent dilutions. 
 
3.9.2 BigDye® Terminator v1.1 cycle sequencing kit (Applied Biosystems) 
 
Excess dNTPs and primers were removed using ExoSAP-IT (USB) by mixing 5 µL 
of PCR product with 2 µL of ExoSAP-IT and incubated at 37 ˚C for 15 minutes to 
remove dNTPs and primers followed by an inactivation step at 80 ˚C for 15 minutes. 
The product of this reaction was then was used in a cycle sequencing reaction as 
described below (Table 3.1). 
Positive control was set up using pGEM-3Zf (+) as a template and -21 M13 control 
primer (forward) both of which were supplied by the manufacturer. The cycling 
conditions used for the sequencing PCR were an initial denaturation at 96 ˚C for one 
minute followed by 25 cycles of 96 ˚C for 10 seconds, 50 ˚C for 5 seconds and 60 ˚C 
for 4 minutes. The Products from the cycle sequencing reaction were purified using 
ExoSAP-IT (USB) as described above.  
3.9.3 ABI PRISM® 3130 Genetic Analyzer sample electrophoresis 
 
The purified products were desiccated in a vacuum centrifuge so that the correct 
concentration for the sequencing reaction was achieved. The samples were pipetted 
in to 1.5 mL microfuge tubes with lids open into a vacuum centrifuge and dried at 60 
ºC for approximately 30 minutes (until volume is 1-2 µL).  
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Table 3.1. Cycle sequencing reaction setup 
 
 
Reagent 
Positive 
control (µl) 
Negative control 
(µl) 
PCR product 
(µl) 
Ready reaction mix 0.5 0.25 0.5 
BigDye sequencing 
buffer 
1.75 1.875 1.75 
Primer (1 pmol/µl) 2.0 2.0 3.2 
Template 2.0 0.0 3-10 ng 
Sterile 18.2 Ω/cm 
H2O 
5.25 5.875 To 10 µl 
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A 10 µL aliquot of Hi-Di™ Formamide (Applied Biosystems) was added to the 
almost dry sequencing PCR product. The sample was pipetted into a MicroAmp® 
optical 96 well reaction plate (Applied Biosystems) secured in a Plate base 96 well 
(Applied Biosystems). Once loaded a 96 well Plate Septa (Applied Biosystems) was 
used to seal the plate to prevent evaporation of the products during the sequencing 
electrophoresis. The samples were run using a 36 cm capillary array and polymer 
POP-7™ (Applied Biosystems) under manufacturers recommended conditions. The 
sample electropherograms were analysed on SeqScape® software (v2.5) with 
integrated KB™ Basecaller algorithm to generate pure and mixed signal base calls 
with quality values.  
 
3.9.4 NCBI BLASTn search  
 
Any sequences obtained from DGGE band excision and re-amplification was 
compared with known sequences using the NCBI BLASTn tool. All sequences were 
input in FASTA format and the nucleotide collection was used for comparison.  
 
3.10 Statistical analysis of DGGE gels 
 
3.10.1 Bio-Rad Quantity One 
 
The image that was captured in TDS 1-D scan file format using Quantity One 
software was opened. The application tab was then selected and relative quantity to 
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the percentage of bands in lane and relative front (Rf) were selected so that reports 
were generated with the appropriate information. At this stage the image was 
converted so that black bands were set against a white background to obtain a clearer 
image. The background was subtracted from the inverted image manually using a 
rolling ball algorithm so that only peaks relating to bands and not artefacts were used 
for band detection. The lanes of the gel were framed manually so that „smiling‟ or 
„leaning‟ of the lanes could be corrected by creating anchors to shift the frame to 
centralise the bands. Once the frames of the lanes have been manipulated the auto-
detect bands option was used and lane width set to 4.100 mm to prevent overlap 
between lanes for darker bands. The detected bands were then assessed by eye and 
either added or removed using the Create/Remove bands tool. The bands were then 
matched against the DGGE ladder created using reference strains with extra bands 
not included in the ladder being matched manually and repeated until all bands had 
been assigned a band number. An „All Lanes Report‟ was then created which 
contains Lane Number, Band Number and relative quantity which was subsequently 
input into a Microsoft Excel spreadsheet to create a band matrix.  
Once the band matrix was input into the spreadsheet the total intensity for each lane 
was calculated using the autosum formula. The relative intensity of each band was 
normalised by dividing the relative intensity by the total intensity of the lane in 
which the band was present to give a value between zero, indicating no band was 
present in that position and 1, indicating that the band in question accounted for the 
entire intensity found in that lane (i.e. there was only one band present). 
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3.10.2 Quantity One statistical analysis 
 
To determine the variance present in the samples the band matrices were input into 
PAST and a principle component analysis was performed (Hammer et al. 2001).   
 
3.10.3 TotalLab Phoretix 1D and 1D Pro 
 
Images captured using Quantity One were exported in tagged image file format 
(.TIFF) at 276 dots per inch (DPI). A new experiment file was created and the 
appropriate .TIFF files were added. The lanes of the gels were framed using the 
automatic lane creation function and the frames adjusted so that all bands were 
central in the lanes then the changes were accepted. The background from the lanes 
was subtracted using a rolling ball method with a radius of 200 pixels. The detect 
band setting was applied to the gels using the preset conditions then bands were 
added/removed by eye, the band width was also adjusted by eye. The most important 
stage when aligning multiple gels is the Rf calibration function (Tourlomousis et al. 
2010). As stated previously a ladder of known organisms was loaded on each DGGE 
gel in the experiment so that successful gel alignment could be achieved. The bands 
from the DGGE ladder were assigned standard Rf values based upon the distance 
they had migrated through the gel and these were the same for each gel in the 
experiment. A minimum of five bands per standard has been suggested for accurate 
interpolation of multiple gels which was maintained or exceeded throughout our 
bacterial analysis (Tourlomousis et al. 2010). The Rf lines were then manually 
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manipulated to correct for any „smiling‟ or „leaning‟ present in the gel image. The 
final experiment was then saved and closed. 
A new database was created in Phoretix 1D Pro and then the gels analysed in the 
Phoretix 1D programme were added. The alignment of the gels was checked by eye 
using the ladders from multiple gels using the compare lanes function. If the 
alignment was deemed satisfactory then the gels were matched using the ladder lanes 
and the match gel function. Once matched, the software created a band matrix using 
the Rf values of all bands and the relative intensities which is exported to Microsoft 
Excel to be used for further statistical analysis. The band matrix was normalised in 
the same way as the matrix produced using Quantity One. 
3.10.4 Ecological analysis 
 
To examine the structure of the microbial communities present in the CF lung, 
species richness, evenness and Shannon diversity were calculated using the DGGE 
band matrix. Species richness (R) was calculated by simply counting the total 
number of bands present per sample from the DGGE band matrix. The Shannon 
diversity index (H’) was calculated using the formula; 
 
 H’ = -∑ (pilog[pi])  
 
The symbol pi is the relative intensity of each band in a lane. This was calculated 
using the function in Microsoft Excel. Firstly, the log of the relative intensity was 
multiplied by the relative intensity for every band in all of the lanes (pilog[pi]). Then 
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the sum of these values for each lane was taken and multiplied by -1 (-∑) which 
gives the Shannon diversity of the sample. Species evenness (E) was calculated 
using Microsoft Excel by dividing H’ by the log of R.  
 
3.10.5 Raup-Crick Similarity index  
 
The Raup-Crick (SRC) measures the presence/absence of bands between two samples 
where a value of 1 refers to two identical samples and a value of 0 refers to two 
completely unrelated samples. The advantage to the Raup-Crick similarity index is 
that the output generates an indicator of statistical significance where a value of ≤ 
0.05 indicates that the two samples are less similar than would be expected by 
chance and a P-value of ≥ 0.95 indicates that the samples are more closely related 
then would be expected by chance. The probabilities are calculated by 200 pair-wise 
Monte Carlo simulations using PAST programme (Hammer et al. 2001). 
 
3.10.6 Canoco analysis 
 
The band matrix for both bacterial and fungal community analysis was further 
analysed using Canoco (v4.5.1) and images were produced using Canodraw (v4.14). 
Firstly, the normalised band matrices were copied from the Microsoft Excel 
spreadsheet to the clipboard. The information from the clipboard was input into 
Canoco using WCanoImp (4.5.2.0) to convert the data from the band matrices in to a 
format compatible with Canoco. The discrete patient variables were assigned 
positive (1) or negative (0) values and the continuous patient variables were not 
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manipulated before input into the spreadsheet. The band matrices were first analysed 
by detrended correspondence analysis (DCA) using normalised relative intensities 
followed by either redundancy discriminate analysis (RDA) or canonical 
correspondence analysis (CCA) in combination with Monte Carlo permutation 
testing depending on the DCA axis length (<3.5 RDA; >3.5 CCA). The results from 
the Monte Carlo permutations were deemed statistically significant if the P-value 
was < 0.05. The analysed data was then opened in Canodraw and a biplot was 
created for samples and environmental variables. In order to distinguish between 
discrete and continuous variables, discrete variables were assigned a centroid 
whereas continuous variables were represented by an arrow. The other visual 
parameters that were changed on the biplot were that the shape and colour of sample 
points were changed according to important variables. 
 
3.10.7 Sensitivity 
 
The sensitivity for analysis of the applicability of molecular and culture techniques 
was determine using the formula true positive divided by the true positives plus the 
false positive (Sensitivity = TP/ TP + FP). 
 
3.10.8 Dice coefficient measures 
 
The Dice (Sorensen) coefficient was used to compare the temporal stability of 
bacterial communities and was calculated using PAST (Hammer et al. 2001). The 
Dice index gives values between 0 and 1 where a value of 1 between two samples 
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means the two samples are identical. The Dice coefficient measures presence 
absence and does not therefore take into account relative abundance of species. The 
following formula was used to calculate the Dice coefficient; 
 
Dice Similarity = 2M/(2M+N) 
 
Where M is the number of matches and N is the number of taxa in just one column. 
 
3.11 Cloning 
 
3.11.1 Preparation of competent cells 
 
The method for preparation of competent cells was derived from the method of 
Hanahan (Hanahan 1983). 100 µL of JM109 competent cells were inoculated onto 
M9 minimal media supplemented with Vitamin B1 (Appendix 7) and incubated 
overnight at 37 ºC. A single colony was taken from the agar and a starter culture of 5 
ml of LB broth was inoculated with the colony. A 0.5 mL aliquot of the starter 
culture was removed and used to inoculate 50 mL of LB broth (1% v/v). The culture 
was grown in an orbital shaking incubator at 37 ºC and 200 rpm until an OD550 nm of 
0.55 was reached at which point the culture was placed on ice for 30 minutes. The 
culture was centrifuged for 10 minutes at 4 ºC and 2,000 x g after which the 
supernatant was discarded. The cell pellet was resuspended in 4 mL ice cold FSB 
solution (Appendix 8) and incubated on ice for 15 minutes and then centrifuged for 
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10 minutes at 4 ºC and 2,000 x g after which the supernatant was discarded. The 
pellet was resuspended in 720 µL of ice cold FSB solution and 26 µL of Dimethyl 
sulfoxide was added in a drop-wise fashion. The JM109 cells were checked using 
positive control from pGEM-T kit (Promega). Successful preparations found to be 
competent were dispensed into 50 µl aliquots and stored at -80ºC. 
 
3.11.2 Ligation 
 
Ligation reactions were performed as set out according to Table 3.2. The ligation 
reaction(s) were mixed by pipetting and incubated at room temperature for 1 hour or 
alternatively overnight at 4 °C to increase the number of transformants. 
3.11.3 Transformation 
 
Tubes of JM109 High efficiency competent cells were removed from storage (-80 
°C) and thawed on ice for approximately 5 minutes. Subsequently, 2 µL of ligation 
reaction were transferred to a sterile microfuge tube on ice and 50 µL of JM109 cells 
were added to the ligation reaction and mixed by gentle flicking. The tubes were put 
on ice for 20 minutes and then Heat-shocked at 42 °C for 50 seconds and then 
returned to ice for a further 2 minutes. Following this, 950 µL of room temperature 
SOC medium (Appendix 9) was added to the tube and incubated for 1.5 hours at 37 
°C in an orbital incubator with shaking at ~150 rpm. Two JM109 LB plates 
(Appendix 2) were warmed in an incubator at 37 °C for 30 minutes prior to 
spreading a lawn from a 100 µL aliquot of the ligation reaction onto each of the two 
plates which were incubated overnight (16-24 hours) at 37 °C. The presence of white  
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Table 3.2. Ligation reaction setup 
 
Reagent  Positive control  Standard reaction  
2x Rapid Ligation Buffer 5 µl 5 µl 
pGEM-T® Easy Vector 1 µl 1 µl 
PCR product - 3 µl 
Control insert DNA 2 µl - 
T4 DNA Ligase (3 Weiss 
units/µl) 
1 µl 1 µl 
H2O 1 µl - 
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colonies was used as a marker of successful incorporation of the PCR product into 
the plasmid and this was confirmed by restriction digest. 
 
3.12 Plasmid purification - PureYield™ Plasmid Miniprep kit 
 
Antibiotic selection broth (5 mL) (Appendix 2) was prepared and individual broths 
were inoculated with a single white colony from the transformation stage and 
incubated overnight at 37 ºC. Prior to beginning the experiment the cell lysis buffer 
was warmed to 37 ˚C and inverted to dissolve any precipitate. To ensure maximum 
yield was achieved the alternative protocol for larger volumes was used. A 1.5 mL 
aliquot of overnight culture was added in to a microfuge tube and centrifuge at 
13,000 x g for 30 seconds and the supernatant discarded, this step was repeated once 
to process a total volume of 3 mL. The cell pellet was resuspended in 600 µL of 
sterile 18.2 MΩ/cm water and 100 µL of cell lysis buffer was added. The cell lysis 
buffer contains SDS to lyse cell membrane and sodium hydroxide which breaksdown 
the cell wall but also causes DNA to linearise by breaking hydrogen bonds. The tube 
was inverted 6 times until the solution changed from opaque to clear blue. Within 2 
minutes 350 µL of neutralization solution was added and the solution was mixed by 
inversion and a precipitate was formed. The neutralisation solution contains 
potassium acetate which reduces the alkalinity of the solution causing renaturation of 
the plasmid DNA but leaving gDNA insoluble allowing it to be separated from the 
plasmid DNA by centrifugation. The solution was centrifuged at 13,000 x g for 3 
minutes to pellet the precipitate and the supernatant was recovered and placed in to a 
PureYield™ Minicolumn. The column was centrifuged at 13,000 x g for 15 seconds 
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and the flow through discarded. A 200 µL aliquot of Endotoxin removal wash was 
added to the column and centrifuged for 15 seconds, followed by addition of 400 µL 
of column wash solution to the column and a 30 second centrifugation at 13,000 x g. 
The column was removed from the receiver tube and placed in a microfuge tube and 
30 µL of elution buffer was added to the column membrane which was then left to 
stand for 1 minute. The column was centrifuged for 15 seconds and the eluated DNA 
was split in to 10 µL aliquots and stored at -20 ˚C. 
 
3.13 DNA quantification 
 
The DNA concentration of the plasmid extraction(s) was quantified so that 
analogous amounts could be used to calculate the amount required to generate an 
appropriate standard curve for the qPCR reaction and to calculate the amount 
required for a restriction enzyme digest to confirm the correct size fragment was 
incorporated in to the plasmid. The spectrophotometer was blanked with an 
appropriate solution and 5 µL of sample was pipetted in to a cuvette with 65 µL of 
10 mM Tris-HCL pH 7.5. The spectrophotometer was set to read the wavelength 
between 200 nm and 300 nm and the absorbance value at 260 nm was taken to 
calculate the concentration of DNA using the following formula; 
 
[DNA] (µg/mL) = A260nm x DNA coefficient x Dilution factor 
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3.14 Restriction enzyme (RE) digest  
 
Between 0.2-1.5 µg of DNA was used in the RE digest along with 5 U of EcoR1 
(Promega) per µg of DNA; 1x RE buffer; 0.1 mg/mL BSA and made up to 20 µl 
with sterile 18.2 MΩ/cm H2O. The reaction was incubated at 37 ºC for 90 minutes 
followed by a heat inactivation step at 65 ºC for 10 minutes. The glycerol 
concentration was kept below 10% in the final reaction mix so that it did not affect 
enzyme specificity. 
  
3.15 Quantitative PCR (qPCR) 
 
3.15.1 Preparation of qPCR standard curve 
 
The control strains used to prepare qPCR standard curves were cultured and had 
DNA extracted as described above. Conventional PCR was carried out on each strain 
using 1x Buffer I (NEB), 0.5 µM primer, 0.2 mM each dNTP, 1 mM MgCl2, 1 µL 
gDNA made up to 50 µL with sterile 18.2 MΩ/cm H2O under the following 
conditions 97 °C at 3 min for one cycle; 97 °C for 30 s, Annealing temperature (AT; 
Table 3.3) 30 s, 72 °C at 30 s for 30 cycles and a final extension step of 72 °C for 10 
min with successful PCR confirmed by 1% agarose gel electrophoresis as described 
above. The PCR products were cleaned to remove unincorporated dNTPs and 
primers using Exo-SAP-IT as described above and cloned using the p-GEMT easy 
vector cloning kit (Promega).  
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Absolute quantification of the whole or divisions of the microbial community was 
achieved through generation of a standard curve. The first step in the generation of 
the standard curve was to calculate the combined length (bp) of the plasmid and the 
PCR product. The weight of the plasmid was calculated by multiplying the size of 
the plasmid (bp) by the average weight of one bp which is 1.096 x 10
-21
 (g/bp). The 
average weight of one bp was calculated by dividing the average molecular weight 
of a double stranded DNA molecule (660 g) by Avagadro‟s number (6.023 x 10-23). 
The next step was to calculate the mass of plasmid containing the copy number 
needed to achieve a suitable standard curve. The standard curve was prepared to 
quantify between 300,000 and 30 copies/ml in 10-fold dilutions for all primer sets 
except for Eub338/Eub518 which was prepared to quantify between 6,000,000 and 
60 copies/ml also in 10-fold dilutions. Therefore, to calculate the mass of plasmid 
containing the copy number of interest, the mass of the plasmid calculated in stage 
two was multiplied by the desired copy number for the standard curve. Once this 
figure had been achieved the final concentration of the plasmid DNA could be 
calculated by dividing the mass of plasmid required by the volume in the final PCR 
reaction mix. It was then possible to prepare a standard curve by using the formula 
M1V1 = M2V2 where M1 is the final concentration of the plasmid which was 
calculated in the previous step, V1 is the final volume required to achieve the 
concentration which at this stage is unknown, M2 is the concentration of the stock 
plasmid and V2 is the volume in which the plasmid will be diluted. Therefore, the 
equation needs to be rearranged so that V1 can be calculated.  
 
 
 
 
 
65 
 
Table 3.3. Primers used for qPCR assay 
 
 
Primer  Sequence  Target Gene  AT (ºC)  Reference  
Eub 
338 
ACT CCT ACG 
GGA GGC AGC AG 
16S rRNA 65 Lane 1993 
Eub 
518 
ATT ACC GCG 
GCT GCT GG 
Muyzer et al. 1993 
Ps-f GRM CGC TAA 
TAC CGC NTA 
CGT 
16S rRNA 50 Baxter and 
Cummings 2008 
Ps-r TCC TCT CAG 
ACC AGT TAM 
GGA 
HI-IV ACT TTT GGC 
GGT TAC TCT GT 
Outer 
membrane 
protein P-6 
55 Van Ketel et al. 1990 
HI-V TGT GCC TAA TTT 
ACC AGC AT 
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3.15.2 Setup of qPCR reaction mix 
 
Once the standard curve had been prepared using the above protocol the reaction mix 
for the standard curve and reactions could be made. All of the reaction components 
were kept on ice during the reaction setup which was prepared in a PCR 
Workstation™ (C.B.S. Scientific) and pipette filter tips were used to limit the 
potential for contamination. No template controls (NTCs) were setup to ensure that 
all of the reagents, plastics and pipettes used in the reaction were sterile. The 
standard curve, NTCs and unknowns were all setup in triplicate to ensure that the 
protocol had been performed accurately. The qPCR method used herein was as 
described (Baxter & Cummings 2008). Firstly, the plasmid DNA and that of the 
unknowns was heated to 95 °C and held for 10 minutes to ensure that any tertiary 
structures which may have formed had been eliminated so that efficient 
amplification was possible. The plasmid DNA was then used to prepare the standard 
as described above using sterile distilled water as the diluent and filter tips (SLS) to 
reduce the risk of contamination. Once the standard curve dilutions had been 
prepared the reaction mix was prepared ensuring that ABsolute™ QPCR SYBR mix 
(Thermo Scientific) had limited exposure to light to prevent its degradation. The 
final reaction mix contained 1x ABsolute™ QPCR SYBR® Green Mix (Thermo-
Start™ DNA Polymerase, 3 mM MgCl2) , 0.35 mM each primer, 12.5 µg BSA and 5 
µl of DNA in a final volume of 25 µL. The cycling conditions used were an initial 
enzyme activation step at 95 °C for 15 min, then 50 cycles of 95 °C 10 seconds, 
annealing temperature (Table 3.3) for 15 seconds and extension at 72 °C for 20 
seconds on RotorGene RG-3000 instrumentation (Corbett life sciences). Target copy 
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numbers for each reaction were calculated from the standard curve and were used to 
ascertain the number of copies per ml of sputum then log transformed. 
 
3.15.3 Normalisation of qPCR data 
 
The mean copy numbers from the triplicate reactions were calculated using the 
qPCR standard and the value for the refrigerated samples was paired with the same 
room temperature sample and the two values were added together. The 
concentrations for the two temperature conditions were then divided by the two 
values added together to normalise the values and obtain a value between 0 and 1 to 
reduce the noise from biological variance.  
 
3.15.4 One-Way Analysis of variance (ANOVA) 
 
The normalised concentrations from qPCR were then input into Minitab (v16.1.0) 
along with patient number and treatment type input as a number, 1 for fridge and 2 
for room temperature. A One-Way ANOVA was selected with normalised 
concentration as the response and treatment as the factor. This generated a report that 
contained the mean and standard deviation for each treatment as well as a p-value 
depicting the difference between the two means incorporating range. A p-value of 
<0.05 was deemed to be significant.  
 
3.15.5 Pearson product moment correlation 
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Continuous variables (Age, FEV1 % Predicted, Bacterial Shannon diversity, species 
number, community evenness and fungal species richness) associated with qPCR 
were ranked then analysed by Pearson product moment correlation and given P-
values using Minitab 16. Discrete variables (CFTR Genotype, Sex, Pseudomonas 
colonisation and administration of inhaled antibiotics) associated with qPCR, fungal 
or bacterial species number were analysed by One-way ANOVA also using Minitab 
16. A P-value of <0.05 was deemed significant for both tests. 
 
3.16 Ethical Approval 
 
Ethical approval for the project was granted by the School of Applied sciences ethics 
committee at Northumbria University. This included storage of human specimens in 
the secure tissue bank facility within the university. However, this was never utilised 
and samples were stored and processed at the Freeman Hospital.  
Ethical approval for the Freeman Hospital was obtained from County Durham and 
Tees Valley research ethics committee REC (ref 07/H0908/68). The criteria are; 
 
 Such samples would be only those that are sent to the laboratory for 
routine investigation i.e. no additional samples would be requested 
specifically for the study.  
 The additional test(s) performed on the sample would always be 
within the scope of the test that has been requested by the clinician. 
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Test that require specific informed consent e.g. HIV testing would 
not be performed.  
 The fact that extra tests may be performed on patient samples 
would in no way impact  on the routine processing of the samples 
using the standard operating procedures of the laboratory or the 
reporting of results  
 Any data obtained from additional tests would not be reported and 
would not be allowed to impact on patient management in any 
way.  Data would be used solely for the evaluation of methods 
within the laboratory  
 On occasions evaluations may be sponsored by commercial 
companies interested in the performance of new diagnostic 
products.  On such occasions, no patient identifiable data will be 
released to such companies.  
This approach has been approved by our Trust R&D Department and the Chair of the 
Local Ethics Committee. 
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4. Assessment of sample handling practices on microbial activity in sputum 
samples from cystic fibrosis patients 
Abstract 
Aim: The aim of this study was to quantitatively and qualitatively assess the effect 
of sample storage on the metabolically active microbial community found in sputum 
samples from patients with cystic fibrosis (CF). 
Methods: Sputum samples were collected and split in two equal aliquots one of 
which was immersed in RNAlater and refrigerated immediately, the second stored at 
room temperature for 24 h and RNAlater was subsequently added. mRNA was 
extracted and RT-PCR-DGGE and qPCR analysis of the bacterial and fungal 
communities was carried out using CA, RDA, CCA, and Raup-Crick for DGGE and 
One-way ANOVA for qPCR data. 
Results: Significant differences in the bacterial communities between the two 
protocols were observed but there were no significant difference seen in the fungal 
community analyses. Analysis by qPCR demonstrated that room temperature storage 
gave statistically significant increases in Eubacteria and Pseudomonas spp. and a 
statistically significant decrease in those of H. influenzae.  
Conclusions: The analysis of metabolically active microbial communities from CF 
sputum using molecular techniques indicated that samples should be stored at 4˚C 
upon addition of RNAlater to obtain an accurate depiction of the CF lung 
microbiota. Also, storing respiratory samples at room temperature may cause an over 
representation of P. aeruginosa and mask the presence of other clinically significant 
organisms. 
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4.1. Introduction 
 
The airways of cystic fibrosis (CF) patients have been shown by both culture 
dependent (Baltimore et al. 1982; Tunney et al. 2008) and independent methods, 
which do not require prior cultivation of microorganisms, (van Belkum et al. 2000; 
Rogers et al. 2003) to be a complex microbial environment containing many 
different taxa. Analysis of these microbial communities by culture dependent 
methods shows that CF patients are most likely to suffer from infections due to P. 
aeruginosa, S. aureus and H. influenzae respectively (Cystic Fibrosis Foundation 
2009). Culture independent studies are largely in agreement with culture; however, 
molecular studies also show the increased prevalence of Prevotella spp., Neisseria 
spp. and oral streptococci such as the SMG (Harris et al. 2007; Bittar et al. 2008b; 
Sibley et al. 2008b). Comparisons of culture dependent and independent techniques 
have highlighted the limitations of routine microbial culture to unearth the true 
diversity of this environment. This may be due to the fastidious nature of many 
anaerobic bacteria (Bittar, Richet, et al. 2008) or due to heavy growth of P. 
aeruginosa during aerobic culture making isolation of clinically significant 
organisms difficult. Whilst validation and the improving selectivity of routine culture 
still make this the „gold standard‟ for identification of many CF isolates, the use of 
culture independent techniques is becoming increasingly important as a clinical tool. 
Therefore, it is important to assess the effects of sample storage on microbial nucleic 
acids because many studies are multicentre and require shipping of samples from the 
ward to the laboratory which may be on different sites. 
The effect of sample handling and storage on the results of routine microbial culture 
has previously been assessed. It has been demonstrated that storing samples at 4 °C 
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for 48 h yields reproducible results by culture in up to 75 % of samples (Gould et al. 
1996). A recent study showed that these results held true for the predominant 
organism in samples when cultured immediately versus samples stored at 4 °C and at 
20 °C (room temperature) (Pye et al. 2008). However, quantitative culture of the 
samples demonstrated that in 24 % of samples stored at 4 °C there were at least ten-
fold fewer viable organisms compared to 8 % in the samples stored at 20 °C (Pye et 
al. 2008). The findings of Pye et al. (2008) recommends storage of samples at room 
temperature rather than 4 °C, which is now becoming common practice in many 
studies using both culture dependent and independent methods. The effect of sample 
storage on the results of molecular studies is yet to be defined which may have a 
significant effect on the results of such studies, especially when looking at 
metabolically active members by way of mRNA due to the short half life of this 
molecule.  
In this study we hypothesised that storing samples at room temperature skews the 
data set from what would truly be seen in the CF lung. We propose a simple method 
for processing sputum samples to give a more accurate depiction of how the 
microbial community is composed in-vivo.   
4.2 Methods 
A total of five CF patients were selected for this study based upon the volume of 
sputum they had produced so that aliquots were available for both storage conditions 
and routine microbiological culture. The patient group consisted of three males and 
two females with a mean age of 28 at the time of sampling. 
4.3 Results 
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4.3.1 DGGE Ladder 
 
The initial test of the DGGE ladder for bacteria revealed that a denaturing gradient of 
35-55% was insufficient to encompass the organisms regularly isolated from CF 
sputum by culture (Fig. 4.1). Therefore, the denaturing gradient was increased to 35-
65% and the ladder was run again using the same conditions as before (Fig. 4.2). 
This image revealed that the bands from several organisms denatured at the same Rf 
so organisms were removed from the final ladder based upon their suspected clinical 
relevance leaving seven organisms in total (Fig. 4.3). This ladder was run alongside 
the CF sputum samples to give putative identities to the bands present. 
 
4.3.2 DGGE analysis of microbial communities  
 
The DGGE analyses of the bacterial community produced 32 distinct band positions 
(12-22 bands per lane). Qualitative observation showed that refrigerated samples had 
more bands in the top third of the gel (lower GC content) compared to those stored at 
room temperature (Fig. 4.3). Firstly, correspondence analysis demonstrated that the 
samples appeared to be separated by the first axis (Appendix 10). A DCA axis length 
of 0.745 was observed for the bacterial communities. To determine if this finding 
was significant statistical analysis of the band profiles by RDA including Monte 
Carlo permutation testing demonstrated that samples were significantly grouped (P 
<0.002) according to sample storage (Fig. 4.4). Furthermore, the refrigerated sputum 
samples show a greater variance over the y-axis than the samples stored at room 
temperature. In order to investigate the effects on ecological analysis of the bacterial  
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Figure 4.1. Preliminary analysis of the separation of common CF isolates on a 35-
55% denaturing gradient  
Lane 1 ladder Lane 2 P. aeruginosa Lane 3 S. aureus Lane 4 Steno. maltophilia 
Lane 5 H. influenzae Lane 6 B. cepacia Lane 7 B. multivorans Lane 8 B.cenocepacia 
Lane 9 B.stabilis Lane 10 B.vietnamiensis Lane 11 B. dolosa Lane 12 A. 
xylosoxidans Lane 13 P. fluorescens Lane 14 R. pickettii Lane 15 P. anaerobius 
Lane 16 Strep. oralis   
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Figure 4.2. Further test of DGGE ladder and single isolates on a 35-65% denaturing 
gradient  
Lane 1 ladder Lane 2 P. aeruginosa Lane 3 S. aureus Lane 4 Steno. maltophilia 
Lane 5 H. influenzae Lane 6 B. cepacia Lane 7 B. multivorans Lane 8 B.cenocepacia 
Lane 9 B.stabilis Lane 10 B.vietnamiensis Lane 11 B. dolosa Lane 12 A. 
xylosoxidans Lane 13 P. fluorescens Lane 14 R. pickettii Lane 15 P. anaerobius 
Lane 16 Strep. oralis  
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Figure 4.3. DGGE analysis using a 35-65% denaturing gradient showing the effect 
of storage on the bacterial communities of the five patients  
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Figure 4.4. RDA analysis of the bacterial DGGE profiles for the samples stored in 
the fridge and at room temperature  
78 
 
Table 4.1. Comparison between samples handling protocol using Raup-Crick similarity index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fridge Room Temp. 
  
1 2 3 4 5 1 2 3 4 5 
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1 
 
0.84 0.46 0.95 0.38 0.63 0.61 0.73 0.58 0.43 
2 
  
0.77 0.71 0.63 0.85 0.99 0.87 0.57 0.65 
3 
   
0.84 0.65 0.22 0.28 0.90 0.10 0.26 
4 
    
0.81 0.62 0.30 0.66 0.56 0.34 
5 
     
0.47 0.49 0.71 0.23 0.75 
R
o
o
m
 T
em
p
. 
1 
      
1.00 1.00 1.00 0.89 
2 
       
0.99 1.00 0.99 
3 
        
0.99 0.84 
4 
         
0.93 
5 
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community Raup-Crick similarity index was calculated for both storage conditions. 
This analysis found that when comparing the samples stored at 4˚C with each other 
that only one (n = 10) was significant in comparison to seven (n = 10) for the 
samples stored at room temperature (Table 4.1). Furthermore, when  
comparing between the two sample handling protocols only one was significant (n = 
25).  
DGGE analysis of the fungal community gave a total of 17 distinct bands (4-10 per 
lane; Appendix 10). The DCA analysis of fungal DGGE gave an axis length of 
4.450. There was no significant difference between sputum collection protocols as 
determined by CCA (P = 0.180; Appendix 10) but the band intensities were less in 
the samples that were stored at room temperature as compared to those that were 
refrigerated (Fig. 4.5). This difference was demonstrated by CA of the fungal DGGE 
profile which showed a separation of the samples by handling protocol rather than by 
patient (Fig. 4.6). Four bands (F1-F4) were excised, sequenced and deposited in 
GenBank (accession numbers GU001640, GU065334-36 respectively). The NCBI 
BLASTn tool was used to search for closest deposited sequence match. The closest 
related sequences were Candida dubliniensis (FM992695.1) 99%, C. albicans 
(GQ495089.1) 100%, C. parapsilosis (AY497686.1) 99% and Aspergillus fumigatus 
(FM197606.1) 99% respectively.  
4.3.3 Real-time PCR results  
 
Quantification of metabolically active total bacteria and Pseudomonas spp. using the 
mean copy number of the 16S rRNA gene, indicated a greater than 2-fold increase of 
Pseudomonas spp. 16S rRNA gene in the samples stored at room temperature  
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Figure 4.5. DGGE analysis using a 30-55% denaturing gradient showing the effect 
of storage on the fungal communities of the five patients.  
F1-F4 represent excised bands which were subsequently sequenced  
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Figure 4.6. CA analysis of the fungal DGGE profiles from the five patients samples 
stored in the fridge and at room temperature  
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Figure 4.7. Normalised qPCR data to demonstrate the mean  effect of sample storage 
on bacterial 16S rRNA.  
Grey bars indicate samples stored at 4 
O
C; white bars indicate samples stored at 
room temperature  
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compared to the refrigerated samples (Fig. 4.7). This finding was statistically 
significant for both taxa (P <0.001). In contrast, quantification of the mean H. 
influenzae P6 outer membrane protein copy number revealed a  greater than 
50%decrease in P6 gene copy numbers in the samples stored at room temperature 
compared to the sample stored at 4°C that was statistically significant (P <0.001). 
 
4.4 Discussion 
 
Preparation of  a DGGE ladder of known organisms revealed one the the caveats of 
16S rRNA PCR-DGGE in that bands from different organisms can posess the same 
migration rate (Jackson et al. 2000). Furthermore, it was noted from the construction 
of the DGGE ladder that an individual organism can contain several heterogeneous 
copies of the 16S rRNA gene which has been noted previously (Dahllöf et al. 2000). 
The caveats identified from the construction of the DGGE ladder show that obtaining 
an accurate depiction of the bacterial communities present is difficult at best. 
However, it has been shown that PCR-DGGE can be utilised to identify the major 
changes that occur due to pertubation or identify difference between bacterial 
communities in different habitats (van der Gast et al. 2008). Therefore, this 
technique, in combination with qPCR should give a clear indication of any changes 
which may occur due to the differing sample storage. 
Many studies on CF therapies are multicentre and involve both qualitative and 
quantitative bacterial analysis. This usually entails shipping of samples from study 
sites to a central processing laboratory. Here we show that the storage of sputum 
samples can have a powerful effect on the results of culture independent techniques 
84 
 
for detection of bacteria. In most situations, it is not feasable or in some cases 
possible to process sputum samples immediately especially if they need to be 
transported from the ward to the laboratory or from one site to another. In this study  
we take samples that have been immersed in RNAlater and stored at 4˚C to be an 
accurate representation of the microbial community as it would be observed in the 
lung. We have based this assuption on the preservatative property of RNAlater 
preventing RNA degradation as well as the bacteriostatic properties it possess 
preventing any change in the RNA profile of the sample. DGGE analysis of the 
bacterial community indicated that storage of samples significantly affected the 
bacterial community in the sputum (P <0.002). It appears from the change in the 
DGGE profiles that storage at 4°C is more favorable for visualising organisms with a 
lower 16S rRNA GC content (Fig 4.3). Statistical analysis of the profiles showed 
that the samples stored at room temperature clustered together more along the y-axis 
than the samples stored at 4°C suggesting that storage at room temperature masks 
intersample variability (Fig 4.4). Further evidence of this was demonstrated using 
Raup-Crick similarity index where samples stored at room temperature appeared to 
be statistically similar on seven occasions compared to only one when the samples 
stored at 4˚C were analysed (Table 4.1). If the samples stored at room temperature 
were taken to be true then this would suggest a mostly deterministic bacterial 
community assembly for the CF lung whereas analysis of the samples stored at 4˚C 
suggests that community assembly is, in fact, stochastic. The stochastic community 
assembly seen in the samples stored at 4°C is in line with that found in previous 
studies (Rogers et al. 2005). 
Culture independent techniques have previously been shown to idenify many more 
taxa in CF sputum samples than the corresponding sample analysed using culture 
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dependent techniques our data supports those of previously published work (van 
Belkum et al. 2000). Moreover, quantification using qPCR data showed a significant 
increase (P <0.001) in the number of total bacteria and Pseudomonas spp. in the 
sputum samples stored at room temperature (Fig 4.7). These observations may 
indicate that growth of some microbial taxa, particularly P. aeruginosa,  are 
favoured at room temperature in comparison to 4 °C. The increase in numbers of 
Pseudomonas spp. after storage at room temperature may explain the overgrowth of 
P. aeruginosa, commonly seen in routine microbiology. This might result in the 
clinical significance of P. aeruginosa being overestimated in such samples. It was 
also shown that H. influenzae numbers are significantly decreased after storage at 
room temperature when compared to storage at 4 °C (P <0.001). It has been shown 
previously that H. influezae has been difficult to recover from transport swabs due to 
its fastidious nature (Rishmawi et al. 2007). It has also been observed that H. 
influenzae is more difficult to recover from sputum samples after postage than from 
fresh samples processed immediately (May & Delves 1964). However, our data 
contradict those of Pye et al. (2008) who suggest that storage at room temperature 
produces more favorable conditions for the recovery of H. influenzae.  
The numbers of active bacteria present in CF sputum has not previously been 
assesed using culture independent methods. Using culture dependent techniques, 
between 10
8
 and 10
9
 cfu/ml were observed for the predominant organism in the 
sample (Pye et al. 2008). In contrast, the total bacterial 16S rRNA copy number/ml 
in our sample set is between 10
7
 and 10
9
 with a mean of 1.00 x 10
9
 and between 10
5
 
and 10
7
 copies/ml of this relates to Pseudomonas spp.. With most organisms having 
more than one copy of this gene our account of the active bacteria in CF sputum is 
significantly lower than the number of viable cells as determined by culture when 
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using this gene as a target. Pye et al. (2008) also showed that H. influenzae was 
present at 10
9
 cfu/ml when it is the predominant organism, whereas, H. influenzae 
was not isolated by culture from any of our patient cohort but was identified using 
molecular techniques. This highlights the increased sensitivity of molecular 
techniques compared to culture which supports the findings from previous studies 
(van Belkum et al. 2000; Dalwai et al. 2007). However, the fact the H. influenzae 
was not cultured from our cohort could be due to several factors. Firstly, all of our 
patients were culture positive for P. aeruginosa which may have overgrown on the 
culture media and masked the growth of H. influenzae. This finding is supported by 
our qPCR data which suggests that most of the metabolic activity in our samples was 
due to Pseudomonas spp. even when the samples were stored at 4°C in RNAlater 
when compared with the total number of bacteria.  
There has been no previous work done by culture dependent or independent methods 
showing the effect of storage on fungi from CF sputum. The results of this study 
show that, although there was a decrease in band intensity for fungi when stored at 
room temperature, there was no significant difference between the sample collection 
proceedures (P = 0.180). Due to there being a slightly lower band intensity for the 
samples stored at room temperature our data suggests that samples required for 
fungal analysis should be stored at 4°C to preseve the nucleic acids in the sample. 
Sequence analysis of DGGE bands allowed the identification of A. fumigatus, a 
fungal pathogen that is known to adversley effect lung function (Amin et al. 2010). 
Also several species of Candida were found by PCR-DGGE analysis which were 
absent from the culture data. Due to the increased recovery rate of metabolically 
active fungi in CF sputum by molecular techniques it may be fruitful to utilise these 
techniques to identify colonising fungal species and then to asses their role as 
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potential pathogens. There is currently very little information pertaining to the fungal 
members of the CF lung microbiota and how they persist in the CF lung. Further 
work is required to fully analyse this community.   
 
4.5 Conclusions 
 
In conclusion, this study, although small, supports handling protocols where 
respiratory samples being used in molecular studies should have RNAlater added 
immediately and then to be subsequently stored at 4 °C until required for processing 
if an accurate depiction of the community is to be observed and accurate 
quantification of bacterial numbers is to be achieved. However, for fungi, sample 
handling proceedures are less crucial.  
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5. Bacterial and fungal communities present in the lungs of cystic fibrosis 
patients with a severe genotype are affected by genetic and environmental 
factors 
 
Abstract 
Aim: The microbiology of the CF lung has been well characterised by both culture 
and molecular techniques and have been shown, in both instances, to be 
polymicrobial. The aim of this study was to investigate the CF lung microbiota in an 
adult population to determine the extent that environmental and genetic factors affect 
the microbial communities in patients with the most common CFTR mutation, 
F508del. 
Methods: DNA was extracted from sputum samples of 29 adult patients who were 
either homo- or heterozygous for the F508del mutation. Universal bacterial and 
fungal primers were used to amplify the 16S rDNA and 28S rDNA. These fragments 
were analysed by DGGE. Universal bacteria primers were used to quantify the total 
bacterial load from the sputum using qPCR. 
Results: Bacterial communities present in the CF lung were found to be 
stochastically assembled. Furthermore, CCA analysis of the bacterial DGGE profiles 
found that sex (P = 0.046) and being colonised by P. aeruginosa as determined by 
culture (P = 0.034) were driving forces that shape changes in the bacterial 
communities of the CF lung. Further investigation found that bacterial diversity and 
bacterial community evenness were significantly reduced in females (P = 0.006 and 
0.003 respectively). These diversity indices were also reduced in patients colonised 
by P. aeruginosa but this was not significant. An inverse relationship was seen 
between age and FEV1 in our patient cohort which has been demonstrated in 
previous studies (P = 0.012). Fungal community analysis found that patients 
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homozygous for F508del had a greater number of fungal species than those who 
were heterozygous (P = 0.007). 
Conclusions: This study has demonstrated that many factors affect microbial 
community assembly in the CF lung. Recent work has found that the CF lung 
consists of core and satellite communities of bacteria in a CF population. 
Understanding the factors that cause these communities to develop will hopefully 
lead to more effective treatment strategies, especially for patients with a more severe 
disease phenotype. 
 
5.1 Introduction 
 
Cystic fibrosis is a lethal autosomal recessive condition most prevalent in 
Caucasians. Most of the morbidity and mortality in CF can be attributed to the 
chronic lung pathology caused by microbial infection and the subsequent 
hyperinflammatory response. The microbiology of CF has been well characterised 
over recent years by both molecular and culture based methodologies (Burns et al. 
1998; Emerson et al. 2010; Rogers et al. 2003; Rogers et al. 2005; Harris et al. 
2007). Common CF pathogens routinely identified by conventional microbiology 
include P. aeruginosa, H. influenzae, S. aureus, B. cepacia complex, C. albicans and 
A. fumigatus (Burns et al. 1998; Emerson et al. 2010). However, more recently 
anaerobic bacteria such as those belonging to the genus Prevotella and Veillonella as 
well as facultative anaerobes such as Streptococci have been identified using both 
culture dependent and independent methods (Harris et al. 2007; Bittar et al. 2008b; 
Tunney et al. 2008; Worlitzsch et al. 2009). Furthermore, the interactions between 
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common CF isolates have been investigated (Duan, 2003; Sibley et al. 2008a). These 
include the increased virulence of P. aeruginosa in co-culture with oral streptococci 
and that production of the signalling molecule Farnesol by C. albicans represses 
pyocyanin production by P. aeruginosa (Cugini et al., 2007; Duan et al. 2003). 
Although both culture dependent and independent methodologies can be utilised to 
investigate the microbiology of the CF lung, culture independent techniques such as 
microarray, T-RFLP and clone libraries suggest that there is a greater microbial 
diversity in the CF lung than is found by culture dependent techniques alone (Rogers 
et al. 2004; Harris et al. 2007; Klepac-Ceraj et al. 2010; Guss et al. 2011). However, 
the discrepancy in bacterial community richness between culture dependent and 
independent techniques will be due, in part, to the inability/difficulty in culturing 
some microorganisms (Rogers et al. 2004; Guss et al. 2011). Furthermore, single 
bacteria species may harbour several heterogeneous copies of the 16S rRNA genes 
which means that culture independent analysis could lead to an overestimation of the 
bacterial species richness. 
Although culture independent analysis of the CF lung microbiology has been on-
going for over a decade it was only very recently that multivariate analysis has been 
used to assess the effects of clinical factors on these microbial communities (Cox et 
al., 2010; Giraud et al., 2010; Klepac-Ceraj et al., 2010). Klepac-ceraj et al. (2010) 
found that CFTR genotype, inhaled antibiotics and P. aeruginosa isolation by culture 
affected the composition of bacterial taxa in a group of paediatric CF patients. 
Similarly, CFTR genotype has also been implicated in susceptibility to fungal 
infections with F508del homo- and heterozygous patients being more susceptible to 
infection by G. argillacea than patients with no F508del mutation (Giraud et al. 
2010). These studies suggest that microbial community assembly in the CF lung is 
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affected by environmental factors (i.e. use of inhaled antibiotics) which lends itself 
to the hypothesis that a niche based model may be useful to predict the colonisation 
patterns of the CF lung based upon patient specific factors. However, other evidence 
suggests that neutral community assembly, in which community assembly is due to 
random immigration from a meta-community, might be more applicable to CF lung 
microbiology. Firstly, Rogers et al. (2005) found that each CF patient in their study 
had a unique bacterial fingerprint suggesting that the microbial community 
assembles stochastically. Similarly, work examining the geographical relationship 
between the microbial communities of the CF lung found that patients residing in the 
United Kingdom (UK) and the United States of America (USA) did not have either 
significantly different or significantly similar bacterial communities within paired 
patients (Stressmann et al., 2011). Instead the communities had no greater 
relationship than one would expect by chance. This observation supports a stochastic 
(neutral) community assembly model both within and between the cohorts 
suggesting that neither selective pressures within the lung or biogeography affects 
the microbial community composition (Stressmann et al. 2011). 
 However, recent work finds that a core bacterial community does exist for CF lung 
microbiology (van der Gast et al. 2010). This strongly suggests that some species are 
merely transient or found in low abundance and, therefore, may not play a key role 
in lung pathology. Intrestingly, however, the only routinely cultured CF pathogen to 
be identified as part of the core community was P. aeruginosa, whilst S. aureus, H. 
influenzae and S. maltophilia are members of the satellite community (van der Gast 
et al. 2010).  
The aim of this research was to characterise the intrinsic and extrinsic factors which 
have an effect on bacterial and fungal communities present in the CF lung in a cohort 
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of patients who were homo- or heterozygous for the F508del CFTR allele. 
Furthermore, the aim was to investigate whether microbial community assembly in 
the CF lung is stochastic or deterministic. 
5.2 Methods 
 
The patients enrolled in this study were selected for the study by the perception of 
the clinician that they were stable at the time of sampling but were frequently 
presenting at the clinic with exacerbations. All of the patients selected were either 
homo or heterozygous for the F508del CFTR mutation. A summary of patient age, 
gender, CFTR mutation, FEV1 (% Predicted), BMI, current routine antibiotics and 
microbial culture data are presented in Table 5.1. 
5.3 Results 
 
5.3.1 Culture based microbiology 
 
Microbial culture was carried out by State-registered biomedical scientists using 
methods recommended by the HPA for the detection of pathogens in CF sputum 
(Health protection agency 2009). Bacterial pathogens were detected in 25/29 patients 
enrolled in the study with polymicrobial communities being present in 8 of those 
patients, as determined by culture, which gave a mean bacterial species number of 
1.14 pathogens/patient. However, microbial culture identified ten patients who had 
more than one morphotype of P. aeruginosa which were investigated as separate 
species. With these morphotypes taken into consideration the mean number of 
bacterial pathogens rises from 1.14 to 1.52 pathogens/patient. 
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Table 5.1 Mean clinical demographics of the 29 patient cohort 
 
Gender Genotype 
Age (years ± 
SD) 
FEV1 % Predicted (± 
SD) BMI (± SD) 
Inhaled 
antibiotic 
therpay  
Microbiological culture 
P. 
aeruginosa 
Candida 
spp. 
A. 
fumigatus 
16 Male 
17 
F508del/F508del 29.55 ± 10.99 56.59 ± 22.94 21.94 ± 3.28 23 23 15 3 
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Microbial culture was also used to detect any fungal pathogens present in the 
sputum. Fungal pathogens were detected in 17/29 patients enrolled in the study 
which gave a mean of 0.62 pathogens/patient. Of the patients‟ positive for fungal 
pathogens by culture, 16/17 had monomicrobial fungal communities.  
 
5.3.2 Ecological analysis 
 
The DGGE analyses of the bacterial community produced 37 distinct band positions 
(Fig 5.1) with a mean of 12.24 bands per lane (Range 6-22 bands per lane; Appendix 
11). Each individual DGGE band was presumed to be a single taxon and was used as 
a measure of species richness. The mean Shannon index was 1.87 (Range 0.91 - 
2.65; Appendix 11) which was used to give an overall indication of bacterial 
diversity which takes into account both species richness and evenness. The mean 
evenness of the bacterial communities was 0.76 (Range 0.44 – 0.87; Appendix 11). 
The mean Dice similarity between all of the patients was 41%.  
The DCA analysis gave an axis length of 3.862, therefore CCA was used to analyse 
the species and environmental data. Monte Carlo permutation testing under full 
model (499 permutations) was used to analyse the relationship between the discreet 
and continuous variables and the DGGE band matrix which included age, sex, CFTR 
genotype, FEV1 % predicted, BMI, culture positive for P. aeruginosa. The factors 
that were least significant (Use of inhaled antibiotics, BMI and CFTR genotype, P = 
0.990, 0.664 and 0.304 respectively) were removed to produce the final image (Fig. 
5.2). Permutation testing found that P. aeruginosa colonisation by culture and 
gender was statistically significant with P-values of 0.032 and 0.046 respectively.  
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Figure 5.1 Bacterial DGGE profiles using a 35-60% denaturing gradient showing the 
bacterial community profiles from the 29 patients   
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Figure 5.2 Canonical correspondence analysis of bacterial DGGE profiles including 
environmental variables  
■ P. aeruginosa negative males, □ P. aeruginosa positive males, ● P. aeruginosa 
negative females, ○ P. aeruginosa positive females. ▲ Discrete variables (Gender 
and P. aeruginosa detected by culture). ↑ Continuous variables (FEV1 % Predicted 
and age) 
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(a) 
 
 
(b) 
 
 
Figure 5.3 Comparison of the Shannon Diversity (a) and Bacterial community 
evenness (b) between male and female patients  
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This finding was further investigated to examine which aspects of the bacterial 
community differed between the sexes using one-way ANOVA analysis against the 
Shannon diversity, species richness and species evenness. The analysis found that 
Shannon diversity and community evenness were significantly lower in females than 
in males (P = 0.006 and 0.003 respectively; Fig 5.3 a & b). Further analysis was also 
carried out to investigate how P. aeruginosa colonisation affected the bacterial 
communities. This analysis found that the values for Shannon diversity, Richness 
and evenness were lower in patients colonised by P. aeruginosa, however, none of 
these values were significant (P = 0.166, 0.408 and 0.112 respectively. Both FEV1 
(% predicted) and age were not significant but still included (P = 0.086 and P = 1.94 
respectively). Patients who were culture negative for P. aeruginosa were more likely 
to have a higher FEV1 (% Predicted) than those who were positive as analysed by 
routine culture as indicated by the arrow for FEV1 included in the CCA analysis (Fig 
5.2.).  
5.3.3 Raup-Crick Similarity index 
 
The DGGE band matrix was used to calculate Raup-Crick pair-wise similarities for 
the 29 patients in the study to test whether the bacterial communities displayed 
stochastically or niche driven community assembly (Table 5.2). A total of 406 pair-
wise comparisons were carried out and the analysis found that 12 (3.0 %) of pair-
wise comparisons yielded statistically different (P ≤0.05) communities than would 
be expected by chance; 41 (10.1 %) of pair-wise comparisons were statistically 
similar (P ≥ 0.95) and the remaining 353 (86.9 %) were neither statistically similar 
nor different (P 0.05 ≥ ≤ 0.95).  
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Table 5.2 Raup-Crick similarity index analysis of bacterial community assembly between the 29 patients  
 
 
Number (%) of pair-wise comparisons   
≤ 0.05  ≥ 0.95  0.05 ≥ ≤ 0.95  Total No. (%) of SRC 
comparisons  
12 (3.0)  41 (10.1)  353 (86.9)  406 (100)  
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5.3.4 Bacterial qPCR 
 
The relationship between bacterial load (qPCR value) and discrete variables (sex, 
CFTR genotype, P. aeruginosa status according to culture data) was examined using 
one-way ANOVA analysis. Sex, CFTR genotype and P. aeruginosa colonisation 
according to culture data were not statistically significant (P = 0.500, 0.564, 0.254 
respectively). The relationship between continuous variables (FEV1 % predicted, 
BMI, Bacterial community H‟, R and E and fungal species richness) and bacterial 
load was examined using Pearson product moment correlation (Table 5.3). None of 
the continuous variables displayed a significant relationship with bacterial load. 
However, the analysis did demonstrate a significant negative correlation between age 
and FEV1 % predicted (P = 0.030; Fig 5.4). 
 
5.3.5 Fungal community analysis 
 
Fungal DGGE gels were aligned using sequence analysis due to the lack of a 
standard ladder. DGGE analysis of the fungal community gave a total of 11 distinct 
band positions with a mean of 1.41 taxa per lane (Range 0 - 5 per lane; Fig 5.5). 
Bands present on the fungal DGGE gels were used as a measure of species richness 
where one band was presumed to be a single taxon. Eleven bands, from two DGGE 
gels were excised and sequenced. The NCBI BLASTn tool was used to search for 
closest deposited sequence match. The closest related sequences were from seven 
different species (Table 5.4)  
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Figure 5.4 Relationship between lung function decline and patient age observed in 
the 29 patient cohort   
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Table 5.3 Pearson product moment correlation for comparison of bacterial load and 
continuous variables 
 Age FEV1 (% 
Predicted) 
Shannon 
Diversity 
Fungal 
Richness 
Bacterial 
Load 
FEV1 (% 
Predicted) 
-0.404     
 P = 0.030     
Shannon 
Diversity 
-0.194 0.274    
 P = 0.312 P = 0.150    
Bacterial 
Richness 
-0.118 0.131    
 P = 0.544 P = 0.497    
Fungal 
Richness 
-0.329 0.172 0.166   
 P = 0.082 P = 0.373 P = 0.388   
Bacterial 
Load 
-0.076 0.288 -0.303 0.205  
 P = 0.696 P = 0.130 P = 0.110 P = 0.285  
BMI 0.337 0.063 -0.273 -0.085 0.189 
 P = 0.074 P = 0.744 P = 0.152 P = 0.661 P = 0.327 
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Figure 5.5 Aligned DGGE gel showing fungal diversity in the 29 patient cohort  
Numbers correspond to fungal species. Band 1 C. parapsilosis, Band 2 Unknown, 
Band 3 C. dubliniensis, Band 4 D. hansenii, Band 5 Unknown, Band 6 C. albicans, 
Band 7 S. cerevisiae, Band 8, C. glabrata, Band 9, A. fumigatus Bands 10 & 11 
Unknown  
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Table 5.4 Sequence data from the bands excised from the fungal DGGE analysis 
 
Band number Closest match Max identity 
1 
Candida parapsilosis strain CBS 604 
26S ribosomal RNA gene, partial 
100 % 
2 
Candida dubliniensis CD36 chromosome 
R, complete sequence 
100 % 
3 
Debaryomyces hansenii strain LL2 26S 
ribosomal RNA gene, partial 
98 % 
4 
Candida albicans isolate CA-ALBIC-
SW008 large subunit ribosomal 
100 % 
5 
Saccharomyces cerevisiae strain YM3-1 
26S ribosomal RNA gene, partial 
sequence 
100 % 
6 
Candida glabrata strain QD3.3 26S 
ribosomal RNA gene, partial sequence 
100 % 
7 
Aspergillus fumigatus partial 28S rRNA 
gene, strain INFU/Jc/KF/6 
100 % 
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Bands representing C. parapsilosis, C. albicans, C. dubliniensis and A. fumigatus 
were present on both gels and it was these bands that were used to align the DGGE 
gels (Fig. 5.5).   
The ability of PCR-DGGE and culture to detect fungal species present in the CF 
lung was assessed. In this study, fungal species were detected by culture in 59% 
(17/29) of patients whereas PCR-DGGE detected fungal species in 72% (21/29) of 
patients. Further investigation revealed that the data from both techniques found 
fungal species in a total of 83% (24/29) of patients. Therefore, the sensitivity for 
culture and molecular tests are 71% and 88% respectively. Culture analysis of fungal 
communities found that mixed fungal infection occurred in two patients (7%) 
whereas PCR-DGGE analysis found that ten patients (34%) had mixed fungal 
infections. The most predominant fungi found by PCR-DGGE was C. albicans 
(38%) followed by C. parapsilosis (24%), C. dubliniensis (24%), A. fumigatus (7%) 
S. cerevisiae (7%), C. glabrata (3%) and D. hansenii (3%) by matching with 
sequenced band positions. 
Due to fungal communities being of low diversity, it was decided not to perform 
multivariate analysis. Therefore, fungal community richness was assessed against 
discrete variables (Sex and CFTR genotype) using one-way ANOVA analysis. 
Analysis of the fungal species number against the discrete variables demonstrated 
that patients who are homozygous F508del had a greater species richness (Mean = 
1.9) compared to heterozygous F508del patients (Mean = 0.67) (Fig 5.6; P = 0.007). 
Fungal community richness was included in the Pearson product moment correlation 
described above and was not found to be significantly affected by any of the 
continuous variables tested (Table 5.3).  
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Figure 5.6 Fungal species richness in F508del homo- and heterozygotes 
F508del/F508del =Homozygous F508del mutation, F508del/OM = Heterozygous 
F508del CFTR mutation   
107 
 
5.4 Discussion 
 
Studies examining polymicrobial communities in the environment demonstrate that 
more diverse communities tend to be more resistant to perturbations from invaders or 
external stress than less diverse communities (Girvan et al. 2005). Therefore, in 
order to select the most effective therapeutic intervention, polymicrobial infections 
need to be characterised using both molecular techniques and cultivation techniques 
so that „unculturable‟ microorganisms can be detected. Our aim was to analyse the 
microbial diversity observed within the lower respiratory tract of CF patients who 
were homo- or heterozygous for the F508del mutation. This mutation is by far the 
most common mutation seen in CF sufferers with 66% of mutations seen worldwide 
(Dorfman et al. 2008). Furthermore, CF patients who possess an F508del mutation 
have a more severe disease phenotype which is characterised by an earlier death. 
McKone et al. (2006) demonstrated that high risk CF patients had a mean survival 
age of 24.2 years and low risk patients had a mean survival age of 37.6 years.  
 
5.4.1 Bacterial community analysis 
 
Molecular microbial analysis of the CF sputum samples collected during this study 
gave a far larger estimate of microbial species diversity than did microbial culture. 
However, the culture methods used were designed to culture the traditional CF 
pathogens with other microbial species being selected against or discarded which 
may account for this disparity. Several recent studies have examined the ability of 
culture to detect a wide range of bacteria in CF. Rogers et al. (2009) used the HPA 
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guidelines to culture bacteria that were used in our study and compared them with T-
RFLP on whole sputum. They found that molecular analysis found a mean of 16.3 
unique profiles when sputum was directly analysed and a mean of 8.8 unique profiles 
when the analysis was culture dependent. In our study we found a mean of 1.14 
pathogens per patient which is indicative of only reporting organisms perceived to be 
detrimental to patient health and highlights the fact that other bacteria can be 
identified using the HPA recommended guidelines. Using a non-selective culture 
method, Guss et al. (2011) found a mean bacterial species number of 5.75 per 
patient. As both studies (Rogers et al. 2009; Guss et al. 2011) used a variety of 
culture media and conditions this suggests that a large proportion of bacteria residing 
in the CF lung cannot be cultured using currently available media. Although the 
culture methods used in this study showed a lower microbial species diversity, 
further insights were made using this method which it is unlikely would be seen with 
the molecular methods employed. Firstly, antibiotic sensitivity testing was possible 
for cultured microbes and MRSA isolates were identified in 4/5 patients who were 
culture positive for S. aureus. However, further molecular investigation using PCR 
primers that were specific for MRSA may have allowed for identification of 
antibiotic resistant isolates present in the samples (Huletsky et al. 2004). Secondly, 
microbial culture allowed for the identification of different morphotypes of P. 
aeruginosa present in the same sample. The ability to differentiate these 
morphotypes is important for the management of CF patients. Foweraker et al. 
(2005) found that the antibiotic susceptibilities within morphotypes varied 
considerably which is important in clinical decisions regarding administration of the 
appropriate antibiotics.  
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Analysis of the bacterial community present in sputum from our CF cohort found a 
mean bacterial species richness of 12.24 ± 4.09 species (DGGE bands) per patient. 
This is in line with the techniques used by Rogers et al. (2004) for examining the 
polymicrobial communities present in the CF lung who found 13.4 ± 6.7 species per 
patient. However, this number is far less than those produced by the microarray 
analysis performed by Klepac-ceraj et al. (2010) and Cox et al. (2010) which could 
detect >1000 taxa per patient. However, early culture independent techniques, such 
as DGGE, are still able to provide valuable insights into microbial community 
structure (van der Gast et al. 2008). Patients who were culture positive for P. 
aeruginosa (n = 23) had significantly different bacterial community profiles from 
those who were culture negative (n = 6) (P = 0.032; Fig 8). This finding supports the 
finding of Klepac-ceraj et al. (2010) who found a similar link in a group of CF 
children. Klepac-ceraj et al. (2010) posit that the differences observed in P. 
aeruginosa colonisation may be due to long term antibiotic therapy reducing 
taxonomic richness allowing P. aeruginosa to flourish which had been previously 
demonstrated in ventilator associated pneumonia (Flanagan et al. 2007). Although 
our study shows a greater species richness in patients culture negative for P. 
aeruginosa (mean = 13.5) when compared to those who are culture positive (mean = 
12.0) this was not significant (P = 0.408). Furthermore, all of the patients enrolled on 
our study are receiving at least one long term oral antibiotic therapy which was 
chosen based on culture results from pathology. Our data, taken together with those 
of Klepac-ceraj et al. (2010) clearly show that P. aeruginosa colonisation in both 
adults and children affects the bacterial community present in the CF lung. Further 
investigation comparing Shannon diversity, richness and evenness against P. 
aeruginosa colonisation found that although all of the ecological measures were 
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lower for patients colonised by P. aeruginosa none of these variables were 
significant. Another contributing factor for the effect of P. aeruginosa colonisation 
on CF microbial diversity could be the effect it has on the environment in the CF 
lung. Yoon et al. (2002) demonstrated that P. aeruginosa colonisation of the CF lung 
had the capacity to change the environment on the mucus from aerobic to either 
microaerophilic or anaerobic. Tunney et al. (2008) found, using microbial culture 
that patients who were colonised by P. aeruginosa were more likely to be colonised 
by anaerobic bacteria. Therefore, the observation that patients who were culture 
positive for P. aeruginosa had significantly different community profiles from those 
who were culture negative in our study may be due to a shift in environmental 
conditions in the lung from aerobic to anaerobic allowing anaerobes to replace 
aerobes.  
Furthermore, CCA analysis of the bacterial community composition found that the 
profiles between the sexes was significantly different (P = 0.046; Fig 5.2). Females 
had a significantly reduced Shannon diversity and bacterial community evenness 
when compared to males (P = 0.006 and P = 0.003 respectively; Fig 5.3). 
Community evenness is used to describe the distribution of taxa. A low evenness is 
associated with a high dominance of one or a few taxa and a high evenness 
demonstrates that taxa are present in similar abundances. When applying ecological 
theory to bacterial communities, evenness is thought to be one of the most important 
measures (Wittebolle et al. 2009). High community evenness is thought to protect 
bacterial communities from perturbation due to the increase in functional redundancy 
(Wittebolle et al. 2009). However, these findings relate to the functionality of the 
ecosystem which we have not analysed in this study. Furthermore a reduction in 
diversity has been associated with a more severe disease phenotype (Flanagan et al. 
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2007). An increased rate of lung function decline and mortality in females with CF 
has been identified for decades, especially in those who are less than twenty years of 
age (Kerem et al. 1992; Corey et al. 1997; Rosenfeld et al. 1997). Furthermore, 
females colonised with multidrug resistant bacteria are more prone to pulmonary 
exacerbation than their male counterparts (Block et al. 2006). Increased incidence of 
pulmonary exacerbations is linked to premature mortality (Amadori et al. 2009). The 
disparity between the sexes has also been linked to colonisation by mucoid P. 
aeruginosa (Levy et al. 2008) which has significant effects on CF lung function 
decline and prognosis (Henry et al. 1992). These factors may be the reason that 
different bacterial communities are observed between males and females with CF. 
However, the reason for the increased susceptibility to infection in females is not 
clear, although immune response has been implicated. In a study examining the 
effect of gender in P. aeruginosa colonisation in a mouse model found that females 
were more susceptible to infection than males (Guilbault et al. 2002). Furthermore, it 
was also demonstrated that females produced a more profound inflammatory 
response than males (Guilbault et al. 2002). This may be due, in part, to the ability of 
gender specific hormones to regulate the immune response. Wang et al. (2010) found 
that male mice who were administered the female sex hormone E2 produced an 
increased inflammatory immune response to P. aeruginosa than controls. The 
increased inflammatory response observed in females may be the cause of reduced 
bacterial diversity and community evenness in females. Therefore, our data suggests 
that the gender difference observed in CF patients is apparent in entire bacterial 
community not just P. aeruginosa colonisation.  
Our data shows that the majority (86.9%) of pair-wise comparisons using the Raup-
Crick similarity index indicated that bacterial community assembly in the CF lung is 
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stochastic, not deterministic. Furthermore, a recent study examining the relationship 
between the bacterial community in American and British CF patients also found a 
stochastic community assembly in most cases suggesting that the microbial 
community is indeed stochastically assembled (Stressmann et al. 2011). However, 
recent work examining bacterial communities present in the CF lung found that 
fifteen bacterial species made up the core community whilst other species identified 
were categorised as part of the satellite community due to the infrequent isolation 
from patients and their low abundance in the system. This data suggests that the 
fifteen core bacteria have a selective advantage over other species which suggests 
that the core community is deterministically assembled. Further evidence for 
deterministic community in the CF lung has been identified, whereby the bacterial 
communities, over-time, display increased relatedness which suggests that species 
found in older CF patients have adapted to the environment of the CF lung (Cox et 
al. 2010). There is research that supports this finding in P. aeruginosa, one of the 
phyla found to be present in older CF patients and also to be part of the core CF 
bacterial community. It has been well established that during acute infection P. 
aeruginosa undergoes conversion from non-mucoid to mucoid strains which is 
thought to aide biofilm formation which, in turn, reduces the susceptibility to 
antibiotics and the immune response (Stewart & Costerton 2001; Leid et al. 2005). 
During chronic infection strains of P. aeruginosa have been monitored over an eight 
year period in the CF lung and found to reduce expression of virulence factors which 
will reduce the immune response (Smith et al. 2006). Furthermore, the structure of 
cell surface receptors which are known pathogen associated molecular patterns 
targeted by the immune response undergo structural changes during chronic CF lung 
infection which reduces cytokine production and leukocyte recruitment (Cigana et al. 
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2009). Raup-Crick similarity index data suggests that bacterial communities in the 
CF lung are stochastically assembled. However, the identification of a core 
community suggests that some species of bacteria are deterministically assembled. 
These datasets taken together suggests that certain bacterial species have a selective 
advantage when colonising the CF lung and that these species are able to exploit a 
niche or outcompete other species, whereas, others are stochastically assembled by 
random immigration of the meta-community. A study examining species of fish in 
the Bristol Channel supports this theory (Magurran & Henderson 2003). In this study 
they partitioned the species of fish into a core and satellite community based upon 
the species frequency and abundance over 21 years. They found that the core 
community were ecologically adapted to life in the estuary whereas satellite species 
were adapted to survive in deep water or rocky shores. The authors follow up this by 
suggesting that when applying niche based community assembly models that the 
satellite species are ignored as they are not adapted to survive and persist in the 
environment (Magurran 2007). 
Our findings show that there was an inverse relationship between age and FEV1 (P = 
0.030; Fig 4) which supports the findings of Cox et al. (2010) who found the same 
relationship in an age stratified study of CF patients. However, Cox et al. (2010) also 
found that species diversity decreased with age whereas our findings only found a 
very tenuous inverse relationship between age and diversity. This is most likely due 
to DGGE only being able to identify the major taxa present in a given environment 
whereas the methodology employed by Cox et al. (2010) as a greater resolution. The 
fact that FEV1 declines with age is due to the amount of time that the insults of 
infection and inflammation have had to damage lung tissue which is in line with 
common findings in the clinic. This phenomenon has been demonstrated in several 
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studies looking at differences in spirometry and lung tissue damage in CF patients of 
different ages. The utility of spirometry, especially FEV1, to assess lung function in 
CF has been assessed on several occasions and proven to be the most indicative 
predictor of clinical status (Kerem et al. 1992; Corey et al. 1997). Kerem et al. 
(1992) found that a FEV1 (% predicted) below 30% was linked to a high risk of 
mortality in CF patients. Similarly, Corey et al. (1997) found a link between age and 
the rate at which lung function declined in a longitudinal study. Furthermore, 
physical changes in lung architecture that are most likely to be the cause of long term 
lung function decline have also been identified (Helbich et al. 1999). Helbich et al. 
(1999) used a stratified study to examine three groups of patients (group 1; 0-5 years, 
Group 2; 6-16 years, Group 3; 17 years and over) and found that both the severity 
and extent of lung tissue damage increased with age using CT score. Furthermore, 
CT score and CT findings had a significant correlation with the spirometry results 
(Helbich et al. 1999).  
 
5.4.2 Fungal community analysis 
 
In our study 59% (n = 17/29) patients were culture positive for fungal isolates with a 
mean fungal species number of 0.62 per patient. Using culture techniques the only 
genera isolates were Candida (n = 15) and Aspergillus (n = 3) possibly because these 
organisms are screened for in CF sufferers and deemed potential pathogens. Only 
one patient in the cohort had polymicrobial fungal communities present in the culture 
data, which consisted of two species, A. fumigatus and Candida spp. On some 
occasions Candida spp. were fully elucidated to C. albicans based upon colour 
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change on ChromID Candida (Biomerieux) which may mean that communities that 
consist of several Candida spp. could be present but have not been fully elucidated. 
PCR-DGGE analysis found that 72% (n = 21/29) of patients were positive for fungi 
which shows improved sensitivity when compared to conventional methods which 
had a sensitivity of 59% (n = 17/29). On seven occasions PCR-DGGE identified the 
presence of fungi which were not detected using culture which is what would be 
expected based upon previous comparisons between culture and molecular 
techniques (Bouchara et al. 2009). Further investigation of this data revealed three 
instances where PCR-DGGE had failed to identify fungi in a sample where a patient 
was culture positive. This means that between the two datasets (molecular and 
culture) 83% (n = 24/29) of patients were positive for fungi. Therefore, sensitivity 
for culture and molecular tests are 71% and 88% respectively, suggesting that 
molecular techniques can better detect fungi than culture based techniques. 
Furthermore, the techniques were in disagreement regarding the identity of the fungi 
present in many cases, although all but one were due to Candida spp not being fully 
identified to the species level by culture methods.  The other instance was where the 
molecular methods detected a band with the same Rf as C. parapsilosis in patient 4 
whereas culture detected A. fumigatus as well as Candida spp.  
A total of 41 fungal taxa were identified by PCR-DGGE across the twenty nine 
patients studied which is greater than the number detected by culture (n = 18). 
Furthermore, polymicrobial fungal communities were identified in eleven patients 
using PCR-DGGE and only one patient by culture. We found, by molecular analysis 
that the mean number of fungal species was 1.41 (Range 0 – 5) which is similar to 
the results of Bouchara et al. (2009) who found a mean of 1.74 species per sample 
using microarray analysis. This data suggests that PCR-DGGE is capable of a similar 
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resolution in terms of fungal diversity as the microarray produced by Bouchara et al. 
(2009) and has the advantage of being an open rather than a closed system so that 
unusual fungal isolates can be identified. However, the microarray approach has an 
advantage in that once conducted, there was no need for any further analysis whereas 
our method required DNA sequencing for identification. With further development 
the PCR-DGGE method could display similar advantages by running a ladder of 
known isolates alongside the unknown CF sputum samples allowing for 
identification of fungal species without any need for DNA sequencing. However, 
this would depend upon the heterogeneity of fungal 28S rRNA sequences as well as 
the coverage of the primers.  
A total of 14 unique bands relating to seven fungal species which belonged to four 
genera were identified by PCR-DGGE followed by sequence analysis (Table 5.4). 
An attempt was made to sequence all eleven unique bands identified by PCR-DGGE 
but this was not possible due to the close migration distance between bands which 
yielded mixed PCR products even after five cycles of band excision, re-amplification 
and visualisation by DGGE analysis. As a ladder of known CF organisms had not 
been compiled for fungi, bands were excised and sequenced so that different gels 
could be matched. Bands from C. albicans, C. dubliniensis, C. parapsilosis and A. 
fumigatus were identified on both gels so these bands were used for alignment. In 
addition, bands relating to C. glabrata, D. hansenii and S. cerivisiae were also 
identified by band excision followed by sequence analysis. In our study, 38% 
(11/29) of patients had bands relating to C. albicans by PCR-DGGE analysis. C. 
albicans has been isolated in up to 80% of CF patients during one study which is not 
uncommon using either culture or molecular techniques (Haase et al. 1991; 
Peltroche-Llacsahuanga et al. 2002; Bakare et al. 2003; Bouchara et al. 2009). 
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Patients with pancreatic insufficiency, osteopenia and patients who are also 
colonised by P. aeruginosa are most likely to be colonised by C. albicans 
(Chotirmall et al. 2010). However, our data did not show a significant relationship 
between P. aeruginosa colonisation and C. albicans infection (P = 0.803). Recently 
C. albicans has been identified to be a cause of lung function decline and to increase 
the rate of hospital-treated exacerbation in CF suggesting that fungi may be more 
important in the lung pathology in CF than was originally thought (Chotirmall et al. 
2010). Therefore, accurate identification is required so that appropriate treatment can 
be administered. In our study, one sample that was positive for C. albicans by 
culture was identified as C. dubliniensis by PCR-DGGE. This discrepancy may be 
due to both C. albicans and C. dubliniensis producing green colonies on ChromID 
Candida. It is commonly hypothesised that fungal colonisation of the CF lung is 
transient and does not contribute to lung function decline in CF. However, Duan et 
al. (2003) have shown that C. albicans is present in the majority of samples over a 
ten year period, suggesting that fungi are capable of chronically colonising the lung. 
In total, 24% (7/29) of patients had bands with the same migration distance as C. 
dubliniensis by PCR-DGGE analysis. Previously, C. dubliniensis has been isolated 
from CF sputum at a prevalence of 11.1% in a study utilising microbial culture 
techniques (Peltroche-Llacsahuanga et al. 2002). However, previous studies suggest 
that colonisation by C. dubliniensis does not lead to invasive infection and its role as 
a pathogen in CF is yet to be defined (Peltroche-Llacsahuanga et al. 2002). In our 
study 24% (7/29) and 3% (1/29) of patients were colonised by C. parapsilsos and C. 
glabrata respectively. Both C. glabrata and C. parapsilosis have previously been 
identified from the CF lung with relatively low frequency and neither species has 
been implicated in the deterioration of lung function or has a negative impact on the 
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prognosis of respiratory disease in CF (Bouchara et al. 2009). Furthermore, mixed 
Candida infections were present in 24% (7/29) of patients usually with only two 
Candida spp, although one patient did have three. The clinical significance of mixed 
Candida infection is unknown at present but requires further investigation if the 
prevalence is high as our data suggests. In contrast, A. fumigatus, found in 7% of 
patients by PCR-DGGE, is a fungal pathogen that is known to adversley effect lung 
function. Amin et al. (2009) found that patients colonised with A. fumigatus had 
significantly reduced lung function compared to controls and had increased risk of 
hospitalisation. Futhermore, patients who are receiving antibiotics are at increased 
risk of A .fumigatus infection compared to controls (Bargon et al. 1999). All of the 
patients enrolled in our study were receiving at least one group of antibiotics 
suggesting that A. fumigatus colonisation perhaps should have been greater than 
observed if prophylaxis is indeed a contributing factor. It is now the case that 
atypical fungal species are being isolated from the CF lung (Cimon et al. 2005). S. 
cerevisiae was identified in two patients by PCR-DGGE. S. cerevisiae is commonly 
known as bakers or brewer‟s yeast and has only previously been identified as a 
respiratory infectious agent in immuno-compromised patients (Tawfik et al. 1989). 
D. hansenii, halotolerant yeast usually found to produce the veins in blue cheese was 
also isolated from one patient. D. hansenii has previously been found to cause 
extrinsic allergic alveolitis in one elderly patient and was contracted from a 
contaminated humidifier (Yamamoto et al. 2002). It may be the case that these 
organisms merely contaminate the oesophagus after consumption and have 
contaminated the sputum sample during expectoration. A recent study found that C. 
albicans, C. parapsilosis and S. cerevisiae which were identified in our study, were 
also members of the healthy oral mycobiome (Ghannoum et al. 2010). Therefore, the 
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oral cavity may also act as a reservoir for opportunistic infection by fungal species in 
CF. The emergence of other fungal pathogens in CF suggests that close monitoring 
and more robust techniques are required to detect the prevalence of pathogenic fungi. 
The data from our study suggests that both molecular and culture based techniques 
can fail to isolate or identify fungi and that the techniques may need to be used in 
tandem to obtain full coverage.  
Analysis of the fungal communities against discrete and continuous variables found 
that patients who were homozygous for F508del mutation had more diverse fungal 
communities than heterozygotes (P = 0.007). The relationship between CFTR 
genotype and fungal infection has been identified previously but only in regards to a 
single fungal species (Giraud et al. 2010). The increased susceptibility of patients 
who are homozygous F508del to fungal infection needs to be monitored closely now 
that fungi are being linked to lung function decline in CF (Amin et al. 2010; 
Chotirmall et al. 2010). Investigation into fungal infection in CF has been mostly 
limited to investigation of C. albicans and A. fumigatus. However, our findings 
along with those of previous studies reveal that fungal colonisation of the CF lung is 
not limited to the traditional CF pathogens and can involve multiple fungal species 
colonising the lung at once (Cimon et al. 2005; Giraud et al. 2010). Further 
characterisation of the CF lung „mycobiome‟ is required along with further 
investigation to define their role as pathogens. 
 
5.5 Conclusions 
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The CF lung houses a polymicrobial community consisting of both bacterial and 
fungal species. Bacterial community assembly in the CF lung is influenced by 
stochastic processes as well as genetic and environmental factors. We found the 
bacterial community present in the lungs of female patients displayed reduced 
diversity and evenness when compared to male patients. Furthermore, P. aeruginosa 
colonisation also significantly affected the bacterial communities present in the CF 
lung. Although bacterial diversity, richness and evenness were lower in patients who 
were colonised by P. aeruginosa this was not significant suggesting that other 
factors may be the cause. A possible explanation for the difference seen between 
patients who are colonised by P. aeruginosa and those who are not could be due to 
the change in environmental conditions, namely a change from an aerobic to an 
anaerobic environment, resulting in the replacement of bacteria that prefer an aerobic 
environment with anaerobic bacteria.  
Analysis of the fungal communities present in the CF lung found that patients who 
were homozygous for the F508del CFTR mutation were more susceptible to fungal 
infection than heterozygotes. Furthermore, PCR-DGGE analysis of fungal 
communities was a more sensitive technique and revealed a greater diversity than 
culture based techniques. Therefore, further investigation into the utility of molecular 
techniques in the identification of fungal pathogens is needed.  
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6. Temporal dynamics of the microbial communities in the Cystic Fibrosis lung  
 
Abstract 
 
Aim: Recently, the effects of aging on the lung microbiota have been elucidated for 
CF patients, demonstrating that older CF patients have less diverse, rich and even 
bacterial communities. Furthermore, the relatedness of the organisms colonising the 
CF lung increases with age. However, there is very little longitudinal data on 
dynamics of bacterial and fungal colonisation in the CF lung.  Therefore, we aimed 
to examine the temporal aspects of CF microbial diversity in individual CF patients 
to examine the stability of these communities and to examine if any key changes 
occur during presentation with an exacerbation. 
Methods: A total of 149 samples were collected from 18 adult CF patients attending 
a clinic at the RVI hospital, Newcastle upon Tyne. The samples were subject to 
DNA extraction followed by bacterial and fungal community analysis as well as 
qPCR analysis of the bacterial load.  
Results: Bacterial diversity, species richness and FEV1 % predicted displayed a 
negative correlation with patient age. Analysis of the individual patients found that 
there was a constant turnover of bacterial taxa across the sampling period which was 
increased depending on the number of I.V. antibiotic therapies the patient received 
during the study. Fungal taxa identified in our study displayed both chronic and 
transient colonisation of the CF lung. 
Conclusions: Our data suggests that the bacterial and fungal communities of the CF 
lung do not fluctuate to create a characteristic community profile that is associated 
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with acute exacerbations. Furthermore, the abundance of bacterial species and the 
bacterial load were not the cause of exacerbations in our cohort. 
 
6.1 Introduction 
 
Longitudinal studies in CF have provided useful insights into the risk of aging in CF 
with clinical parameters such as lung function decline and the increased incidence of 
cystic fibrosis related diabetes (Corey et al. 1997; Marshall et al. 2005). Furthermore, 
bacterial succession in the major CF pathogens has been well characterised by the 
CF foundation which shows that children are most likely to be colonised by S. 
aureus and H. influenzae and during adolescence these organisms will largely be 
replaced by P. aeruginosa (Cystic Fibrosis Foundation 2009). Many studies in CF 
focus on P. aeruginosa due to its association with an increased incidence of 
morbidity and mortality (Sagel et al. 2009). These studies find that P. aeruginosa 
strains alter their gene expression profiles, switch to a mucoid phenotype and invoke 
changes in cell surface receptors to evade the immune response (Stewart & Costerton 
2001; Leid et al. 2005; Smith et al. 2006; Cigana et al. 2009). 
Although the polymicrobial nature of the CF respiratory tract has been well 
established by culture and molecular techniques, only recently has the investigation 
into the temporal variation in the microbial communities has been undertaken using 
molecular techniques (Cox et al. 2010; Tunney et al. 2011). Cox et al. (2010) used 
an age stratified study of CF patients to determine how the CF lung microbiota may 
change over time. The advantage to a stratified study is that patients need only give 
one sample and are not followed over a period of years and therefore, patient 
compliance is not an issue. Using this technique, Cox et al. (2010) demonstrated that 
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bacterial diversity, community richness and evenness decreased with increasing age 
and, that members of the family Pseudomonaceae are most predominant in older CF 
patients. This finding suggests that eventually all CF patients may succumb to 
colonisation by P. aeruginosa regardless of genotype, sex or any other parameter 
that has been investigated thus far. However, the mechanisms regarding the ability of 
P. aeruginosa to colonise the vast majority of CF patients and why particular 
patients become colonised sooner than others cannot be elucidated using a stratified 
study. Tunney et al. (2011) examined the relationship between bacterial richness and 
load during times of pulmonary exacerbation. They found that, as expected, I.V. 
antibiotics reduced the numbers of viable aerobic and anaerobic bacteria present in 
the lung. However, very little change in the overall community richness was 
observed between exacerbation, post-I.V. antibiotics and stable bacterial 
communities. These data suggests that the bacterial communities present in the CF 
lung are resistant to perturbation by antibiotics which is supportive of earlier data 
(Mulcahy et al. 2010).  
Many species of fungi have been identified that can colonise the CF lung but very 
little work has been carried out on the persistence of these organisms (Haase et al. 
1991; Bouchara et al. 2009). The longitudinal analysis of fungal colonisation in 
individual patients is yet to be assessed over a long period. However, a short follow 
up during the assessment of a new microarray for detection of fungal pathogens in 
CF found that fungi could be chronic or transient coloniser over a short period 
(Bouchara et al. 2009). This was supported by the culture data they collected during 
the study. 
Here, we aimed to assess the diversity and stability of both bacterial and fungal 
communities in a longitudinal study. We investigated whether changes in the 
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bacterial and fungal community structure and diversity have a demonstrable link to 
pulmonary exacerbations in CF and whether fungal species are chronic colonisers of 
the CF lung. 
6.2 Methods 
 
An 18 patient cohort was followed over a 20 month period, where both stable and 
exacerbation samples were collected. A total of 149 samples comprosed of 100 
stable and 49 exacerbation samples with a mean of 8.2 samples collected from each 
patient (Range 4-15). Patient age (32.33 ± 13.00), gender (9 Males: 9 Females), 
genotype (10 F508del:F508del, 8 F508del:OM), FEV1 (% Predicted), clinical status 
(100 stable:49 exacerbation), microbiological culture results, routine and I.V. 
antibiotics were collected at each sampling point (Appendix 12).  
6.3 Results 
 
6.3.1 Whole cohort analysis 
 
Shannon diversity index, bacterial species richness and bacterial community 
evenness were calculated to assess the relationship between patients. These data 
along with FEV1 % predicted, age and fungal species richness were analysed using 
Pearson product moment correlation to assess which of the continuous variables 
affected the microbial community (Table 6.1). Pearson product moment correlation 
found that FEV1 % predicted, Shannon diversity and bacterial species richness had a 
significant negative correlation with age (P = <0.0001, 0.004 and <0.001 
respectively; Table 6.1).  
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Table 6.1 Pearson product moment correlations demonstrating the relationship 
between the continuous variables collected from the patient cohort 
 
   Age   FEV1 (% Predicted) Bacterial load  
FEV1 (% Predicted)  -0.607      
   P < 0.0001      
Bacterial load  0.005  0.045    
   P = 0.947  P = 0.587    
Shannon Diversity  -0.233  0.308 0.034  
   P = 0.004   P = <0.0001 P = 0.680  
Bacterial Richness  -0.270  0.245 0.014  
   P = 0.001   P = 0.003 P = 0.865  
Bacterial Evenness  -0.112  0.220 0.048  
   P = 0.173  P = 0.008 P = 0.557  
Fungal Richness  0.075  -0.032 0.125  
   P = 0.361  P = 0.705 P = 0.130  
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Figure 6.1 Whole cohort analysis of FEV1 (% Predicted) when stable and presenting 
with an exacerbation 
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Furthermore, Shannon diversity, bacterial species richness and bacterial community 
evenness displayed a positive correlation with FEV1 % predicted (P = <0.001, 0.003 
and 0.008 respectively).  
One way ANOVA comparing clinical status with FEV1 % predicted, Shannon 
diversity, bacterial species richness, bacterial community evenness, fungal species 
richness and bacterial load found that when patients presented with an exacerbation 
they had a significant reduction in FEV1 % predicted compared to samples collected 
when stable (P = 0.023; Fig 6.1).  
6.3.2 Stability of bacterial communities 
 
Dice similarity was calculated using PAST (Hammer et al. 2001) to evaluate the 
percentage similarity of banding patterns over time between consecutive sampling 
points for individual patients. The mean pair-wise percentage similarity over the 
entire sampling period was 72.0% (Range 60.9 – 92.2%). Analysis on our cohort as a 
whole and the results from previous studies suggests that bacterial diversity declines 
with age. In order to determine if our study period was of sufficient length to 
determine this change, Pearson product moment correlation was calculated using 
Shannon diversity, bacterial species richness and bacterial community evenness and 
time across the study period (months). A significant reduction in bacterial diversity 
was observed in only one patient (Table 6.2). To assess the effect of I.V. antibiotics 
on bacterial community stability the number of I.V. antibiotic therapies was 
normalised against the total number of samples for each patient and compared to the 
mean percentage similarity. The normalised values and the mean similarities were 
then analysed using Pearson product moment correlation and a significant negative  
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Table 6.2 Correlation analysis of bacterial diversity, richness and evenness over the 
duration of the study 
 
 
Richness Shannon diversity Evenness 
Patient Correlation P-value Correlation P-value Correlation P-value 
1 -0.328 0.298 0.384 0.218 0.732 0.007 
2 -0.317 0.250 -0.455 0.088 -0.389 0.152 
3 -0.721 0.067 -0.611 0.145 0.536 0.215 
4 0.406 0.367 -0.160 0.731 -0.730 0.062 
5 0.649 0.115 0.605 0.150 0.262 0.571 
6 0.069 0.849 0.208 0.564 0.229 0.524 
7 -0.504 0.202 -0.692 0.057 -0.699 0.054 
8 0.891 0.017 0.502 0.311 -0.282 0.588 
9 -0.769 0.006 -0.754 0.007 -0.474 0.140 
10 0.067 0.853 0.430 0.215 0.458 0.183 
11 0.088 0.821 0.401 0.285 0.492 0.178 
12 0.538 0.213 0.633 0.127 -0.427 0.340 
13 -0.111 0.834 0.747 0.088 0.844 0.035 
14 0.775 0.225 0.855 0.145 0.622 0.378 
15 0.098 0.817 0.025 0.954 -0.029 0.946 
16 -0.553 0.198 -0.569 0.182 -0.153 0.744 
17 0.866 0.058 0.332 0.586 -0.200 0.746 
18 -0.103 0.776 -0.099 0.786 -0.091 0.802 
Mean 0.058 
 
0.099 
 
0.039 
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Figure 6.2 Bacterial communities are less similar when patients have had a greater 
number of I.V. antibiotic therapies during the course of the study 
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correlation was observed suggesting more I.V. interventions led to a decrease in the 
similarity of the bacterial communities (P = 0.02; Fig 6.2).  
 
6.3.3 Relationship between bacterial communities and exacerbation in CF 
 
To determine whether bacterial load was related to exacerbations one-way ANOVA 
analysis was carried out on the entire cohort. This analysis found that the total 
bacterial load was not significantly different between samples obtained when the  
patients were stable or having an exacerbation (P = 0.580). This analysis was 
repeated for each individual to examine whether changes in bacterial load were being 
masked by the variation between patients. The bacterial load for individual patients 
was not significantly different between samples obtained when the patients were 
stable or presenting with an exacerbation (Table 6.3). 
A cluster analysis was performed on the presence/absence (binary) band matrix to 
determine if samples obtained when the patients presented with an exacerbation 
group separately from those obtained when the patients were stable. The cluster 
analysis shows that there is no split between stable and exacerbation derived samples 
(Fig 6.3). Therefore, DCA analysis was used to determine whether RDA or PCA 
should be used to further examine the band matrices for presence absence and 
abundance of bacterial taxa. The DCA gave an axis length of 2.58 for the binary 
band matrix and 2.50 for the abundance band matrix which indicated that RDA 
analysis should be used for further analysis. The RDA analysis was performed for 
both band matrices with clinical status as the only environmental variable 
considered. The RDA analysis found that neither was significantly correlated to  
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Table 6.3 Individual patient analysis of bacterial load when stable and presenting 
with an exacerbation 
 
Patient 
Stable mean 
Bacterial load  
Exacerbation mean 
Bacterial load  
Bacterial load v Clinical 
status (P-value) 
1 9.02 9.37 0.639 
2 8.09 8.37 0.424 
3 9.04 8.79 0.261 
4 8.96 9.50 0.550 
5 9.15 9.25 0.809 
6 7.87 7.55 0.521 
7 8.76 8.79 0.924 
8 9.13 N/A N/A 
9 8.54 8.42 0.784 
10 7.84 8.57 0.255 
11 9.39 8.81 0.625 
12 8.39 8.93 0.481 
13 8.67 8.73 0.671 
14 9.61 9.40 0.822 
15 9.62 9.97 0.404 
16 8.90 8.92 0.905 
17 9.00 9.15 0.388 
18 9.10 N/A N/A 
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Figure 6.3 Cluster analysis of the entire patient cohort  
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Figure 6.4 RDA showing the relationship of the presence of each bacterial taxa with 
clinical status  
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Figure 6.5 RDA showing the relationship of the abundance of each bacterial taxa 
with clinical status 
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clinical status, yielding P values of 0.192 for the binary band matrix and 0.236 for 
the abundance band matrix. Biplots of species against clinical status were created to 
see if individual bands in either profile displayed a strong correlation with clinical 
status. The biplots show that there were no significant correlation present between 
individual taxa and clinical status when examining the entire cohort (Fig 6.4 & 6.5 
respectively). In order to determine if there was a change in any aspects of the 
community, Shannon diversity index, bacterial species richness and bacterial 
community evenness were calculated for the abundance profiles and analysed against 
clinical status using one-way ANOVA. None of these factors were significantly 
different between samples obtained when the patients were stable or having an 
exacerbation (P = 0.774, 0.285 and 0.675 respectively). 
The binary and abundance DGGE profiles for individual patients against clinical 
status were then analysed using RDA to see if the overall variance was masking 
changes in individual patients. Only patients who had greater than one exacerbation 
were included in this analysis to prevent casual trends being linked to exacerbations. 
These analyses found that none of the patients had significantly different bacterial 
communities in the stable and exacerbation samples (Table 6.4). 
Biplots were created using the RDA data for the binary band matrix of each patient 
to see if the presence of particular bacterial taxa were linked to clinical status. The 
biplot from patient 16 shows that two taxa that were strongly correlated with an 
exacerbation (Fig 6.6). Further investigation found that bands 21 and 76 were present 
in all of the samples obtained when the patient presented with an exacerbation (n = 
3) and none of the samples obtained when the patient was stable (n = 4). The RDA 
analysis was repeated for the abundance band matrix for each patient who had  
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Table 6.4 Bacterial community binary and abundance RDA P-Values comparing 
stable and exacerbated bacterial communities 
 
  Presence band matrix  Abundance band matrix  
Patient P-value P-value 
P1 0.888 0.570 
P2 0.098 0.320 
P3 0.948 0.546 
P5 0.652 0.446 
P6 0.514 0.304 
P7 0.450 0.776 
P9 0.918 0.404 
P10 0.516 0.492 
P11 0.892 0.724 
P12 0.860 0.600 
P13 0.904 0.720 
P16 0.096 0.104 
P17 0.700 0.902 
   
137 
 
 
 
Figure 6.6 RDA analysis of the binary band matrix for patient 16   
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greater than one exacerbation and found that none of the cohort had the increased 
abundance of any taxa associated with an exacerbation. 
6.3.4 Fungal community analysis  
 
From the cohort, 94% (17/18) of the patients had a fungal isolate detected from at 
least one of the samples during the study period. Of the 149 samples collected, 42% 
(63/149) were positive for fungal species. A total of 89 bands were identified in the 
positive samples. Analysis of the fungal communities by DGGE found that all but 
one patient had fungal colonisation on at least one sampling date; however, this 
patient was receiving antifungal therapy for part of the study period. The Dice index 
could not be calculated for fungal communities due to at least one sample being 
negative for fungal species in the majority of patients. Therefore, cluster analysis 
was performed and qualitative analysis of the gels was used to examine fungal 
colonisation patterns. Cluster analysis found that patient 17 was colonised by the 
same fungal species for the entire sampling period (Fig 6.7a). Similarly, patient 13 
was colonised by fungi from the second sample date and this taxa persisted for the 
remaining samples collected (Fig 6.7b). The cluster analysis from the remainder 
patients revealed that particular taxa were present in the patient on at least one 
sampling date but then disappeared. Interestingly, in eight of the patients, several 
bands went through periods of presence and absence throughout the sampling period. 
 
The Pearson product moment correlation of fungal species richness against the 
continuous variables (described above) found that there were no significant 
correlations present. One-way ANOVA analysis found that fungal species richness  
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(a) 
  
 
 
(b) 
  
Figure 6.7 Cluster analysis for (a) patient 17 who was chronically colonised for the 
duration of the sampling period and (b) patient 13 who acquired a fungal pathogen 
on the second sampling date  
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was significantly greater in patients who were homozygous F508del compared to 
heterozygotes (P = 0.016). The presence and richness of fungal species was used to 
determine whether fungi were a cause of exacerbations in CF. The analysis found 
that fungal presence and richness were not the cause of exacerbation in CF (P = 
0.802 and 0.795 respectively). 
6.4 Discussion 
 
The progression of CF lung disease is known to be a constant decline in lung 
function towards respiratory failure due to inflammation and infection. Recent 
evidence has found that exacerbations in CF contribute to lung function decline 
(Amadori et al. 2009; Sanders et al. 2010a). A great deal of research has been aimed 
at finding the cause of exacerbation, with bacterial and viral agents being implicated. 
However, a definitive conclusion has yet to be reached. A recent study has 
demonstrated that the bacterial community richness does not change significantly 
after an exacerbation, despite a decrease in bacterial load (Tunney et al. 2011). 
However, the data from this study demonstrates that, although species richness 
remains stable, the community composition is subject to change. Further work 
examining the temporal dynamics of CF microbial communities may provide useful 
information on the susceptibility of these communities.  
Statistical analysis of the entire cohort using diversity measures against continuous 
variables found that FEV1 % predicted, Shannon diversity index and the bacterial 
community richness displayed a significant negative correlation with age (P < 
0.0001, P = 0.004, 0.001 respectively). The decline of FEV1 with age confirms the 
data derived from our cross sectional study and other studies examining lung 
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function in CF (Kerem et al. 1992; Corey et al. 1997). Similarly, the decline of 
bacterial diversity and bacterial community richness has also been identified in a 
recent study (Cox et al. 2010). Our data suggests that, as has been previously 
reported, DGGE analysis is capable of detecting major changes in bacterial 
communities (0.1 – 1 %) which are normally due to the more prevalent taxa (Muyzer 
et al. 1993). However, the methodology used by Cox et al. (2010) does have a 
number of advantages over DGGE. Firstly, microarray analysis can detect bacterial 
taxa that represent as little as 0.01% of the total community with an increased 
sensitivity of up to two orders of magnitude compared to DGGE (Cox et al. 2010). 
The ability to detect the rarer species in a community can be important, especially 
when looking at perturbations (Flanagan et al. 2007; Szabo et al. 2007). Szabo et al. 
(2007) found in a study examining lake water microcosms that certain more 
abundant species in the community were unable to cope with the perturbation 
because they lacked a particular functional gene. As a consequence, rarer members 
of the community with the gene were able to take advantage of the new resource and 
flourish (Szabo et al. 2007). Similarly, in a study examining the microbial 
communities of patients on mechanical ventilation, microarray analysis identified 
Klebsiella as a minor component in the starting community composition that 
eventually became dominant after antibiotic administration. This observation was 
missed by clone library analysis, adding weight to the findings that under the right 
conditions rare taxa can become dominant under specific conditions and more robust 
techniques are required to detect these changes (Flanagan et al. 2007). An additional 
advantage of microarray analysis is that it identifies the bacterial taxa present in the 
lung without the need for further laboratory work, whereas, DGGE analysis requires 
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multiple rounds of band excision and re-amplification prior to DNA sequence 
analysis of the band.  
Current ecological thinking suggests that niche (deterministic) community assembly 
will lead to a single stable equilibrium as species sorting occurs along the gradients 
present in the environment. In contrast, a neutral (stochastic) community assembly 
model predicts multiple stable equilibria as species randomly arrive, with each 
species being regarded as ecologically equivalent, resulting in divergent community 
assembly (Fargione et al. 2003). In reality, microbial communities are likely to 
assemble by neither strictly niche or neutral mechanisms. A study by van der Gast et 
al. (2008) demonstrated that environmental selective pressure switches community 
assembly from stochastic to more deterministic assembly. Therefore, the addition of 
selective pressure to the CF lung microbiota may select for bacterial taxa that 
possess the fitness traits to survive. Cox et al. (2010) found that bacterial 
communities in the CF lung became more diverse until patients reached adolescence 
which was followed by a decrease in bacterial diversity, richness and evenness. This 
finding suggests that the decreased diversity in bacterial communities between older 
CF patients may be driven by selective pressures towards a deterministic community 
assembly model. We also found that bacterial diversity (P = 0.004) and community 
richness (P = 0.001) decreased with age but we did not find a significant relationship 
between bacterial evenness and age when examining the whole cohort (P = 0.173). 
Furthermore, Cox et al. (2010) found that as patients age the bacterial community 
composition becomes more closely related to those of other patients than between 
younger individuals. This data suggests that bacterial community assembly in 
younger patients obeys a stochastic assembly rule, whereas in older patients a more 
deterministic community assembly is observed. However, the selective pressures that 
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cause the community assembly to shift from a stochastic to a more deterministic 
community assembly remain to be elucidated.  
 
6.4.1 Temporal dynamics of the CF lung microbiota 
 
Although we have demonstrated that diversity and richness displayed a significant 
reduction as patients age, the temporal dynamics within patients has yet to be 
elucidated. We monitored bacterial diversity, species richness and community 
evenness in each patient throughout the study period. We detected a reduction in 
diversity and richness between patients, however, the within patient diversity, 
richness and evenness did not change significantly over the study period in most 
cases. We found that only patient 9 had a significant reduction in sputum bacterial 
diversity over the study period (Table 6.2). The mean Bacterial diversity, richness 
and evenness were close to zero. However, it was evident from visual analysis of the 
DGGE profiles that immigration and extinction of bacterial taxa was occurring. 
Therefore, the Dice pair-wise similarity between consecutive sample points within 
individual patients was used to measure the stability of the bacterial community 
profiles. The Dice similarities observed in the patient cohort had a mean of 72.0% 
(Range 60.9 – 92.2%) within individual patients. This is greater than the similarity 
between patients observed in our cross sectional study where the bacterial 
communities displayed only 41% similarity (Page 90). The greater variation seen 
between patients compared to within patients has been demonstrated in other human 
body sites. For example, the mean stability of the bacterial communities in the oral 
cavity was approximately 88% within patients and only 66% between patients 
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(Rasiah et al. 2005). Our data adds weight to the claim that microbial communities 
are patient specific in CF.  
We also found that in all patients, certain taxa persist throughout the sampling period 
regardless of the number of perturbations. This finding is in concordance with a 
recent study that identified a core CF microbiome (van der Gast et al. 2010). 
Furthermore, evidence from the CF Foundation found that P. aeruginosa had been 
isolated from up to 80% of CF adults suggesting that these organisms have a 
selective advantage when colonising the CF lung (Cystic Fibrosis Foundation 2009). 
Using the aligned PCR-DGGE banding pattern for bacteria alongside the ladder of 
known organisms we attempted to define the frequency of P. aeruginosa across the 
entire patient cohort. There are some caveats for identifying bacteria by DGGE using 
a ladder of known organisms. The first is that single species of bacteria can carry 
several heterogeneous copies of the 16S rRNA gene (Dahllöf et al. 2000) 
Furthermore, the predominant band from several organisms can have the same 
migration distance through the gel resulting in one band possibly relating to several 
bacterial taxa (Jackson et al. 2000). The most predominant organism identified was 
P. aeruginosa which was present in 91% of the samples. However; bands relating to 
P. aeruginosa have a similar Rf to other Pseudomonas spp, such as P. fluorescens 
(Fig 4.1). In contrast, recent work suggests that other members of the genus are not 
regularly colonising CF patients (Spilker et al. 2004). One reason that P. aeruginosa 
and other organisms may be able to persist in the CF lung is the formation of 
biofilms which increase resistance to the immune response and antibiotics (Stewart 
& Costerton 2001; Leid et al. 2005). Furthermore, recent evidence suggests that 
persister cells may also contribute to the maintence of P. aeruginosa (Mulcahy et al. 
2010). Persister cells are a phenotypic variant of P. aeruginosa that display reduced 
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levels of metabolic activity and, therefore, increased tolerance to antimicrobials 
(Mulcahy et al. 2010). The two mechanisms may contribute to the maintenance of 
bacterial diversity seen in our patient cohort in-spite of repeated antimicrobial 
perturbation.  
A study on the bacterial communities of the gut has found that administration of 
antibiotics reduces the similarity between sampling points within patients by 
removing susceptible bacterial species (Donskey et al. 2003). Further research on the 
effect of antimicrobials on the gut microbiome has revealed that the majority of the 
bacterial taxa in the pre-treatment sample recovered within 4 weeks but some taxa 
failed to repopulate the gut during the study period (Dethlefsen et al. 2008). 
Therefore, the use of oral antibiotics used to manage the bacterial communities of the 
CF lung coupled with the sporadic administration of I.V. antibiotics may cause a 
decrease in similarity between sampling points as seen in the bacterial communities 
of the gut. The similarity of the gut community has been previously examined using 
PCR-DGGE and the mean within patient similarity was between 88 and 91% for 
samples collected over an eight month period (Donskey et al. 2003). However, when 
the patients received ciprofloxacin and clindamycin the consecutive similarity 
dropped to 73% and 11% respectively. The mean similarity seen for our CF cohort 
was 72% which suggests that routine antibiotics may contribute to species turnover 
in the CF lung as indicated by the reduced similarity between samples but the 
relative stability of bacterial diversity across the study period. As all of the patients 
were receiving at least one oral antibiotic, the number of I.V. antibiotic therapies was 
used to see if the administration of I.V. antibiotics increased bacterial species 
turnover. We compared the mean similarity from each patient to the number of 
perturbations by I.V. antibiotic therapies received during the study period. We found 
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a significant negative correlation between the normalised number of I.V. antibiotic 
therapies and the mean percentage similarity between the sampling dates from the 
patients (P = 0.02). However, the lowest mean pair-wise similarity was 60.9% which 
suggests that the bacterial communities of the CF lung are not as susceptible to 
perturbation as those of the gut. Tunney et al. (2011) compared the bacterial richness 
pre and post exacerbation and this did not change significantly even after I.V. 
therapy. Their data suggests that the hypothesis of I.V. antibiotic administration 
reducing bacterial diversity and thus, increase the risk of invasion may not be 
accurate. However, we have shown here that, although diversity, richness and 
evenness remained fairly constant over the study period that the composition of the 
community was subject to change and that this was affected by the number of I.V. 
antibiotic treatments received. Therefore, it would also be interesting to study the 
effects of different combinations of I.V. antibiotics on community composition 
within individual patients (Tunney et al. 2011). We have some anecdotal evidence 
surrounding this relationship within individual patients. However, a major caveat in 
examining this relationship in our study is the length of time between receiving I.V. 
antibiotic treatment and the next sampling date. Therefore, a more controlled 
sampling regimen would be required to analyse this relationship.  
One relationship that remains to be examined is the community dynamics regarding 
exacerbations in CF. It may be the case that the rate of change in the community is 
indicative of an exacerbation, where communities with an increased turnover are 
more susceptible to exacerbation. However, as the patients received I.V. antibiotics 
after presenting with an exacerbation, and we have shown that this affects species 
turnover, the relationship between species turnover and exacerbations could not be 
examined in this study.  
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In the cross sectional study, we found the fungal communities of CF sputum to be 
more diverse than is suggested by culture. Here, we aimed to follow patients 
longitudinally to determine if fungi are persistent or transient colonisers of the CF 
lung. We demonstrated that fungal bands were identified in at least one sample by 
DGGE in 94% (17/18) of patients. The patient who did not give a sample that was 
positive for fungi was receiving the antifungal agent itraconazole for part of the 
sampling period and was the only patient who received antifungal therapy at any 
point during the study. Fungal species were identified in 42% (63/149) of the 
samples collected from the entire patient cohort. From the samples positive for fungi, 
a total of 10 distinct fungal species were identified. In total, 89 fungal species were 
identified from the positive samples. We used cluster analysis to determine the 
similarity between fungal communities within individual patients (Fig 6.7). We 
found that patient 17 had chronic fungal colonisation that persisted for the entire 
sampling period. Furthermore, we found that patient 13 was positive for fungi on the 
second sampling date and this persisted in the samples collected subsequently. The 
band that persisted throughout the sampling period in patient 17 related to C. 
parapsilosis and the band that colonised and persisted in patient 13 related to C. 
albicans. This data suggests that fungal species can chronically colonise the LRT of 
CF patients. However, the other patients enrolled in the study only sporadically 
presented with fungal positive specimens. Interestingly, in eight of the patients who 
sporadically presented with fungal species, the same band seemed to re-colonise the 
lung across the sampling period. These bands related to C. albicans in 3 of the 
patients, C. dubliniensis in 3 patients and C. parapsilosis in 2 of the patients. Patient 
4 was sporadically colonised by C. dubliniensis and C. albicans across the study 
period. These data taken together suggest that fungal species have the ability to 
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chronically colonise the CF lung but that they do not always persist. Furthermore, 
the same fungal species seem to cycle through periods of presence and absence 
during the sampling period that we tested. These data may suggest that these patients 
are being re-exposed to the same pathogen repeatedly, which may implicate the oral 
cavity as a reservoir for fungal, as well as bacterial pathogens. The fungal 
microbiome of the oral cavity of CF patients has not been assessed regarding fungal 
pathogens. However, a recent study on the fungal species present in the oral cavity of 
healthy subjects found that common CF pathogens were present (Ghannoum et al. 
2010). These included members of the genus Aspergillus, although not A. fumigatus, 
C. albicans, C. paprapsilosis which we identified in our cross sectional study as well 
as C. tropicalis that has been identified from CF sputum in previous studies 
(Bouchara et al. 2009) and S. cerevisiae which we also identified in the cross 
sectional study (Ghannoum et al. 2010). 
 
6.4.2 Exacerbations in CF 
 
It has been shown that exacerbations cause not only a short bout of ill health, but 
also over time, they contribute to lung function decline (Amadori et al. 2009; 
Sanders et al. 2010a). Pre-emptive treatment of patients thought to be in the early 
stages of an exacerbation without severe symptoms has been vindicated in adults and 
children (Sanders 2010a; Sanders et al. 2010b). Current theories regarding 
exacerbations include acquisition of bacterial or viral pathogens and an increase in 
the bacterial load. In our study, an exacerbation was defined as deterioration in their 
clinical status with an increase in cough, sputum or chest symptoms, and/ or a fall in 
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FEV1. Therefore, we wanted to ensure that clinical symptoms, indicated by a 
decrease in FEV1, were the main prognostic indicator in the study. In order to 
achieve this aim, we compared the FEV1 when patients were stable to when they 
presented with an exacerbation to see if there was a significant difference in lung 
function. We found that there was a significantly lower FEV1 in patients when they 
presented with an exacerbation compared to when they were stable (P = 0.006; Fig 
6.1). 
 
6.4.3 Diagnostic bacterial community 
 
Evidence from bacterial vaginosis suggests that a shift in environmental conditions 
can cause a pathologic community to assemble which causes disease (Oakley et al. 
2008). Anecdotal evidence from a study in CF found that a shift in bacterial 
community structure during an exacerbation was not evident in CF (Sibley et al. 
2008b). Recently, Tunney et al. (2011) examined the relationship between Bacterial 
diversity and load during times of pulmonary exacerbation. They found that, as 
expected, I.V. antibiotics reduced the numbers of viable aerobic and anaerobic 
bacteria present in the lung. However, very little change in the overall community 
composition was observed between exacerbation, post-I.V. antibiotics and stable 
bacterial communities using T-RFLP. In order to examine this relationship further, 
we examined the binary band matrix for the entire cohort using cluster analysis to 
see if samples obtained during an exacerbation clustered separately from the stable 
samples (Fig 6.3). However, this analysis did not demonstrate separate clustering of 
stable and exacerbation samples. In order to confirm that a diagnostic bacterial 
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community was not responsible for exacerbations we analysed the binary band 
matrix against clinical status using RDA to see if a significant difference was 
observed. This analysis confirmed that the samples obtained when the patients 
presented with an exacerbation were not significantly different from the stable 
samples across the entire cohort (P = 0.192). In order to investigate if there was a 
change in any aspects of the community Shannon diversity index, bacterial species 
richness and bacterial community evenness were calculated for the abundance 
profiles and analysed against clinical status using one-way ANOVA. None of these 
factors were significantly different between samples obtained when the patients were 
stable or having an exacerbation (P = 0.774, 0.285 and 0.675 respectively). 
However, evidence from our previous work and from other studies suggests that 
patients have their own characteristic bacterial community (Rogers et al. 2004; 
Rogers et al. 2005; Harris et al. 2007). Therefore, we decided to examine the binary 
band matrix of each patient individually to see if a patient specific bacterial 
community assembled to cause an exacerbation using RDA with clinical status as the 
environmental variable (Table 6.4). The data from the cohort suggests that a shift in 
bacterial community composition, at least in terms of the major taxa that can be 
detected using the methods employed in the study, is most likely not the cause of 
exacerbations in CF which confirms the findings of previous studies (Sibley et al. 
2008b; Tunney et al. 2011). A potential reason for this may be the sampling 
strategies used in this study to sample the microbial communities. Davis et al. (2007) 
found that inflammation in the lung is confined to a small area during exacerbations. 
Therefore, sampling whole sputum may be inadequate to examine effects that are 
being confined to a localised area. However, to circumvent this problem and analyse 
the appropriate region of the lung would require utilising computerised tomography 
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scans of the patients when they present with an exacerbation, followed by a BALF 
sample to sample the appropriate lobe. Although invasive, this approach does 
demonstrate the heterogeneity of bacterial distribution throughout the CF lung 
(Gutierrez et al. 2001; Davis et al. 2007).  
6.4.4 Acquisition of new taxa 
 
The acquisition of new bacterial taxa has been suggested as a possible cause for 
exacerbation in CF (Sibley et al. 2008b). Sibley et al. (2008) found that members of 
the SMG were only isolated when patients presented with an exacerbation. 
Furthermore, they found that treatment directed at these organisms resolved the 
exacerbation. The binary band matrix for the whole cohort was analysed using RDA 
to see if individual taxa, defined as bands in the DGGE profile, displayed a strong 
correlation with clinical status. This analysis found that there were no significant 
correlation present between individual taxa and clinical status (Fig 6.4). We then 
repeated this analysis for the binary matrix for individual patients. Only patients who 
had greater than one exacerbation were included in this analysis because any species 
acquired in patients with only a single exacerbation would display a strong 
correlation when this could be merely due to species turnover. Biplots were created 
for each patient to see if the presence of particular bacterial taxa were linked to 
clinical status. This analysis found strong correlations in only one patient (Fig 6.6). 
Further investigation found that bands 21 and 76 were present in all of the samples 
obtained when the patient presented with an exacerbation (n = 3) and none of the 
samples obtained when the patient was stable (n = 4). Unfortunately, neither of these 
bands corresponded with the ladder of common CF isolates that were included on the 
DGGE gel so they could not be identified. It may be the case that this phenomenon is 
152 
 
present in other patients included in the study but the bands are being obscured by 
co-migration of the 16S rRNA fragments with those from other taxa. Using a more 
robust methodology such as microarray will give a more in-depth understanding of 
bacterial community dynamics during exacerbations.  
6.4.5 Increased bacterial burden 
 
Treatment strategies for CF exacerbations are targeted at reducing the load of 
pathogenic bacteria, namely P. aeruginosa (Regelmann et al. 1990). To determine 
whether bacterial load was related to exacerbations one-way ANOVA analysis was 
carried out on the entire cohort. This analysis found that the total bacterial load was 
not significantly different between samples obtained when the patients were stable or 
having an exacerbation (P = 0.580). This analysis was repeated for each individual to 
examine whether changes in bacterial load were being masked by the variation 
between patients. The bacterial load for individual patients was not significantly 
different between samples obtained when the patients were stable or presenting with 
an exacerbation (Table 6.3). We then went on to examine whether the abundance of 
individual bacterial taxa was the cause of exacerbation in CF. The abundance band 
matrix for the bacterial profiles from the whole cohort was analysed using RDA to 
see if there was a significant difference between stable and exacerbation samples. 
This analysis found no significant differences between the stable and exacerbation 
samples (P = 0.236). From the RDA analysis, a biplot of species against clinical 
status was created to see if the abundance of individual bacterial taxa was strongly 
correlated with an exacerbation. However, this analysis found no strong correlation 
between bacterial abundance and clinical status (Fig. 6.5). We then repeated this 
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analysis for patients who had greater than one exacerbation and also found no strong 
correlations between abundance and clinical status.  
 
6.4.6 Fungal acquisition 
 
Traditionally in CF, only A. fumigatus and C. albicans were identified as fungal 
pathogens. However, it is only recently that these species are being linked with CF 
exacerbations (Amin et al. 2010; Chotirmall et al. 2010). Amin et al. (2010) found 
that patients colonised with A. fumigatus were at an increased risk of hospitalisation 
but that A. fumigatus infection was not significantly associated with an increased risk 
of exacerbations. However, recent work on C. albicans has found that both chronic 
and intermittent infection is significantly associated with an exacerbation 
(Chotirmall et al. 2010). Therefore, we decided to examine the relationship between 
fungi and clinical status in CF. The presence and richness of fungal species was used 
to determine whether fungi were a cause of exacerbations in CF. The analysis found 
that fungal presence and richness were not significantly different between stable and 
exacerbation samples (P = 0.802 and 0.795 respectively). Therefore, the diversity of 
fungi is not significantly different between stable and exacerbation samples. 
Suggesting, the presence of fungi is unlikely to be the cause of exacerbations in CF. 
However, particular species, such as C. albicans, may predispose patients to 
exacerbations. 
 
6.5 Conclusions 
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In this study we have followed 18 adult CF patients over a 20 month period to assess 
the dynamics of the bacterial and fungal communities. We have found, by examining 
between patients, that the bacterial diversity and community richness is significantly 
lower in older patients with CF, which is concordance with a previous study (Cox et 
al. 2010). However, we found that a reduction in diversity, richness and evenness 
was not seen within patients over the course of the study period. We have also 
demonstrated that, within patients, the bacterial communities fluctuate between 
sampling dates but that certain taxa persist throughout the study period. Furthermore, 
the degree of variance between the samples is increased in patients who received a 
greater number of I.V. antibiotic interventions during the study. However, we could 
not assess whether the dynamics of the bacterial communities where indicative of an 
exacerbation due to the administration of I.V. antibiotics. It would be interesting to 
investigate whether an increased rate of species turnover in the bacterial 
communities was correlated with an increase in the number of exacerbations. 
However, I.V. antibiotics are an important intervention which alleviate the 
symptoms of exacerbations and improve patient quality of life. Therefore, any study 
examining this relationship would have to be investigated using an appropriate 
animal or in-vitro model.  
Recent studies have found that a pathogenic bacterial community assembles to cause 
bacterial vaginosis which is thought to be initiated by changes in environmental 
conditions (Oakley et al. 2008). Therefore, a shift in environmental conditions may 
cause the assembly of a characteristic community and cause exacerbations in CF. 
However, we have demonstrated that a diagnostic bacterial community does not 
assemble to cause exacerbations in CF which supports the work from previous 
studies (Sibley et al. 2008b; Tunney et al. 2011). Furthermore, we have examined 
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the link between acquisition and abundance of key taxa using PCR-DGGE and found 
no evidence that these factors are linked with exacerbations in CF. However, DGGE 
analysis can only identify the most dominant taxa in the community and further work 
using more sensitive techniques will be required to make any solid conclusions.  
Traditionally, only C. albicans and A. fumigatus were considered as pathogens in CF 
respiratory infection (Amin et al. 2010; Chotirmall et al. 2010). However, recent 
work has found that many more fungal taxa are capable of colonising the CF lung 
(Cimon et al. 2005; Bouchara et al. 2009). Therefore, it is important to assess the 
prevalence and pathology caused by these organisms. We have found that fungal 
species were found in at least one sample from all but one patient in this study. 
Furthermore, we found that fungal species could persist in the CF lung, although 
some were only transient colonisers. The factors that affect fungal colonisation in CF 
need to be investigated to achieve a better understanding of their role in the 
community. However, research suggests that colonisation with particular fungal taxa 
can reduce lung function and increase the risk of exacerbations in CF patients 
(Cimon et al. 2005; Bouchara et al. 2009). Our data shows that the presence and 
richness of fungal taxa is not the cause of exacerbations in CF.  
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7. Concluding Remarks 
 
The lower respiratory tract is a diverse environment harbouring complex microbial 
communities. In previous studies, it has been demonstrated that bacterial, fungal and 
viral pathogens cause lung function decline and ultimately result in death due to 
respiratory failure. However, how these communities interact and the factors that 
cause particular organisms to frequently colonise this environment remains to be 
elucidated. In this study we aimed to characterise the intrinsic and extrinsic factors 
which have an effect on bacterial and fungal communities present in the CF lung in a 
cohort of patients who were homo- or heterozygous for the F508del CFTR allele. A 
further objective was to follow these patients longitudinally, to determine the 
stability of the CF lung microbiota, the effects of antibiotic therapy, and to assess if 
any changes occurred in the CF lung during times of pulmonary exacerbation which 
could be identified as the causative agent. 
 
7.1 Assessment of sample handling practices on microbial activity in sputum 
samples from cystic fibrosis patients 
 
The aim of element of the project was to examine the effects of sample storage on 
molecular microbiological analysis of the communities in CF sputum. We found that 
storage of samples at room temperature caused a shift in the bacterial communities 
present in the CF sputum. This shift was characterised by an over estimation of the 
bacterial load and the numbers of Pseudomonas spp. and a reduction in the numbers 
of H. influenzae. Furthermore, the bacterial communities detected by DGGE 
demonstrated an increased similarity when stored at room temperature whereas the 
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refrigerated samples appeared to be less similar. This phenomenon may be due to the 
overgrowth of particular bacterial taxa, such as Pseudomonas spp., masking the 
variability between the lung microbiome of different CF patients.  
However, sample storage appeared to have less of an effect on the fungal 
communities present in CF sputum samples. The PCR-DGGE analysis of these 
communities demonstrated that the bands found in the samples stored at room 
temperature were less intense than those that had been refrigerated immediately. 
 
7.2 Bacterial and fungal communities present in the lungs of cystic fibrosis patients 
with a severe genotype are affected by genetic and environmental factors 
 
In this study we aimed to characterise the intrinsic and extrinsic factors which have 
an effect on bacterial and fungal communities present in the CF lung in a cohort of 
patients who were homo- or heterozygous for the F508del CFTR allele. 
Additionally, we investigated whether microbial community assembly in the CF lung 
is stochastic or deterministic. We found that sex was a significant factor in the 
assembly of bacterial communities, due to a reduction in bacterial diversity and 
community evenness. Previous studies have found that less diverse bacterial 
communities are associated with a more severe disease and this may be the reason 
for female CF patients having a poorer prognosis than males. Furthermore, we 
identified that P. aeruginosa colonisation affected bacterial community composition. 
We have yet to identify a reason for this but changes in oxygen availability after P. 
aeruginosa colonisation may be the cause. We have also identified that bacterial 
community assembly in the CF lung appears to be predominantly stochastic. 
However, our data also shows that sex and P. aeruginosa colonisation affect 
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assembly suggesting that some deterministic factors play a role in community 
assembly.  
Fungal communities consisting of up to five different taxa were identified using 
molecular techniques. This data suggests that fungal communities are more diverse 
than is currently recognised. We have also identified that patients who are 
homozygous for the F508del CFTR mutation harbour more rich fungal communities 
than patients who are heterozygous. Therefore, further analysis of the interactions 
with other species and their role in the pathogenesis of CF lung disease is required to 
see if more in depth routine screening for fungal pathogens is required. 
 
7.3 Temporal dynamics of the microbial communities in the Cystic Fibrosis lung  
 
The aim of this study was to assess the diversity and stability of both bacterial and 
fungal communities in individual CF patients. To determine whether changes in the 
bacterial and fungal community structure and diversity have a demonstrable link to 
pulmonary exacerbations in CF and whether fungal species are chronic colonisers of 
the CF lung. We demonstrated that the bacterial communities in older CF patients 
are less diverse and rich than those of younger patients. However, we did not observe 
this relationship over the study period within individual patients. We did observe that 
the bacterial communities within individual patients were not in a steady state and 
that immigration and extinction of species was occurring between consecutive 
sampling dates. However, we also found that some of the species were present 
throughout the sampling period, suggesting that these species may be chronic 
colonisers of the CF lung. To assess the factors that affect species turnover we 
159 
 
compared the stability of the bacterial communities with the number of I.V. 
antibiotic treatments received during the study and found that patients who had 
received a greater number of treatments had less stable communities than patients 
who received fewer treatments.  
We also examined whether fungal species were capable of chronic colonisation of 
the CF lung. We found that in most cases that fungal colonisation was transient, 
although there was evidence in two patients that suggests that fungi can chronically 
colonise the CF lung. We also observed that patients appeared to be repeatedly 
colonised with the same species of fungi, suggesting that they are being repeatedly 
exposed to the source of infection. 
The relationship between bacterial communities and exacerbations in CF was also 
examined. A significant relationship between exacerbations and the bacterial 
communities present was not identified in this study. However, in one patient we 
found that bacterial taxa were present when the patient presented with an 
exacerbation but was absent when the patient was stable, suggesting that acquisition 
of a new bacterial taxa can potentially cause an exacerbation. We also found that an 
increase in bacterial load was not the cause of exacerbations in our cohort. 
Furthermore, the presence and abundance of fungal species was found not to be the 
cause of exacerbations.  
 
7.4 Future work 
 
In this study we have demonstrated that the bacterial communities in the CF lung are 
affected by patient specific factors. However, we have not examined the relationship 
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between these factors and bacterial taxa. Using primers that focus on particular 
groups of bacteria, for example γ-proteobacteria, we could examine whether 
particular groups of CF patients are more prone to infection by particular taxa. 
Furthermore, using more specific primer sets may reveal taxa that were previously 
below the detection threshold when examining the entire bacterial population. 
Furthermore, specific primers sets could be used to assess whether particular groups 
of bacterial taxa are more likely to be chronic colonisers of the CF lung than others. 
Similarly, the efficacy of antibiotics against these organisms could be assessed more 
effectively when examining single groups of taxa compared to the community as a 
whole.  
In this study we have used PCR-DGGE to assess the fungal communities present in 
the CF lung. We have found that this was an effective technique at identifying 
diverse fungal communities. However, the ability of the primer set to detect a wide 
range of CF fungal pathogens has not been assessed. In order to fully determine 
whether these primer sets could be used routinely to differentiate fungal pathogens a 
wide range of known and emerging fungal pathogens is required as well as the 
assessment of similar sets of primers. 
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Appendix 1 - NADsens agar 
 
NADsens agar was prepared at the Freeman hospital microbiology department as 
part of their routine media consortia by a member of staff. The media is based upon 
isosensitest agar which is used in antibiotic disk diffusion assays and is comprised 
of; 
Step 1; 
Hydrolysed casein 
Peptones 
Glucose 
Sodium chloride 
Starch 
Disodium hydrogen phosphate 
Sodium acetate 
Magnesium glycerophosphate 
Calcium gluconate 
Cobaltous sulphate 
Cupric sulphate 
Zinc sulphate 
Ferrous sulphate 
Manganous chloride 
Menadione 
Cyanocobalamin 
L-cysteine hydrochloride 
L-tryptophan 
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Pyridoxine 
Pantothenate 
Nicotinamide 
Biotin 
Thiamine 
Adenine 
Guanine 
Xanthine 
Uracil 
Agar 
Autoclave at 121°C for 60 minutes 
Step 2; 
Cool to 50°C and supplement with 5% whole horse blood and 20mg/l NAD 
 
NB For NADsens broth omit agar from step 1. 
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Appendix 2 – Luria-Bertani media 
 
Basic recipe (per litre) 
Tryptone        10g 
Yeast Extract     5g 
Sodium Cholride    5g 
Agar      15g 
 
Autoclave at 121°C for 45 minutes, cool to 50°C and pour 20ml in to each Petri dish 
 
N.B. For broth omit agar from the recipe 
JM109 LB plates 
Once the media from the basic recipe has cooled to 50°C supplement with 
Ampicillin (100µg/ml) and  X-gal (400µg/ml) and pour as described above. 
 
Antibiotic selection broth 
Omit agar from the basic recipe and then proceed as described above. When the 
media has cooled to 50°C supplement with Ampicillin (100µg/ml) and dispense in to 
5ml aliquots.  
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Appendix 3 – TAE Buffer 
 
TAE buffer was prepared at 50x concentrate then diluted as required. 
Step 1 – 100ml EDTA pH 8.0; 
18.61g EDTA 
100ml dH2O 
The beaker containing the EDTA and 50ml dH2O was placed on to a magnetic stirrer 
and the pH was measured throughout. Sodium hydroxide pellets were added to the 
solution until the solution was at pH 8.0. Addition dH2O was added as required to 
achieve a final volume of 100ml.   
Step 2 
242g Tris base ultrapure 
57.1ml Glacial acetic acid 
100ml EDTA pH 8.0 
dH2O to 1L 
The Tris base was weighed and placed into a 1L Duran bottle along with the glacial 
acetic acid and the EDTA which was prepared fresh as described above. The buffer 
was then made up to 1L with dH2O. 
To make 1x TAE dilute 1 part 50x TAE in 49 parts dH2O. 
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Appendix 4 – Dyes 
 
Bromophenol blue (6x concentrate) 
Bromophenol blue was prepared at 6x concentrate and diluted appropriately with the 
sample as required. The solution was prepared as follows; 
0.025g Bromophenol blue 
4.0g Sucrose 
dH2O up to 1L 
DCode Dye 
DCode dye was added to the „high‟ denaturing solution so that the efficacy of mixing 
between the low and high solutions when pouring the gradient for the DGGE gel 
could be established. The solution was prepared as follows; 
 
0.05g Bromophenol blue 
0.05g Xylene cyanol 
1x TAE up to 10 ml 
 
DGGE loading dye (2x concentrate) 
DGGE loading dye was prepared at 2x concentrate and diluted appropriately with the 
sample as required. The solution was prepared as follows; 
Step 1 
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A 2% (w/v) solution of bromophenol blue and a 2% (w/v) solution of xylene cyanol 
were prepared by dissolving 0.002g of each solid in 1ml dH2O. 
Step 2 
The solution was prepared as follows; 
0.25ml 2% (w/v) bromophenol blue  
0.25ml 2% (w/v) xylene cyanol  
7.0ml 100% glycerol 
2.5ml dH2O 
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Appendix 5 – Denaturing solutions 
 
Reagent 30% 35% 55% 60% 65% 
40%(v/v) acrylamide 
(37.5:1 
acrylamide:bisacrylamide) 
30ml 30ml 30ml 30ml 30ml 
50x TAE 2ml 2ml 2ml 2ml 2ml 
Deionised formamide 12ml 14ml 22ml 24ml 26 
Urea (electrophoresis 
grade) 
12.6g 14.7g 23.1g 25.2 27.3 
dH2O To 
100ml 
To 
100ml 
To 
100ml 
To 
100ml 
To 
100ml 
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Appendix 6 – Hyperladder I concentrations 
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Appendix 7 – M9 minimal media 
 
Step 1 
Prepare 5x M9 salt solution as described below 
Reagent Amount 
Sodium phosphate 64g 
Potassium phosphate 15g 
Sodium chloride 2.5g 
Ammonium chloride 5g 
18.2Ω H20 1L 
Autoclave 
 
The salts can then be used to make M9 minimal media with Vitamin B1 as described 
below.# 
Step 2 
Reagent Amount 
Bacteriological agar No. 1 (OXOID) 15g 
18.2Ω H20 750ml 
Autoclave at 121˚C 
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5x M9 salts 200ml 
1M magnesium sulphate (filter sterilise) 2ml 
20% (v/v) Glucose (filter sterilise) 20ml 
1M Calcium chloride (filter sterilise) 0.1ml 
10mg/ml Thiamine hydrochloride (filter 
sterilise) 
0.1ml 
 
Add 20ml of molten M9 minimal agar with Vitamin B1 to a Petri dish and allow 
cooling at room temperature. Dry the plates and store at 4ºC (up to 1 month).  
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Appendix 8 – FSB solution 
 
Reagent Amount 
1mM Potassium acetate 0.009814g 
45mM Manganese chloride 0.89055g 
10mM Calcium chloride 0.1470g 
100mM Potassium chloride 0.7455g 
3mM Hexamine cobalt chloride 0.08024g 
10% (v/v) Glycerol 10ml 
18.2Ω H20 90ml 
Filter sterilise (0.22µm) and store at 4ºC 
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Appendix 9 – SOC media 
 
Make the following solutions; 
1M NaCl 
0.5844g NaCl 
dH2O to 10ml 
1M KCl 
0.7455g KCl 
dH2O to 10ml 
2M Mg
2+
 stock 
2.330g MgCl2 • 6H2O 
2.465g MgSO4 • 7H2O 
dH2O to 10ml filter sterilise with a 0.22µM filter 
2M glucose 
3.603g Glucose 
dH2O to 10ml filter sterilise with a 0.22µM filter 
To make the media add; 
2.0g Tryptone 
0.5g Yeast extract 
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1ml 1M NaCl 
1ml 1M KCl 
dH2O to 100ml 
Autoclave and allow to cool to room temperature. Then add; 
1ml 2M Mg2+ 
1ml 2M Glucose 
Check the pH is 7.0, adjust accordingly if it is not. 
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Appendix 10 - Assessment of sample handling practices on microbial activity in 
sputum samples from cystic fibrosis patients 
 
192 
 
Bacterial DGGE band matrix (Part 1) 
  
  
Band Number 
Patient Treatment 1 2 3 4 5 6 7 8 9 10 
1 
Fridge 
 
0.00082 0 0.000581 0.000561 0 0.001785 0.008444 0.004374 0 0 
2 
Fridge 
 
0.001035 0 0 0 0 0 0.008205 0.000745 0 0 
3 
Fridge 
 
0.000252 0.000188 0 0 0.000218 0 0.003543 0.00094 0 0.000621 
4 
Fridge 
 
0.000491 0.000632 0 0.00038 0 0 0.008118 0.002949 0 0 
5 
Fridge 
 
0.000377 0 0 0 0.000439 0 0.003677 0 0.001701 0 
1 
Room 
Temp. 
0.000481 0 0 0 0 0.000497 0.001715 0 0 0 
2 
Room 
Temp. 
0.000701 0 0 0 0 0 0.001262 0 0 0 
3 
Room 
Temp. 
0.00052 0 0 0 0 0 0.001102 0 0 0 
4 
Room 
Temp. 
0.000451 0 0 0 0 0.000556 0.002968 0 0 0 
5 
Room 
Temp. 
0.000517 0 0 0.000349 0 0 0.000892 0 0.001154 0 
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Bacterial DGGE Band matrix continued (Part 2)  
  
Band Number 
Patient Treatment 11 12 13 14 15 16 17 18 19 20 
1 
Fridge 
 
2.1E-05 0 
1.49E-
05 
1.44E-
05 
0 
4.58E-
05 
0.000217 0.000112 0 0 
2 
Fridge 
 
2.93E-
05 
0 0 0 0 0 0.000232 2.11E-05 0 0 
3 
Fridge 
 
4.5E-06 
3.36E-
06 
0 0 3.9E-06 0 6.33E-05 1.68E-05 0 
1.11E-
05 
4 
Fridge 
 
1.21E-
05 
1.56E-
05 
0 
9.37E-
06 
0 0 0.0002 7.26E-05 0 0 
5 
Fridge 
 
7.33E-
06 
0 0 0 
8.54E-
06 
0 7.15E-05 0 
3.31E-
05 
0 
1 
Room 
Temp. 
8.57E-
06 
0 0 0 0 
8.85E-
06 
3.05E-05 0 0 0 
2 
Room 
Temp. 
1.41E-
05 
0 0 0 0 0 2.54E-05 0 0 0 
3 
Room 
Temp. 
9.82E-
06 
0 0 0 0 0 2.08E-05 0 0 0 
4 
Room 
Temp. 
8.17E-
06 
0 0 0 0 
1.01E-
05 
5.38E-05 0 0 0 
5 
Room 
Temp. 
9.61E-
06 
0 0 
6.49E-
06 
0 0 1.66E-05 0 
2.14E-
05 
0 
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Bacterial DGGE band matrix Continued (Part 3)  
  
Band Number 
Patient Treatment 21 22 23 24 25 26 27 28 29 30 
1 
Fridge 
 
5.4E-07 0 
3.82E-
07 
3.69E-
07 
0 
1.17E-
06 
5.56E-
06 
2.88E-
06 
0 0 
2 
Fridge 
 
8.31E-
07 
0 0 0 0 0 
6.58E-
06 
5.98E-
07 
0 0 
3 
Fridge 
 
8.05E-
08 
6.01E-
08 
0 0 
6.97E-
08 
0 
1.13E-
06 
3E-07 0 
1.98E-
07 
4 
Fridge 
 
2.98E-
07 
3.83E-
07 
0 
2.31E-
07 
0 0 
4.92E-
06 
1.79E-
06 
0 0 
5 
Fridge 
 
1.43E-
07 
0 0 0 
1.66E-
07 
0 
1.39E-
06 
0 
6.43E-
07 
0 
1 
Room 
Temp. 
1.53E-
07 
0 0 0 0 
1.58E-
07 
5.44E-
07 
0 0 0 
2 
Room 
Temp. 
2.84E-
07 
0 0 0 0 0 
5.12E-
07 
0 0 0 
3 
Room 
Temp. 
1.85E-
07 
0 0 0 0 0 
3.93E-
07 
0 0 0 
4 
Room 
Temp. 
1.48E-
07 
0 0 0 0 
1.83E-
07 
9.76E-
07 
0 0 0 
5 
Room 
Temp. 
1.78E-
07 
0 0 
1.21E-
07 
0 0 
3.08E-
07 
0 
3.98E-
07 
0 
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Bacterial DGGE Band matrix continued (Part 4)  
  
Band Number 
Patient Treatment 31 32 33 34 35 36 37 
1 
Fridge 
 
0.538669 0.56432 0.589971 0.615621 0.641272 0.666923 0.692574 
2 
Fridge 
 
1.53E-08 0 1.08E-08 1.05E-08 0 3.33E-08 1.57E-07 
3 
Fridge 
 
1.48E-08 0 0 0 0 0 1.18E-07 
4 
Fridge 
 
1.98E-09 
1.48E-
09 
0 0 1.72E-09 0 2.79E-08 
5 
Fridge 
 
5.79E-09 
7.45E-
09 
0 4.48E-09 0 0 9.57E-08 
1 
Room 
Temp. 
2.54E-09 0 0 0 2.96E-09 0 2.48E-08 
2 
Room 
Temp. 
3.07E-09 0 0 0 0 3.17E-09 1.1E-08 
3 
Room 
Temp. 
5.37E-09 0 0 0 0 0 9.66E-09 
4 
Room 
Temp. 
3.36E-09 0 0 0 0 0 7.13E-09 
5 
Room 
Temp. 
2.75E-09 0 0 0 0 3.4E-09 1.81E-08 
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Fungal DGGE Band matrix (Part 1)  
  
Band number 
Patient Treatment 1 2 3 4 5 6 7 8 
1 
Fridge 
 
0 0.24697 0 0 0 0 0 0 
2 
Fridge 
 
0.21001 0.11968 0.18197 0.17614 0 0 0 0 
3 
Fridge 
 
0.06862 0.08944 0.18387 0 0 0 0 0 
4 
Fridge 
 
0 0 0 0 0.33311 0 0 0.29873 
5 
Fridge 
 
0.0954 0.10143 0.1412 0 0 0.11696 0.10299 0 
1 
Room 
Temp. 
0 0 0.32857 0 0 0 0 0 
2 
Room 
Temp. 
0 0 0.50416 0 0 0 0 0 
3 
Room 
Temp. 
0 0 0.32326 0.18203 0 0 0 0 
4 
Room 
Temp. 
0 0 0 0 0.20531 0 0 0.2697 
5 
Room 
Temp. 
0.12715 0 0 0 0 0.25983 0.20344 0 
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Fungal DGGE band matrix continued (Part 2)  
  
Band number 
Patient Treatment 9 10 11 12 13 14 15 16 17 
1 
Fridge 
 
0 0 0.22216 0 0 0 0 0.22576 0.30095 
2 
Fridge 
 
0 0.05672 0.14321 0 0 0 0 0.05456 0.05771 
3 
Fridge 
 
0 0.16746 0.15303 0 0 0 0 0.24977 0.0878 
4 
Fridge 
 
0 0 0 0.04633 0.05239 0.06091 0.12699 0.04158 0.03997 
5 
Fridge 
 
0.0883 0.0544 0.14835 0 0 0 0 0.05731 0.09367 
1 
Room 
Temp. 
0 0 0 0 0 0 0 0.28236 0.38907 
2 
Room 
Temp. 
0 0 0 0 0 0 0 0.20771 0.28814 
3 
Room 
Temp. 
0 0 0 0 0 0 0 0.21351 0.2812 
4 
Room 
Temp. 
0 0 0 0.06281 0.17639 0 0.11887 0.07319 0.09372 
5 
Room 
Temp. 
0.14462 0 0 0 0 0 0 0.10822 0.15673 
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Eubacterial qPCR data 
 
Patient 
Fridge Mean calculated 
concentration (Copies/ml) 
Room Temperature Mean 
calculated concentration 
(Copies/ml) 
Sum of the mean 
calculated 
concentration 
(copies/ml) 
Fridge 
normalised 
value 
Room 
Temperature 
normalised 
value 
1 4.10E+09 7.17E+09 1.13E+10 0.36 0.64 
2 2.57E+08 5.73E+08 8.29E+08 0.31 0.69 
3 8.62E+07 2.98E+08 3.84E+08 0.22 0.78 
4 5.37E+08 7.97E+08 1.33E+09 0.40 0.60 
5 2.42E+07 3.52E+07 5.94E+07 0.41 0.59 
   
Mean 0.34 0.66 
   
Standard error 0.02 
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Pseudomonas Spp. qPCR data 
 
Patient Fridge Mean calculated 
concentration 
(Copies/ml) 
Room Temperature Mean 
calculated concentration 
(Copies/ml) 
Sum of the mean 
calculated concentration 
(copies/ml) 
Fridge 
normalised 
value 
Room 
Temperature 
normalised value 
1 5.66E+07 5.25E+07 1.09E+08 0.52 0.48 
2 1.20E+06 6.34E+06 7.54E+06 0.16 0.84 
3 8.74E+05 3.57E+06 4.44E+06 0.20 0.80 
4 4.60E+06 9.86E+06 1.45E+07 0.32 0.68 
5 3.73E+05 6.19E+05 9.92E+05 0.38 0.62 
   Mean 0.31 0.69 
   Standard error 0.03 
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H. influenzae qPCR data 
Patient 
Fridge Mean 
calculated 
concentration 
(Copies/ml) 
Room Temperature Mean 
calculated concentration 
(Copies/ml) 
Sum of the mean 
calculated 
concentration 
(copies/ml) 
Fridge 
normalised 
value 
Room 
Temperature 
normalised value 
P1 4.13E+03 2.00E+03 6.13E+03 0.67 0.33 
P2 6.22E+03 2.25E+03 8.47E+03 0.73 0.27 
P3 6.76E+03 4.17E+03 1.09E+04 0.62 0.38 
P4 7.49E+03 3.75E+03 1.12E+04 0.67 0.33 
P5 1.22E+04 5.15E+03 1.74E+04 0.70 0.30 
   
Mean 0.68 0.32 
   
Standard error 0.01 
 
 
201 
 
Eubacteria qPCR standard curve 
 
202 
 
Pseudomonas Spp. qPCR standard curve 
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H. influenzae qPCR standard curve 
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Bacterial correspondence analysis 
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Fungal CCA 
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Sequence from Fungal DGGE excised bands 
 
Band Accession 
number 
Sequence 
F1 GU001640 TACCGGGCCAGCATCGGTTTGGAGCGGTAGGATAAATGGCGGGGGAAT
GTGGCACGACTTTGGTTGTGTGTTATAGCCTCTGACGATACTGCCAGC
CTAGACCGAGGACTGCGGTTTTTACCTAGGATGTTGGCATAATGATCT
TAAGTCGCCCGTCTTGAAACACGGACCAAGGAGTCCCCCCCGTGCCCC
CGCCCCG 
 
F2 GU065334 GGATAATGGCGGAGGAATGTGGCACGGCTTCTGCTGTGTGTTATAGCC
TCTGACGATACTGCCAGCCTAGACCGAGGACTGCGGTTTTTACCTAGG
ATGTTGGCATAATGATCTTAAGTCGCCCGTCTTGAAACACGGACCAAG
GAGTCCCCCCCGTGCCCC 
 
F3 GU065335 AATGTGGCACTGCTTCGGTAGTGTGTTATAGTCTTTGTCGATACTGCC
AGCTTAGACTGAGGACTGCGGCTTCGGCCTAGGAGTTGGCATAATGAT
CTTAAGTCGCCCGTCTTGAAACACGGACCAAGGAGTCACCCCCGTGCC
CCCGCCCCGCT 
F4 GU065336 TCCCCGTGGCGGGCCAGCGTCGGTTTGGGCGGCCGGTCAAAGGCCCTC
GGAATGTATCACCTCTCGGGGTGTCTTATAGCCGAGGGTGCAATGCGG
CCTGCCTGGACCGAGGAACGCGCTTCGGCTCGGACGCTGGCGTAATGG
TCGTAAATGACCCGTCTTGAAACACGGACCAAGGA 
 
 
  
207 
 
 
 
 
 
 
 
 
 
 
Appendix 11 - Bacterial and fungal communities present in the lungs of cystic 
fibrosis patients with a severe genotype are affected by genetic and 
environmental factors
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Patient Demographics (Part 1) 
Patient 
No. 
Sex Age Genotype FEV1 (% 
predicated) 
Routine antibiotics BMI Recent History 
1 F 30 F508del/OM 65 COL, FLU, OT 21.7 P. aeruginosa x 3 / MRSA / 
Candida spp.  
2 F 33 F508del/F508del 26 AZI, FLU 20.1 P. aeruginosa  x 2 / Candida 
spp. 
3 M 32 F508del/F508del 58 AZI, FLU 22.5 P. aeruginosa x 2  
4 M 18 F508del/F508del 65 AZI, COL, DOX 21.5 P. aeruginosa  / A. fumigatus / 
Candida spp. 
5 M 27 F508del/F508del 99 AZI, COL FLU 23.0 P. aeruginosa 
6 F 28 F508del/OM 59 AZI 20.9 P. aeruginosa x 2 / C. albicans  
7 M 20 F508del/F508del 66 AZI, COL 19.6 P. aeruginosa x 2 / C. albicans  
8 F 23 F508del/OM 44 AZI, COL FLU 21.2 P. aeruginosa x 2  
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Patient Demographics continued (Part 2)
Patient 
No. 
Sex Age Genotype FEV1 (% 
predicated) 
Routine antibiotics BMI Recent History 
9 M 34 F508del/OM 59 AZI, COL 22.0 MRSA / Candida sp.  
10 M 23 F508del/F508del 62 AZI, COL FLU 16.7 No bacterial pathogens / 
Candida sp. 
11 M 19 F508del/F508del 46 AZI, COL FLU 21.7 No bacterial pathogens / 
Candida sp. 
12 F 19 F508del/F508del 73 AZI, COL FLU 17.9 P. aeruginosa 
13 M 20 F508del/OM 74 AZI, COL 16.7 P. aeruginosa / MRSA 
14 M 29 F508del/F508del 89 AZI 22.0 P. aeruginosa 
15 M 22 F508del/OM 92 COL, FLU  20.0 P. aeruginosa 
16 M 26 F508del/F508del 43 AZI, CEF, FLU, 
TOB 
18.2 No bacterial pathogens / A. 
fumigatus 
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Patient Demographics continued (Part 3) 
 
 
 
Patient 
No. 
Sex Age Genotype FEV1 (% 
predicated) 
Routine antibiotics BMI Recent History 
17 M 25 F508del/F508del 18 AZI, COL FLU 24.1 P. aeruginosa x 2 /  Serratia 
spp. / Candida spp.  
18 F 56 F508del/OM 35 AZI 24.2 MRSA / Candida spp. 
19 M 26 F508del/F508del 30 AZI, COL FLU 19.1 P. aeruginosa x 2  
20 M 56 F508del/OM 28 AZI 22.0 P. aeruginosa / Mycobacterium 
spp./ Candida spp.  
21 F 28 F508del/OM 31 AZI, COL FLU 19.2 P. aeruginosa / A. xylosoxidans 
22 F 19 F508del/OM 104 AZI, COL FLU 25.9 No bacterial pathogens / 
Candida spp. 
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Patient Demographics continued (Part 4) 
 
Patient 
No. 
Sex Age Genotype FEV1 (% 
predicated) 
Routine antibiotics BMI Recent History 
23 F 28 F508del/F508del 49 COL, FLU  18.9 P. aeruginosa x 2 / Candida 
spp. 
24 F 28 F508del/F508del 86 COL, FLU  27.8 P. aeruginosa  / Serratia spp. 
25 F 59 F508del/OM 33 AZI, COL 20.7 P. aeruginosa / Candida spp. 
26 F 23 F508del/F508del 60 AZI, COL FLU 27.0 P. aeruginosa / S. aureus / 
Candida spp. 
27 M 28 F508del/OM 60 AZI, COL 28.3 P. aeruginosa x 2  
28 F 39 F508del/F508del 34 COL, FLU  28.0 P. aeruginosa 
29 M 39 F508del/F508del 53 AZI, COL FLU 25.3 P. aeruginosa / S. aureus / A. 
fumigatus  
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Microbial Community Analysis (Part 1) 
Patient Shannon Richness Evenness 
Rep. Calc. 
Conc. 
qPCR 
(copies/rxn) 
qPCR 
(copies/ml) 
log qPCR 
Fungi 
Richness 
1 1.69 12 0.68 1,339,921.78 133992177.9 6699608893 9.83 1 
2 1.84 15 0.68 7,092.78 709277.776 35463889 7.55 1 
3 2.39 19 0.81 69,566.18 6956618.308 347830915 8.54 2 
4 2.65 22 0.86 65,309.74 6530973.762 326548688 8.51 1 
5 2.24 17 0.79 315,439.28 31543928.17 1577196408 9.20 1 
6 2.04 15 0.75 109,312.47 10931247.15 546562358 8.74 1 
7 1.87 12 0.75 72,912.53 7291252.894 364562645 8.56 5 
8 0.91 6 0.51 4,844.48 484448.405 24222420 7.38 0 
9 2.30 14 0.87 1,200.26 120026.224 6001311 6.78 0 
10 2.00 14 0.76 28,109.97 2810996.79 140549840 8.15 3 
11 2.51 16 0.91 9,144.06 914406.099 45720305 7.66 3 
12 2.01 14 0.76 14,787.47 1478747.201 73937360 7.87 3 
13 2.04 11 0.85 1,399.05 139904.856 6995243 6.84 0 
14 1.75 8 0.84 24,042.89 2404288.88 120214444 8.08 1 
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Microbial Community Analysis continued (Part 2) 
Patient Shannon Richness Evenness 
Rep. Calc. 
Conc. 
qPCR 
(copies/rxn) 
qPCR 
(copies/ml) 
log qPCR 
Fungi 
Richness 
15 2.14 15 0.79 1,162,075.89 116207589.2 5810379461 9.76 2 
16 2.24 14 0.85 84,275.54 8427553.788 421377689 8.62 1 
17 1.61 9 0.73 14,241.75 1424174.744 71208737 7.85 1 
18 2.27 17 0.80 1,759.36 175936.497 8796825 6.94 1 
19 1.94 13 0.76 75,103.87 7510386.754 375519338 8.57 0 
20 1.53 11 0.64 16,881.96 1688196.398 84409820 7.93 0 
21 2.30 15 0.85 3,478.32 347831.529 17391576 7.24 1 
22 1.29 6 0.72 2,601,033.31 260103331.5 13005166574 10.11 2 
23 1.87 10 0.81 1,409,998.93 1040999893 52049994630 10.72 3 
24 1.20 7 0.61 1,571,967.61 157196760.8 7859838038 9.90 0 
25 0.78 6 0.44 326,007.58 32600758 1630037900 9.21 0 
26 1.53 9 0.69 587,636.43 58763642.92 2938182146 9.47 3 
27 1.95 11 0.81 603,779.56 60377955.59 3018897780 9.48 0 
28 1.37 7 0.70 5,317.30 531730.377 26586519 7.42 2 
29 1.99 10 0.86 482,457.09 48245708.73 2412285436 9.38 3 
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Example of Eubacterial qPCR standard curve 
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Appendix 12 - Temporal dynamics of the microbial communities in the Cystic 
Fibrosis  
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Longitudinal Patient Demographics (Part 1) 
DGGE 
Patient 
No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
1 101 F 30 F508del/OM 02/10/2008 Stable 1.65 (59%) OTC,  COL, FLU 
 
P. aeruginosa x 3 / MRSA 
 
102 F 30 F508del/OM 03/11/2008 Exacerbation 1.68 (60%) OTC,  COL, FLU TAZ/TOB P. aeruginosa x 2 / MRSA 
 
103 F 30 F508del/OM 22/01/2009 Stable 1.82 (65%) OTC,  COL, FLU 
 
P. aeruginosa x 3 / MRSA / Candida sp. 
 
104 F 30 F508del/OM 18/02/2009 Exacerbation 1.60 (57%) OTC,  COL, FLU CEF/TOB 
P. aeruginosa / MRSA / Haemolytic Streptococcus 
group C 
 
105 F 30 F508del/OM 01/04/2009 Stable 1.75 (62%) OTC,  COL, FLU 
 
P. aeruginosa x 2 / MRSA / Candida sp. 
 
106 F 30 F508del/OM 24/06/2009 Stable 1.80 (64%) OTC,  COL, FLU 
 
P. aeruginosa x 2 / MRSA 
 
107 F 30 F508del/OM 04/08/2009 Exacerbation 1.56 (56%) OTC,  COL, FLU CEF/COL Pseudomonas aeruginosa x 2 / MRSA 
 
108 F 30 F508del/OM 16/09/2009 Stable 1.76 (63%) OTC,  COL, FLU 
 
Pseudomonas aeruginosa 
 
109 F 30 F508del/OM 02/11/2009 Stable 1.76 (63%) OTC,  COL, FLU 
 
Pseudomonas aeruginosa x 2 / MRSA 
 
110 F 30 F508del/OM 09/12/2009 Exacerbation 1.61 (57%) OTC,  COL, FLU CEF/COL P. aeruginosa x 2 / MRSA / Candida sp. 
 
111 F 30 F508del/OM 04/01/2010 Routine I.V. 1.71 (61%) 
FLU, AZI, COL, 
MIN 
CEF/COL P. aeruginosa x 2 / Candida sp. 
 
112 F 30 F508del/OM 09/06/2010 Stable 1.85(66%) 
FLU, AZI, COL, 
MIN  
P. aeruginosa x 3 
           
2 201 F 33 F508del/F508del 02/10/2008 Stable 1.22 (35%) AZI, FLU 
 
P. aeruginosa x 2 
 
202 F 33 F508del/F508del 08/10/2008 Exacerbation 1.24 (35%) AZI, FLU TAZ/TOB P. aeruginosa x 2 
 
203 F 33 F508del/F508del 05/02/2009 Exacerbation 0.95 (28%) AZI, FLU COL/TAZ P. aeruginosa x 2 
 
204 F 33 F508del/F508del 04/03/2009 Exacerbation 0.94 (28%) AZI, FLU COL/MER P. aeruginosa / Candida sp. 
 
205 F 33 F508del/F508del 15/04/2009 Stable 0.90 (26%) AZI, FLU 
 
P. aeruginosa x 2 / Candida sp. 
 
206 F 33 F508del/F508del 03/06/2009 Stable 1.10 (29%) AZI 
 
P. aeruginosa x 2 / Candida sp. 
 
207 F 33 F508del/F508del 12/08/2009 Exacerbation 1.15 (30%) AZI CEF/TOB P. aeruginosa 
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DGGE 
Patient 
No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
2 208 F 33 F508del/F508del 30/09/2009 Stable 1.28 (37%) AZI 
 
P. aeruginosa 
 
209 F 33 F508del/F508del 04/11/2009 Stable 1.25 (36%) AZI 
 
P. aeruginosa x 2 
 
210 F 33 F508del/F508del 02/12/2009 Routine I.V. 1.24 (36%) AZI CEF/TOB P. aeruginosa x 2 / Candida sp. 
 
211 F 33 F508del/F508del 20/01/2010 Stable 1.25 (36%) AZI 
 
P. aeruginosa 
 
212 F 33 F508del/F508del 02/02/2010 Exacerbation 1.17 (34%) AZI TAZ/TOB P. aeruginosa x 2 
 
213 F 33 F508del/F508del 05/03/2010 Exacerbation 1.15 (33%) AZI COL/TAZ P. aeruginosa / Candida sp. 
 
214 F 33 F508del/F508del 10/03/2010 Exacerbation 1.15 (33%) AZI COL/TAZ P. aeruginosa x 2 
 
215 F 33 F508del/F508del 21/04/2010 Exacerbation 1.00 (29%) AZI COL/TAZ P. aeruginosa x 2 / Candida sp. 
           
3 301 M 32 F508del/F508del 02/10/2008 Stable 2.46 (57%) AZI, COL FLU 
 
P. aeruginosa x 2 
 
302 M 32 F508del/F508del 31/10/2008 Exacerbation 2.46 (57%) AZI, COL FLU MER/TOB P. aeruginosa / Candida sp. 
 
303 M 32 F508del/F508del 01/04/2009 Stable 2.50 (58%) AZI, FLU 
 
P. aeruginosa x 2 
 
304 M 32 F508del/F508del 15/07/2009 Exacerbation 2.06 (48%) AZI, FLU CEF/TOB P. aeruginosa / A. fumigatus 
 
305 M 32 F508del/F508del 14/10/2009 Routine I.V. 2.30 (54%) AZI, FLU CEF/TOB P. aeruginosa 
 
306 M 32 F508del/F508del 27/01/2010 Stable 1.95 (45%) AZI, FLU 
 
P. aeruginosa x 2 / Candida sp. 
 
307 M 32 F508del/F508del 18/05/2010 Stable 2.00 (47%) AZI, FLU 
 
P. aeruginosa x 2 / Candida sp. 
           
4 401 M 27 F508del/F508del 02/10/2008 Stable 3.90 (88%) AZI, COL FLU 
 
P. aeruginosa x 2 
 
402 M 27 F508del/F508del 20/01/2009 Exacerbation 3.35 (76%) AZI, COL FLU TAZ/TOB P. aeruginosa / S. aureus / Candida sp. 
 
403 M 27 F508del/F508del 12/02/2009 Stable 4.30 (99%) AZI, COL FLU 
 
P. aeruginosa 
 
404 M 27 F508del/F508del 11/11/2009 Routine I.V. 4.00 (92%) AZI, COL FLU MER/TOB P. aeruginosa 
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Patient 
No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
4 405 M 27 F508del/F508del 13/01/2010 Stable 3.80 (88%) AZI, COL FLU 
 
P. aeruginosa 
 
406 M 27 F508del/F508del 18/03/2010 Stable 3.95(91%) AZI, COL FLU 
 
P. aeruginosa x 2 
 
407 M 27 F508del/F508del 12/05/2010 Stable 4.15 (96%) AZI, COL FLU 
 
P. aeruginosa 
           
5 501 F 28 F508del/OM 19/02/2009 Stable 1.88 (59%) AZI 
 
P. aeruginosa x 2 / C. albicans 
 
502 F 28 F508del/OM 01/04/2009 Exacerbation 1.10 (34%) AZI GEN/MER P. aeruginosa x 2 
 
503 F 28 F508del/OM 08/07/2009 Exacerbation 1.15 (36%) AZI CIP (Oral) P. aeruginosa x 2 
 
504 F 28 F508del/OM 14/10/2009 Stable 1.20 (38%) AZI 
 
P. aeruginosa x 3 
 
505 F 28 F508del/OM 23/12/2009 Stable 1.20 (38%) AZI 
 
P. aeruginosa 
 
506 F 28 F508del/OM 07/04/2010 Stable 1.50 (47%) AZI 
 
P. aeruginosa / Pseudomonas sp. / Candida sp. 
 
507 F 28 F508del/OM 09/06/2010 Exacerbation 1.35(42%) AZI CIP (Oral) P. aeruginosa x 2 / Candida sp. 
           
6 601 M 34 F508del/OM 12/02/2009 Exacerbation 2.20 (48%) AZI, COL MER/TOB Pseudomonas aeruginosa / MRSA / Candida sp. 
 
602 M 34 F508del/OM 22/04/2009 Stable 2.32 (51%) AZI, COL 
 
MRSA / Candida sp. 
 
603 M 34 F508del/OM 30/07/2009 Stable 2.68 (59%) AZI, COL 
 
MRSA / Candida sp. 
 
604 M 34 F508del/OM 09/09/2009 Stable 2.46 (54%) AZI, COL, TET 
 
Candida sp. 
 
605 M 34 F508del/OM 23/11/2009 Exacerbation 2.40 (53%) AZI, COL MER/TOB P. aeruginosa / MRSA / Candida sp. 
 
606 M 34 F508del/OM 09/12/2009 Stable 2.25 (49%) AZI, COL 
 
P. aeruginosa / MRSA / Candida sp. 
 
607 M 34 F508del/OM 13/01/2010 Exacerbation 
unable to 
do 
AZI, COL MER/TOB P. aeruginosa / MRSA 
 
608 M 34 F508del/OM 10/02/2010 Exacerbation 2.45 (54%) AZI, COL MER/TOB/DOX P. aeruginosa / MRSA / Candida sp. 
 
609 M 34 F508del/OM 28/04/2010 Exacerbation 2.10 (46%) AZI, COL MER/TOB MRSA / Candida sp. 
 
610 M 34 F508del/OM 27/05/2010 Stable 2.10 (46%) AZI, COL 
 
MRSA / Candida sp. 
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DGGE 
Patient 
No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
7 701 M 23 F508del/F508del 13/03/2009 Stable 2.35 (62%) AZI, COL FLU 
 
No bacterial pathogens / Candida sp. 
 
702 M 23 F508del/F508del 29/07/2009 Stable 2.40 (63%) AZI, COL 
 
No bacterial pathogens / Candida sp. 
 
703 M 23 F508del/F508del 03/09/2009 Exacerbation 2.07 (54%) AZI, COL COL/MER P. aeruginosa 
 
704 M 23 F508del/F508del 04/11/2009 Exacerbation 2.14 (54%) AZI, COL CEF/TOB P. aeruginosa / Candida sp. 
 
705 M 23 F508del/F508del 23/12/2009 Stable 2.08 (54%) AZI, COL 
 
P. aeruginosa / Candida sp. 
 
706 M 23 F508del/F508del 23/03/2010 Exacerbation 1.95 (51%) AZI, COL CEF/COL P. aeruginosa / Candida sp. 
 
707 M 23 F508del/F508del 12/05/2010 Stable 2.05 (54%) AZI, COL 
 
P. aeruginosa 
 
708 M 23 F508del/F508del 24/06/2010 Stable 2.0(53%) AZI, COL 
 
P. aeruginosa x 2/ Candida sp. 
           
8 801 M 19 F508del/F508del 13/03/2009 Stable 1.87 (46%) AZI, COL FLU 
 
No bacterial pathogens / Candida sp. 
 
802 M 19 F508del/F508del 11/11/2009 Routine I.V. 1.91 (47%) AZI, COL FLU CEF/TOB No bacterial pathogens / Exophiala sp. 
 
803 M 19 F508del/F508del 30/12/2009 Stable 2.05 (50%) AZI, COL FLU 
 
P. aeruginosa 
 
804 M 19 F508del/F508del 11/02/2010 Routine I.V. 1.98 (48%) AZI, COL FLU CEF/TOB No bacterial pathogens / Exophiala sp. / Candida sp. 
 
805 M 19 F508del/F508del 07/04/2010 Stable 2.05 (50%) AZI, COL FLU 
 
No bacterial pathogens 
 
806 M 19 F508del/F508del 30/06/2010 stable 1.90 (59%) AZI, COL FLU 
 
No bacterial pathogens 
           
9 901 F 19 F508del/F508del 05/03/2009 Exacerbation 1.99 (74%) AZI, COL FLU CEF/MER P. aeruginosa x 2 
 
902 F 19 F508del/F508del 01/04/2009 Stable 1.95 (73%) AZI, COL FLU 
 
P. aeruginosa 
 
903 F 19 F508del/F508del 04/06/2009 Stable 1.75 (66%) AZI, COL FLU 
 
P. aeruginosa 
 
904 F 19 F508del/F508del 05/08/2009 Routine I.V. 1.81 (68%) AZI, COL FLU CEF/COL P. aeruginosa 
 
905 F 19 F508del/F508del 16/09/2009 Stable 1.75 (66%) AZI, COL FLU 
 
P. aeruginosa 
 
906 F 19 F508del/F508del 14/10/2009 Routine I.V. 1.71 (64%) AZI, COL FLU CEF/COL P. aeruginosa 
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No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
9 907 F 19 F508del/F508del 06/01/2010 Routine I.V. 1.88 (71%) AZI, COL FLU CEF/COL P. aeruginosa x 3 
 
908 F 19 F508del/F508del 24/02/2010 Stable 2.05 (72%) AZI, COL FLU 
 
P. aeruginosa 
 
909 F 19 F508del/F508del 21/04/2010 Stable 2.00 (72%) AZI, COL FLU 
 
P. aeruginosa 
 
910 F 19 F508del/F508del 26/05/2010 stable 2.10 (79%) AZI, COL FLU 
 
P. aeruginosa 
 
911 F 19 F508del/F508del 07/06/2010 Exacerbation 1.90 (71%) AZI, COL FLU CEF/COL P. aeruginosa 
           
10 1001 M 20 F508del/OM 11/03/2009 Exacerbation 2.30 (49%) AZI, CIP, COL TAZ/TOB P. aeruginosa / MRSA 
 
1002 M 20 F508del/OM 04/06/2009 Exacerbation 2.40 (52%) AZI, CIP CEF/COL P. aeruginosa / MRSA 
 
1003 M 20 F508del/OM 30/07/2009 Stable 3.24 (74%) AZI, COL 
 
P. aeruginosa / MRSA 
 
1004 M 20 F508del/OM 09/09/2009 Exacerbation 2.65 (61%) AZI, COL 
 
P. aeruginosa x 2 / Candida sp. 
 
1005 M 20 F508del/OM 16/11/2009 Exacerbation 
Unable to 
do 
AZI, COL CEF/TOB P. aeruginosa / MRSA / Candida sp. 
 
1006 M 20 F508del/OM 18/11/2009 Exacerbation 
Unable to 
do 
AZI, COL 
 
P. aeruginosa / MRSA 
 
1007 M 20 F508del/OM 13/01/2010 Exacerbation 2.28 (49%) AZI, COL CEF/TOB P. aeruginosa / MRSA 
 
1008 M 20 F508del/OM 08/02/2010 Stable 2.74 (66%) AZI, COL 
 
P. aeruginosa 
 
1009 M 20 F508del/OM 12/04/2010 Exacerbation 2.45 (52%) AZI, COL CEF/COL P. aeruginosa / MRSA / Candida sp. 
 
1010 M 20 F508del/OM 07/05/2010 Stable 2.75 (66%) AZI, COL 
 
MRSA 
           
11 1101 M 26 F508del/F508del 15/04/2009 Exacerbation 1.54 (41%) AZI, FLU CEF/TOB S. aureus / B. multivorans 
 
1102 M 26 F508del/F508del 14/10/2009 Exacerbation 1.60 (43%) AZI, FLU CEF/TOB S. aureus / H. influenzae 
 
1103 M 26 F508del/F508del 26/10/2009 Stable 1.60 (43%) 
AZI, FLU, CEF, 
TOB  
No bacterial pathogens / A. fumigatus 
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DGGE 
Patient 
No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
11 1104 M 26 F508del/F508del 02/12/2009 Stable 1.94 (52%) 
AZI, FLU, CEF, 
TOB  
No bacterial pathogens / Candida sp. 
 
1105 M 26 F508del/F508del 18/01/2010 Stable 2.21 (59%) AZI, FLU 
 
B. multivorans / Candida sp. 
 
1106 M 26 F508del/F508del 01/03/2010 Exacerbation 1.95 (52%) AZI, FLU CEF/TOB S. aureus / B. multivorans / Candida sp. 
 
1107 M 26 F508del/F508del 12/04/2010 Stable 1.70 (45%) AZI, FLU 
 
S. aureus / B. multivorans 
 
1108 M 26 F508del/F508del 11/05/2010 Routine IV 2.15 (57%) AZI, FLU CEF/TOB No bacterial pathogens 
 
1109 M 26 F508del/F508del 23/06/2010 Stable 2.16 (57%) AZI, FLU 
 
S. aureus 
           
12 1201 F 56 F508del/OM 15/04/2009 Stable 1.04 (35%) AZI 
 
MRSA / Candida sp. 
 
1202 F 56 F508del/OM 03/06/2009 Stable 1.10 (35%) AZI 
 
MRSA / Candida sp. 
 
1203 F 56 F508del/OM 02/10/2009 Exacerbation 1.05 (35%) AZI CEF/TOB MRSA / A. fumigatus 
 
1204 F 56 F508del/OM 09/12/2009 Stable 1.10 (35%) AZI 
 
MRSA / Candida sp. 
 
1205 F 56 F508del/OM 17/02/2010 Stable 0.94 (31%) AZI 
 
MRSA / Candida sp. 
 
1206 F 56 F508del/OM 07/04/2010 Routine I.V. 1.25 (41%) AZI 
 
MRSA / Candida sp. / A. fumigatus 
 
1207 F 56 F508del/OM 02/06/2010 Stable 1.30 (43%) AZI 
DOX (Oral) 
I.V. CEF/TOB 
No bacterial pathogens 
           
13 1301 M 56 F508del/OM 22/04/2009 Stable 1.01 (28%) AZI 
 
P. aeruginosa / Candida sp. / Mycobacterium sp. 
 
1302 M 56 F508del/OM 15/07/2009 Routine I.V. 0.90 (25%) AZI CEF/TOB 
P. aeruginosa x 3 / Ochrobactrum anthropi / 
Mycobacterium chelonae 
 
1303 M 56 F508del/OM 24/09/2009 Exacerbation 0.85 (24%) AZI CEF P. aeruginosa / C. albicans / Mycobacterium sp. 
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Patient 
No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
13 1304 M 56 F508del/OM 02/12/2009 Exacerbation 0.88 (25%) AZI CEF P. aeruginosa x 5 / C. albicans / Mycobacterium sp. 
 
1305 M 56 F508del/OM 31/12/2009 Stable 0.85 (24%) AZI 
 
P. aeruginosa x 3 / C. albicans / Mycobacterium 
chelonae 
 
1306 M 56 F508del/OM 07/01/2010 Exacerbation 0.80 (23%) AZI CEF 
P. aeruginosa x 2 / C. albicans / Mycobacterium 
chelonae 
           
14 1401 F 19 F508del/OM 05/05/2009 Stable 
4.37 
(104%) 
AZI, COL FLU 
 
No bacterial pathogens / Candida sp. 
 
1402 F 19 F508del/OM 06/01/2010 Exacerbation 3.92 (93%) AZI, COL FLU CIP (Oral) Morganella morganii / A. fumigatus 
 
1403 F 19 F508del/OM 12/02/2010 Stable 
4.58 
(109%) 
AZI, COL FLU 
 
P. aeruginosa / Candida sp. / A. fumigatus 
 
1404 F 19 F508del/OM 27/05/2010 Stable 
4.20 
(102%) 
AZI, COL FLU 
 
No bacterial pathogens / Candida sp. 
           
15 1501 F 59 F508del/OM 13/05/2009 Stable 0.85 (33%) AZI, COL 
 
P. aeruginosa / Candida sp. 
 
1502 F 59 F508del/OM 12/08/2009 Routine I.V. 0.95 (37%) AZI, COL CEF/TOB P. aeruginosa 
 
1503 F 59 F508del/OM 23/09/2009 Stable 0.85 (33%) AZI, COL, ITR 
 
P. aeruginosa 
 
1504 F 59 F508del/OM 28/10/2009 Exacerbation 0.86 (33%) AZI, COL, ITR CEF/TOB P. aeruginosa / Candida sp. 
 
1505 F 59 F508del/OM 06/01/2010 Stable 1.00 (39%) AZI, COL 
 
P. aeruginosa / Morganella morganii / Candida sp. 
 
1506 F 59 F508del/OM 17/02/2010 Stable 0.99 (38%) AZI, COL 
 
P. aeruginosa x 2 / Candida sp. 
 
1507 F 59 F508del/OM 18/03/2010 Routine I.V. 0.96 (37%) AZI, COL CEF/TOB P. aeruginosa 
 
1508 F 59 F508del/OM 24/06/2010 Stable 1.00 (39%) AZI, COL 
 
P. aeruginosa / Candida sp. 
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DGGE 
Patient 
No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
16 1601 F 23 F508del/F508del 13/05/2009 Stable 1.67 (60%) AZI, COL FLU 
 
P. aeruginosa / S. aureus / Candida sp. 
 
1602 F 23 F508del/F508del 27/05/2009 Exacerbation 0.74 (26%) AZI, COL FLU CEF/TOB P. aeruginosa / S. aureus / Candida sp. 
 
1603 F 23 F508del/F508del 15/07/2009 Exacerbation 1.42 (51%) AZI, COL FLU CEF/TOB P. aeruginosa 
 
1604 F 23 F508del/F508del 21/10/2009 Stable 1.25 (45%) AZI, COL FLU 
 
P. aeruginosa /  A. fumigatus 
 
1605 F 23 F508del/F508del 21/04/2010 Stable 1.46 (52%) AZI, COL FLU 
 
P. aeruginosa /  A. fumigatus 
 
1606 F 23 F508del/F508del 12/05/2010 Exacerbation 1.50 (53%) AZI, COL FLU CEF/TOB P. aeruginosa /  A. fumigatus 
 
1607 F 23 F508del/F508del 27/05/2010 Stable 1.21 (43%) AZI, COL FLU 
 
P. aeruginosa / Candida sp. / A. fumigatus 
           
17 1701 F 39 F508del/F508del 08/04/2009 Stable 1.00 (34%) COL, FLU 
 
P. aeruginosa 
 
1702 F 39 F508del/F508del 05/08/2009 Stable 0.96 (33%) COL, FLU 
 
P. aeruginosa / Candida sp. 
 
1703 F 39 F508del/F508del 12/10/2009 Exacerbation 1.05 (36%) COL, FLU CEF/TOB P. aeruginosa 
 
1705 F 39 F508del/F508del 02/12/2009 Exacerbation 0.87 (30%) AZI, COL CEF/TOB P. aeruginosa x 2 / Candida sp. / C. albicans 
 
1706 F 39 F508del/F508del 14/04/2010 Stable 0.95 (32%) AZI, COL 
 
P. aeruginosa / Candida sp. 
           
18 1801 M 39 F508del/F508del 20/05/2009 Stable 2.20 (53%) AZI, COL FLU 
 
P. aeruginosa / S. aureus / A. fumigatus 
 
1802 M 39 F508del/F508del 15/07/2009 Stable 2.41 (58%) AZI, COL FLU 
 
P. aeruginosa / S. aureus / A. fumigatus 
 
1803 M 39 F508del/F508del 16/09/2009 Stable 2.31 (55%) AZI, COL FLU 
 
P. aeruginosa / Candida sp. / A. fumigatus 
 
1804 M 39 F508del/F508del 11/11/2009 Stable 2.22 (53%) AZI, COL FLU 
 
P. aeruginosa / A. fumigatus 
 
 
 
224 
 
Longitudinal Patient Demographics continued (Part 9) 
DGGE 
Patient 
No. 
Code Sex Age Genotype 
Date 
collected 
Exacerbation 
FEV1 (% 
predicated) 
Routine antibiotics I.V. Antibiotics Recent History 
18 1805 M 39 F508del/F508del 02/12/2009 Routine I.V. 2.18 (52%) AZI, COL FLU CEF/TOB P. aeruginosa / Candida sp. / A. fumigatus 
 
1806 M 39 F508del/F508del 20/01/2010 Stable 2.26 (54%) AZI, COL FLU 
 
P. aeruginosa / A. fumigatus 
 
1807 M 39 F508del/F508del 10/03/2010 Stable 1.99 (48%) AZI, COL FLU 
 
P. aeruginosa / A. fumigatus 
 
1808 M 39 F508del/F508del 21/04/2010 Stable 2.25 (54%) AZI, COL FLU 
 
P. aeruginosa / A. fumigatus 
 
1809 M 39 F508del/F508del 03/06/2010 Stable 2.40 (57%) AZI, COL FLU 
 
P. aeruginosa / A. fumigatus 
 
1810 M 39 F508del/F508del 01/07/2010 Stable 2.30 (55%) AZI, COL FLU 
 
P. aeruginosa / A. fumigatus 
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Microbial Community Analysis (Part 1) 
Patient Code 
Shannon 
Diversity 
Bacterial 
Richness 
Bacterial 
Evenness 
Fungal Richness 
1 101 1.58 16 0.57 0 
 
102 2.01 19 0.68 1 
 
103 1.92 17 0.68 1 
 
104 1.93 17 0.68 1 
 
105 2.16 21 0.71 1 
 
106 2.26 18 0.78 0 
 
107 2.00 19 0.68 0 
 
108 2.20 18 0.76 0 
 
109 1.85 15 0.68 1 
 
110 2.23 18 0.77 1 
 
111 2.29 19 0.78 1 
 
112 1.80 11 0.75 0 
      
2 201 2.13 11 0.89 0 
 
202 2.29 16 0.83 0 
 
203 2.17 16 0.78 0 
 
204 2.23 17 0.79 2 
 
205 2.42 17 0.85 1 
 
206 1.87 16 0.67 0 
 
207 2.13 13 0.83 0 
 
208 1.82 10 0.79 0 
 
209 1.77 14 0.67 0 
 
210 1.21 9 0.55 3 
 
211 1.85 10 0.81 3 
 
212 2.01 13 0.78 0 
 
213 2.10 13 0.82 3 
 
214 1.80 12 0.72 0 
 
215 2.03 16 0.73 1 
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Patient Code 
Shannon 
Diversity 
Bacterial 
Richness 
Bacterial 
Evenness 
Fungal Richness 
3 301 2.40 19 0.81 0 
 
302 2.18 17 0.77 1 
 
303 2.48 21 0.82 1 
 
304 2.49 21 0.82 0 
 
305 2.34 17 0.83 0 
 
306 2.16 14 0.82 1 
 
307 1.90 10 0.82 0 
      
4 401 2.11 13 0.82 2 
 
402 2.20 13 0.86 1 
 
403 2.45 17 0.86 1 
 
404 2.04 13 0.79 1 
 
405 2.01 13 0.78 0 
 
406 2.28 17 0.81 1 
 
407 2.09 15 0.77 2 
      
5 501 2.02 19 0.69 1 
 
502 1.86 15 0.69 0 
 
503 2.12 17 0.75 0 
 
504 1.98 17 0.70 0 
 
505 1.95 21 0.64 0 
 
506 2.06 22 0.67 0 
 
507 2.38 20 0.80 0 
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Patient Code 
Shannon 
Diversity 
Bacterial 
Richness 
Bacterial 
Evenness 
Fungal Richness 
6 601 2.36 17 0.83 0 
 
602 2.11 18 0.73 1 
 
603 2.22 17 0.78 0 
 
604 2.11 18 0.73 0 
 
605 2.10 20 0.70 0 
 
606 2.33 19 0.79 0 
 
607 2.73 27 0.83 0 
 
608 2.21 17 0.78 0 
 
609 1.97 16 0.71 0 
 
610 2.53 17 0.89 0 
      
7 701 1.83 18 0.63 2 
 
702 2.21 16 0.80 2 
 
703 1.96 15 0.72 1 
 
704 1.31 12 0.53 1 
 
705 1.09 9 0.49 0 
 
706 0.56 8 0.27 0 
 
707 1.03 11 0.43 0 
 
708 1.45 16 0.52 0 
      
8 801 1.87 11 0.78 4 
 
802 1.89 14 0.71 4 
 
803 2.21 15 0.82 0 
 
804 1.98 17 0.70 0 
 
805 2.18 16 0.79 0 
 
806 2.01 17 0.71 0 
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Patient Code 
Shannon 
Diversity 
Bacterial 
Richness 
Bacterial 
Evenness 
Fungal Richness 
9 901 2.58 24 0.81 0 
 
902 2.44 18 0.84 1 
 
903 2.63 24 0.83 2 
 
904 2.59 23 0.82 0 
 
905 2.59 25 0.80 0 
 
906 2.42 21 0.79 1 
 
907 2.50 19 0.85 2 
 
908 2.23 20 0.74 0 
 
909 1.85 13 0.72 0 
 
910 2.38 16 0.86 0 
 
911 1.70 10 0.74 0 
      
10 1001 2.33 20 0.78 0 
 
1002 2.42 25 0.75 0 
 
1003 2.51 31 0.73 0 
 
1004 2.79 31 0.81 0 
 
1005 2.39 21 0.79 1 
 
1006 2.30 25 0.72 0 
 
1007 2.65 26 0.81 0 
 
1008 2.46 25 0.76 0 
 
1009 2.61 25 0.81 1 
 
1010 2.69 26 0.83 0 
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Microbial Community Analysis continued (Part 5) 
Patient Code 
Shannon 
Diversity 
Bacterial 
Richness 
Bacterial 
Evenness 
Fungal Richness 
11 1101 1.84 19 0.62 0 
 
1102 2.57 23 0.82 0 
 
1103 2.37 20 0.79 1 
 
1104 2.78 23 0.89 1 
 
1105 2.65 23 0.85 0 
 
1106 2.79 22 0.90 0 
 
1107 2.90 24 0.91 0 
 
1108 2.68 25 0.83 0 
 
1109 2.23 17 0.79 0 
      12 1201 2.19 17 0.77 1 
 
1202 2.23 20 0.74 0 
 
1203 2.22 19 0.75 2 
 
1204 2.31 19 0.78 1 
 
1205 2.28 27 0.69 1 
 
1206 2.26 21 0.74 1 
 
1207 2.25 21 0.74 1 
      13 1301 1.82 19 0.62 0 
 
1302 2.11 22 0.68 1 
 
1303 2.25 21 0.74 1 
 
1304 2.26 25 0.70 2 
 
1305 2.08 19 0.71 1 
 
1306 2.36 19 0.80 1 
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Patient Code 
Shannon 
Diversity 
Bacterial 
Richness 
Bacterial 
Evenness 
Fungal Richness 
14 1401 2.33 19 0.79 0 
 
1402 2.52 25 0.78 1 
 
1403 2.60 25 0.81 0 
 
1404 2.58 25 0.80 1 
      
15 1501 1.65 13 0.64 0 
 
1502 1.54 11 0.64 0 
 
1503 2.25 14 0.85 0 
 
1504 1.92 17 0.68 0 
 
1505 1.33 7 0.69 0 
 
1506 2.06 17 0.73 0 
 
1507 1.55 12 0.63 0 
 
1508 1.85 14 0.70 0 
      
16 1601 2.40 22 0.78 2 
 
1602 2.70 27 0.82 2 
 
1603 2.59 24 0.81 0 
 
1604 2.37 23 0.76 0 
 
1605 2.52 27 0.77 0 
 
1606 2.42 20 0.81 0 
 
1607 2.22 17 0.78 0 
      
17 1701 2.03 11 0.84 1 
 
1702 1.74 11 0.73 2 
 
1703 1.92 13 0.75 2 
 
1704 1.96 13 0.76 2 
 
1705 2.04 13 0.80 1 
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Microbial Community Analysis continued (Part 7) 
Patient Code 
Shannon 
Diversity 
Bacterial 
Richness 
Bacterial 
Evenness 
Fungal Richness 
18 1801 2.74 22 0.89 0 
 
1802 2.71 18 0.94 1 
 
1803 2.61 18 0.90 0 
 
1804 2.24 15 0.83 1 
 
1805 2.52 17 0.89 1 
 
1806 2.64 19 0.90 0 
 
1807 2.54 19 0.86 0 
 
1808 2.57 19 0.87 0 
 
1809 2.66 19 0.90 1 
 
1810 2.60 18 0.90 1 
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Example of Eubacterial qPCR standard curve 
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